Alexandria Medical Evidence Library
Library/Cancer/Lung Cancer

Cancer evidence library

Lung Cancer

PubMed-indexed evidence for non-small-cell and small-cell lung cancer, including treatment and emerging research.

PubMed only Research ranked Conflicts shown Data downloadable

Living evidence synopsis

What the current PubMed collection shows.

Alexandria currently organizes 1,408 non-retracted PubMed-indexed records for Lung Cancer. The structured collection includes 15 guideline or consensus records, 156 evidence syntheses/systematic reviews/meta-analyses, and 118 randomized or phase III studies. 309 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 754 of 1,408 included records.

Engine 0.3.2 Snapshot v7 Updated 2026-11-02 Download source data · CSV
PubMed records1,408Non-retracted records included
Last 24 months309Records found by the recent-research search
High-priority evidence274Syntheses, reviews, randomized and phase III studies
Effect estimates496Machine-readable values extracted from abstracts
COI statements53.6%Coverage within PubMed records
Funding records400PMIDs with grant/funding metadata
Evidence data

Research landscape

Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.

Publication activity

Records by publication year

Latest 12 represented years
1
2014
1
2016
2
2017
5
2019
5
2020
7
2021
45
2022
205
2023
304
2024
67
2025
732
2026
34
2027
Evidence composition

Study designs

Other or unclassified641
Preclinical/laboratory307
Meta-analyses114
Randomized trials93
Systematic reviews42
Phase II trials41
Cohort studies41
Case reports32
Phase III trials25
Observational studies25
Transparency

Conflict-of-interest reporting

Not reported in PubMed record654
Reported no conflicts377
COI statement present287
Declared financial/industry relationship90

Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.

Abstract result signals

Extracted result direction

Not extractable from abstract1258
Neutral/null signal66
Supportive signal41
Harm signal33
Mixed signal10
Reported outcomes

Numerical results extracted from PubMed abstracts

Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.

Non-pooled ratio measures

Hazard, risk, and odds ratios reported in abstracts

Reference = 1.0
0.250.51.02.04.0
not_reported Odds Ratio · PMID 42662463 · 2027
15.00
not_reported Odds Ratio · PMID 42787797 · 2027
8.00
overall survival Hazard Ratio · PMID 42935798 · 2027
1.11
not_reported Odds Ratio · PMID 41560513 · 2026
4.01
not_reported Odds Ratio · PMID 41560513 · 2026
2.75
not_reported Odds Ratio · PMID 41560513 · 2026
1.80
not_reported Odds Ratio · PMID 41560513 · 2026
1.81
not_reported Odds Ratio · PMID 41871716 · 2026
6.00
not_reported Hazard Ratio · PMID 42127535 · 2026
0.96
not_reported Hazard Ratio · PMID 42127535 · 2026
0.71
not_reported Odds Ratio · PMID 41794665 · 2026
0.26
not_reported Hazard Ratio · PMID 41801367 · 2026
1.36 95% CI 1.06–1.74
not_reported Hazard Ratio · PMID 41801367 · 2026
1.29 95% CI 1.03–1.63
not_reported Odds Ratio · PMID 41825453 · 2026
1.00
View extracted numerical results 60
PublicationOutcomeMeasureReported valueSource
Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunity via coordinated cellular and humoral responses.Bioactive materials · 2027 not_reported Odds Ratio 15.0 PMID 42662463
Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry.Clinical and translational radiation oncology · 2027 not_reported Odds Ratio 8.0 PMID 42787797
Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.Clinical and translational radiation oncology · 2027 not_reported Percentage Comparison 11.0percent vs 4.3percent PMID 42935767
Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.Clinical and translational radiation oncology · 2027 not_reported Percentage Comparison 4.8percent vs 0.8percent PMID 42935767
Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes.Advances in radiation oncology · 2027 overall survival Hazard Ratio 1.11 P = .35 PMID 42935798
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 not_reported Odds Ratio 4.01 PMID 41560513
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 not_reported Odds Ratio 2.75 PMID 41560513
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 not_reported Odds Ratio 1.8 PMID 41560513
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 not_reported Odds Ratio 1.81 PMID 41560513
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Odds Ratio 6.0 PMID 41871716
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2026 not_reported Hazard Ratio 0.96 PMID 42127535
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2026 not_reported Hazard Ratio 0.71 PMID 42127535
Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial.BMC anesthesiology · 2026 not_reported Odds Ratio 0.259 P = 0.003 PMID 41794665
Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.European journal of nuclear medicine and molecular imaging · 2026 not_reported Hazard Ratio 1.36 95% CI 1.06–1.74 PMID 41801367
Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.European journal of nuclear medicine and molecular imaging · 2026 not_reported Hazard Ratio 1.29 95% CI 1.03–1.63 PMID 41801367
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.The Lancet. Oncology · 2026 not_reported Odds Ratio 1.0 PMID 41825453
Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.BMC cancer · 2026 not_reported Hazard Ratio 4.33 95% CI 2.48–7.56 p < 0.001 PMID 41888696
Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.BMC cancer · 2026 not_reported Odds Ratio 4.0 PMID 41888696
Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients.Gut microbes · 2026 survival Hazard Ratio 0.3889 95% CI 0.284–0.5356 p < 0.001 PMID 41933285
Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.International journal of cancer · 2026 not_reported Hazard Ratio 1.16 95% CI 1.03–1.3 PMID 42071337
Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.International journal of cancer · 2026 not_reported Hazard Ratio 1.08 95% CI 1.01–1.16 PMID 42071337
Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.International journal of cancer · 2026 not_reported Hazard Ratio 1.17 95% CI 1.0–1.37 PMID 42071337
Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.International journal of cancer · 2026 not_reported Hazard Ratio 1.11 95% CI 0.99–1.25 PMID 42071337
Safety, pharmacokinetics, pharmacodynamics and antitumor activity of legubicin in patients with advanced solid tumors, including lung cancer: a phase 1 dose-escalation and expansion trial.BMC cancer · 2026 not_reported Odds Ratio 3.0 PMID 42215940
First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial.Cancer · 2026 not_reported Odds Ratio 5.0 PMID 42216493
Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.Pulmonology · 2026 mortality Hazard Ratio 0.75 95% CI 0.62–0.91 PMID 42339520
Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.Pulmonology · 2026 not_reported Hazard Ratio 1.88 95% CI 1.24–2.87 PMID 42339520
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Cancer research communications · 2026 overall survival Hazard Ratio 0.89 PMID 42447505
Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials.European journal of cancer (Oxford, England : 1990) · 2026 not_reported Hazard Ratio 1.59 95% CI 1.33–1.9 p < 0.001 PMID 42520592
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Odds Ratio 45.0 PMID 41921748
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Hazard Ratio 0.82 PMID 41921748
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Hazard Ratio 0.56 PMID 41921748
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Hazard Ratio 0.72 PMID 41921748
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Hazard Ratio 0.68 PMID 41921748
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Hazard Ratio 0.75 PMID 41921748
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 not_reported Hazard Ratio 0.71 PMID 41921748
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.AJR. American journal of roentgenology · 2026 not_reported Odds Ratio 4.0 PMID 41848489
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.AJR. American journal of roentgenology · 2026 not_reported Percentage Comparison 16.9percent vs 10.3percent p = .23 PMID 41848489
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.AJR. American journal of roentgenology · 2026 not_reported Percentage Comparison 52.9percent vs 32.6percent p = .23 PMID 41848489
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.AJR. American journal of roentgenology · 2026 not_reported Percentage Comparison 15.3percent vs 7.4percent p = .23 PMID 41848489
Research transparency

Funding and conflicts of interest

Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.

COI statement coverage53.6%654 records have no COI statement exposed in PubMed.
Funding metadata coverage28.4%Coverage indicates whether grant/funding metadata was present, not independence or study quality.
Most frequently reported funding agencies
NCI NIH HHS184
National Natural Science Foundation of China105
Wellcome Trust25
NIH HHS23
Cancer Research UK22
Medical Research Council21
World Health Organization20
National Natural Science Foundation of China (National Science Foundation of China)20
View records with declared financial or industry relationships 12

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.

In accordance with Taylor & Francis policy and ethical obligation of researchers, WM is reporting having received research funding and honoraria from BMS, Novartis, GSK, Roche, AstraZeneca, MethylGene, MedImmune, Bayer, Amgen, Merck, Incyte, Sanofi, Array, Ocellaris Pharma, Astellas, Alkermes, Exelixis, VelosBio, Genentech, Seagen, Zymeworks and consulting fees for Mylan, EMD Serono, Sanofi. CLe has received honoraria for advisory boards from Ipsen, BMS, Regeneron, Sanofi, Novartis, Pfizer, and Astra-Zeneca. RJ Honoraria from Pfizer, BMS GmbH & Co. KG, Merck KGaA, Novartis and consulting Role to BMS, Medison pharma, Pfizer, Merck KGaA and Novartis. JFC is reporting having received funding, honoraria from Merck, Astra-Zeneca, Novartis. RL is reporting having received funding, honoraria and research contract from BMS, Pfizer, Merck, PREVENT/Folia Biotech and Fondation Famille Diane et Léon Gosselin. RL and JFC are founders and CSO/CMO, respectively, of Cell-Immune Pharma, Inc. Other authors did not report any potential conflict of interest.

PMID 41732954 · 2026

Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).

F. Skoulidis reports personal fees and other support from AstraZeneca, Amgen Inc., Genentech/Roche, Eli Lilly, Merck Sharp & Dohme LLC, Tango Therapeutics, ESMO, Medscape LLC, and Intellisphere LLC; grants, personal fees, and other support from Revolution Medicines, IDEOlogy Health, MJH Life Sciences, CURIO LLC, PER LLC, MI&T, and DAVA Oncology; personal fees from Astellas Pharma, Boehringer Ingelheim, Regeneron, Genmab, Bristol Myers Squibb/Mirati Therapeutics, BridgeBio, Hookipa Pharma, Guardant Inc., BeiGene, BergenBio, Novocure, Nuvalent, Turning Point Therapeutics, Japanese Lung Cancer Society, Aptitude Health, RV Pais Promoção Eventos LTDA, VSPO McGill Université de Montréal, and AImmune; grants and personal fees from Novartis; and other support from the American Association for Cancer Research and IASLC outside the submitted work. S.K. Jabbour reports grants and personal fees from Merck, personal fees from AstraZeneca, and grants from BeOne and Haystack outside the submitted work. E.B. Garon reports grants and personal fees from AstraZeneca during the conduct of the study. E.B. Garon also reports personal fees from AbbVie, Atreca, Bicycle, Black Diamond Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, Hexagon, Hookipa, I-Mab, IO Biotech, iTeos, LianBio, Merus, Nuvalent, Oxford Bio, Pfizer, Samsung, Sanofi, Sumitomo, Strata, Servier, Transcode, and Verastem; grants and personal fees from Arrivent, Bayer, BridgeBio, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, Gilead, Merck, Novartis, Regeneron, and Synthekine; and grants from ABL-Bio, EMD Serono, Genentech, Iovance Biotherapeutics, Prelude, and TILT Biotherapeutics outside the submitted work. In addition, E.B. Garon reports a patent for Motif Neoepitopes for Cancer Immunotherapy pending to Regents of the University of California. P. Iyengar reports other support from AstraZeneca, Johnson & Johnson, Novocure, and Pfizer, as well as grants from Incyte outside the submitted work. G. Scagliotti reports other support from AstraZeneca outside the submitted work. L. Ferrer reports grants from AstraZeneca during the conduct of the study, as well as other support from SOPHiA GENETICS outside the submitted work. G. Etchepare reports grants from AstraZeneca during the conduct of the study, as well as other support from SOPHiA GENETICS outside the submitted work. O. Gallinato reports grants from AstraZeneca during the conduct of the study, as well as other support from SOPHiA GENETICS outside the submitted work. P. Bernard reports grants from AstraZeneca during the conduct of the study, as well as other support from SOPHiA GENETICS outside the submitted work. T. Colin reports grants from AstraZeneca during the conduct of the study, as well as other support from SOPHiA GENETICS outside the submitted work. P. Menu reports grants from AstraZeneca during the conduct of the study, as well as other support from SOPHiA GENETICS outside the submitted work. Y. Lin reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from Novartis outside the submitted work. L. Cai reports other support from AstraZeneca outside the submitted work. A. Remorino reports other support from AstraZeneca during the conduct of the study. R. Stewart reports other support from AstraZeneca during the conduct of the study. L. Luciani-Silverman reports other support from AstraZeneca during the conduct of the study. K. Miller reports employment with AstraZeneca. J. Faria reports employment with AstraZeneca and ownership of AstraZeneca stock. Y. Zhang reports employment with AstraZeneca and ownership of AstraZeneca stock outside the submitted work. No disclosures were reported by the other authors.

PMID 42485106 · 2026

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.

Yuki Yamamoto is the Chief Executive Officer of HiLung. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

PMID 42505144 · 2026

Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial.

Conflict of Interest Dr Kunkyab is currently employed by the Mount Sinai Hospital. Dr Olson reported grants from Varian Medical Systems and personal fees from Need Inc. outside the submitted work. Dr Schellenberg reported grants from Vancouver Coastal Health Research Institute (VCHRI) innovation grant as well as personal fees from AstraZeneca, Pfizer, Bristol Myers Squibb and Merck outside the submitted work. Dr Mou reported personal fees from Amgen, AstraZeneca, and Bristol-Myers Squibb outside the submitted work. Dr Hsu reported honorarium from AstraZeneca. Dr Bergman reported Canadian Institute of Health Research (CIHR) grant and BC Cancer Sprakkar award outside the submitted work. Dr Clark reported grants from Siemens Healthineers outside the submitted work. Dr Baker reported grants from Varian Medical Systems and BC Cancer internal funds. Dr Hyde reported grants from BC Cancer Foundation. No other disclosures were reported.

PMID 41775003 · 2026

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors have completed the ICMJE disclosure form. Dr. Stensland has received honoraria to her institution for a lecture from AstraZeneca and honoraria for advisory board from Merck. Dr. Eide has received honoraria for lectures from AstraZeneca, Janssen and Bristol-Meyer Squibbs and honoraria for advisory boards from MSD and AstraZeneca. Dr. Horndalsveen has received honoraria for lectures from AstraZeneca and Pfizer. Dr. Grønberg has received research support to his institution from AstraZeneca, and honoraria for lectures or advisory boards from AstraZeneca, Pfizer, Accord, Immedica, Pharmacosmos, Johnson & Johnson, Eli Lilly, MSD, Gilead, BMS, MSD and Accord. Dr. Grønberg is also Chairman of the Norwegian Lung Cancer Study Group. Dr. Ekman has received research funding with unrestricted grants from Boehringer-Ingelheim for an Investigator Initiated Study and has participated in non-remunerated expert meetings sponsored by Amgen, AstraZeneca, BMS, Takeda and Boehringer-Ingelheim. Dr. Brustugun has received funding to his institution for the FIOL trial from AstraZeneca, which also provided the study drug, he has received grants to his institution from Amgen and Pfizer and honoraria from lectures or advisory boards to his institution from Roche, MSD, BMS, Sanofi, Boehringer-Ingelheim, AstraZeneca, Pfizer and Daiichi Sankyo. Declarations of interest for the other authors: none.

PMID 41723914 · 2026

Germline variants and impact on lung cancer outcomes following chemotherapy: A systematic review.

Declaration of Competing Interest Author 4 has recived speaker fees from Astellas, BeOne, BMS, Servier, Astra Zeneca, Consultancy fees fromAmgen, AstraZeneca, BMS, Servier, Astellas, BeOne , Platinum Discovery and Travel expenses from•BMS, MSD, BeOne. Author 2 has received speaker fees from Ipsen, Bristol Myers Squibb, AstraZeneca, MSD, and Jazz Therapeutics; consultancy fees from AstraZeneca and Servier; and travel expenses from Ipsen, Servier, and AstraZeneca.

PMID 42342141 · 2026

Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Giannis Mountzios has provided consulting services to and has served as an advisory-board member for Amgen, AstraZeneca, Boehringer Ingelheim, and Bristol-Myers Squibb; served on the global steering and endpoint committees for DeLLphi-304; served on the CANVAS study committee for AstraZeneca; and received travel support from Amgen and AstraZeneca. Philip Lammers reports personal/consulting or advisory fees from Amgen, AstraZeneca, Daiichi Sankyo, Merck, Pfizer, Roche/Genentech, Sanofi, and Teva. Longhua Sun has no potential conflicts of interest. Byoung Chul Cho has provided consulting services to Amgen, AnHeart Therapeutics, Arrivent, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CJ, Cyrus Therapeutics, Daiichi Sankyo, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Ono, Pfizer, Regeneron, Roche, Sanofi, Seagen, Takeda, and Yuhan; research contracts to Yonsei University Health System from AstraZeneca, Champions Oncology, CJ Bioscience, Cyrus, ImmuneOncia, Janssen, JINTSbio, MSD, Therapex, Vertical Pharmaceuticals, and Yuhan; advisory roles with BridgeBio Therapeutics and Cyrus Therapeutics; stock ownership in BridgeBio Therapeutics and others; and intellectual-property–related licensing income from Champions Oncology, PearlRiver Bio, Imagen, and Crown Bioscience. Umut Demirci has provided consulting services to or served in advisory roles with Astellas, Daiichi Sankyo, Novartis, Merck and others; speaker activities for AstraZeneca, Amgen, F. Hoffmann-La Roche and Bristol-Myers Squibb; principal-investigator roles with Merck, Pfizer, Novartis and Regeneron; travel support from Menarini, F. Hoffmann-La Roche. Surein Arulananda has provided consulting services and served on advisory boards to Roche, BeOne, Amgen, Bayer, Astra Zeneca, Merck-Sharpe & Dohme, Johnson & Johnson, Bristol-Myers Squibb, Medison, Race Oncology, Daiichi-Sankyo, Merck Serono and Boehringer-Ingelheim. Mahmut Gumus has provided consulting services to or served in advisory roles with AbbVie, Astellas, Daiichi Sankyo, Janssen, Novartis, Regeneron, Takeda and others; grants or institutional support from Amgen and F. Hoffmann-La Roche; speaker activities for AstraZeneca and Bristol-Myers Squibb; principal-investigator roles with Janssen, Merck, Pfizer, and Regeneron; travel support from Amgen, AstraZeneca, F. Hoffmann-La Roche, Regeneron, and Sandoz; and academic employment at Istanbul Medeniyet University and Prof. Dr. Suleyman Yalcin City Hospital. Salman Punekar has no potential conflicts of interest. Antonio Lugini has no potential conflicts of interest. Bo Zhu has no potential conflicts of interest. Yan Yu has no potential conflicts of interest. Tudor-Eliade Ciuleanu has provided consulting services to or served in advisory roles with travel/expense support, with Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Ipsen, Janssen Biotech, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi/Genzyme, and Servier. Myung-Ju Ahn has provided consulting services to or served in advisory roles with Alpha Pharmaceuticals, Amgen, AstraZeneca, Daiichi-Sankyo, F. Hoffmann-La Roche, Merck, Merck KGaA, Pfizer, Takeda, Genexine, and others, and employment at Samsung Medical Center. Julien Mazieres has provided consulting services to Amgen, Boehringer Ingelheim, and Pfizer; and has received research grants or contracts from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Merck Sharp & Dohme, Pierre Fabre, and Takeda. Martin Schuler has provided consulting services to Amgen, AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Immunocore, Janssen Pharmaceuticals, Merck Sharp & Dohme, Novartis, Regeneron Pharmaceuticals, Sanofi, and Takeda Oncology; his institution, University Hospital Essen, has received research grant support from AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, and the German Cancer Aid; and his institution has received funding from the German Federal Ministry of Education and Research for the National Center for Tumor Diseases (NCT) West. Fiona Blackhall has served on scientific advisory boards for AbbVie, Amgen, AstraZeneca, and Boehringer Ingelheim; served on a data and safety monitoring committee for AstraZeneca; and received institutional research funding from Cancer Research UK and the National Institute for Health Research. Tatsuya Yoshida has received research grants to his institution, the National Cancer Center Hospital, from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Ono Pharmaceuticals, Pfizer, Takeda Pharmaceuticals, and Thermo Fisher Scientific; and received honoraria or advisory role payments from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Ono Pharmaceuticals, Pfizer, Takeda Pharmaceuticals, and Thermo Fisher Scientific. Franziska Dirnberger, Jessie Wang, Shuang Huang, and Diana Gauto are employees of Amgen and reports stock ownership. Charles M. Rudin has provided consulting services to Amgen, AstraZeneca, Boehringer Ingelheim, Chugai, D2G Oncology, Daiichi Sankyo, F. Hoffmann-La Roche, Jazz Pharmaceuticals, Legend, Novartis, and Scorpion Therapeutics; scientific advisory-board roles with Auron, Bridge Medicines, DISCO, Earli, and Harpoon with equity/options as stated; and support from the National Cancer Institute (Outstanding Investigator Award R35 CA263816). No other potential competing interests beyond those listed were reported in the disclosure forms.

PMID 42679738 · 2026

Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

Declaration of competing interest J.R disclosed relationships with Sanofi, Pierre Fabre, Takeda, BMS, Astrazeneca, Regeneron, Janssen, Amgen, MSD, Pfizer, Roche, Daiichi Sankyo and Pharmamar, outside the submitted work D.B. reports consulting honoraria/board from Servier, Amgen, Merck, Pierre Fabre, Daichii Sankyo, MSD, BMS, Takeda, Viatris, Accord Healthcare and Chugai S.P reports consulting honoraria/board from Servier Amgen, Merck, Pierre Fabre, Astrazeneca, MSD, BMS, Takeda, Incyte, Novocure, Astellas, Beone, outside the submitted work V.B disclosed relationships with Bayer Schering Pharma, Ipsen, Merck Serono, MSD Oncology, Roche/Genentech, Astellas, Oseus, BMS, Stargen, AstraZeneca, Pierre Fabre, outside the submitted work MDS disclosed relationships with Merck, Servier, Astellas, Takeda, Incyte, Perre Fabre, outside the submitted work C.C. reports personal fees as speaker and/or in an advisory role from Amgen, Astra-Zeneca, Pierre Fabre, Daiichy Sankyo, BMS, MSD, Merck Serono, Servier, outside the submitted work. CDLF disclosed relationships with AbbVie, Agenus, Amgen, Astellas Pharma, AstraZeneca, Beigene, BMS, Daiichi Sankyo, Gilead Sciences, Incyte, Jazz Pharm., MSD, Pierre Fabre, Servier, Summit Therapeutics & Takeda

PMID 42669571 · 2026

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.

Declaration of competing interest Shota Omori has received personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Merck, Eli Lilly, Ono Pharmaceutical, AstraZeneca, Novartis, MSD, Bristol-Myers Squibb, Kyowa Hakko Kirin, Nippon Kayaku, and Amgen, all outside of the submitted work. Hirotsugu Kenmotsu has received grants from Ono Pharmaceutical, Novartis, Eli Lilly, AstraZeneca, and Loxo Oncology and personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Merck, MSD, Novartis, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, Takeda Pharmaceutical, Janssen Pharmaceutical, Thermo Fisher Scientific inc., and Guardant, all outside of the submitted work. Shogo Nomura has received grants from AstraZeneca, MSD, and Chugai Pharmaceutical; consulting fee from Daiichi Sankyo and Takeda Pharmaceutical; and personal fees from AstraZeneca, Chugai Pharmaceutical, Kyowa Hakko Kirin, MSD, Takeda Pharmaceutical, and Eli Lilly, all outside of the submitted work. Hideyuki Harada has received personal fees from AstraZeneca, Accuray, Chugai Pharmaceutical, Takeda Pharmaceutical, MSD, Eizai pharmaceutical, Pfizer, Brainlab, Hitachi, Novartis, Guerbet Japan, GE Healthcare, Nihon Medi-Physics, NovoCure, Regeneron Japan and Taiho Pharmaceutical, all outside of the submitted work. Satoshi Ishikura has received personal fee from AstraZeneca, outside of the submitted work. Masahiko Ando has received grant from Kyowa Hakko Kirin, outside of the submitted work. Hiroki Izumi has received personal fees from Amgen, AstraZeneca, Eisai, Ono Pharmaceutical, Takeda Pharmaceutical, MSD, Bristol-Myers Squibb, Merck, and Chugai Pharmaceutical, all outside of the submitted work. Izumi has received grants from Ono Pharmaceutical, Janssen Pharmaceutical, Japan Clinical Research Operations, Taiho Pharmaceutical, Bayer, Gilead, CMIC, AstraZeneca, Merck, Daiichi Sankyo, and GlaxoSmithKline and personal fees from Ono Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, and Eli Lilly, all outside of the submitted work. Yuki Shinno has received grants from Ono Pharmaceutical, Janssen Pharmaceutical, Taiho Pharmaceutical, Bayer, AstraZeneca, and Merck, and personal fees from Daiichi Sankyo, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, Janssen Pharmaceutical, and Takeda Pharmaceutical, all outside of the submitted work. Masahide Oki has received grants from AbbVie, GlaxoSmithKline, MSD, Parexel International, Sanofi, AstraZeneca, ArriVent Biopharma, Janssen Pharmaceutical, Gilead Sciences, Kaneka Medix, and Ono Pharmaceutical and personal fees from AstraZeneca, AMCO, Novartis, Canon Medical Systems, Eli Lilly Japan, MSD, Merit Medical Japan, Olympus Marketing, and Fujifilm, all outside of the submitted work. Takeshi Masuda has received personal fees from Daiichi Sankyo, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical, Astra Zeneca, Otsuka Pharmaceutical, Kyowa Kirin, Daiichi Sankyo, and Taiho Pharmaceutical, all outside of the submitted work. Toshihide Yokoyama has received grants from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Delta Fly Pharma, Janssen Pharma, and MSD and personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Biopharma, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical, all outside of the submitted work. Yukio Hosomi has received personal fees from AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, Nippon Kayaku, Takeda Pharmaceutical, Eisai, Novartis, Pfizer, and MSD, all outside of the submitted work. Yukiko Nakamura has received grants from AstraZeneca, Bristol-Myers Squibb, and AbbVie and personal fees from AstraZeneca, MSD, Chugai-pharm, and Eli Lilly, all outside of the submitted work. Shuji Murakami has received grants from AstraZeneca, Takeda Pharmaceutical, Chugai Pharmaceutical, Sanofi, MSD, Daiichi Sankyo, Ono Pharmaceutical, and Janssen Pharma and personal fees from AstraZeneca, Chugai Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, MSD, Pfizer, Novartis, and Taiho Pharmaceutical, all outside of the submitted work. Hiroshige Yoshioka has received grants from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Delta Fly Pharmaceutical, Janssen Pharmaceutical, MSD, Novartis, and Regeneron and personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Kyowa Kirin, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Taiho Pharmaceutical, Takeda Pharmaceutical, and Janssen Pharmaceutical, all outside of the submitted work. Koichi Azuma has received grants from MSD, Janssen Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, Amgen, Taiho Pharmaceutical, Daiichi Sankyo, IQVIA, EPS, and Syneos and personal fees from AstraZeneca, MSD, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Takeda Pharmaceutical, Taiho Pharmaceutical, and Amgen, all outside of the submitted work. Hiroshi Nokihara has received personal fee from Taiho Pharmaceutical, outside of the submitted work. Satoru Miura has received personal fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer, Eli Lilly, Boehringer Ingelheim Japan, Ono Pharmaceutical, AstraZeneca, Novartis, MSD, Bristol-Myers Squibb, Kyowa Hakko Kirin, Daiichi Sankyo, Nippon Kayaku, Amgen, Merck, Takeda Pharmaceutical, Eizai, Shionogi, Janssen Pharmaceutical, Novocure, and GSK, all outside of the submitted work. Haruko Daga has received personal fee from AstraZeneca, outside of the submitted work. Hironori Yoshida has received grant from AstraZeneca and personal fees from Chugai Pharmaceutical, AstraZeneca, MSD, Takeda Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, and Taiho Pharmaceutical, all outside of the submitted work. Satoshi Hirano has received personal fee from AstraZeneca, outside of the submitted work. Haruhiko Fukuda has received grants from the National Cancer Center Research and Development Fund, AstraZeneca, Ono Pharmaceutical, Chugai Pharmaceutical, and Takeda Pharmaceutical and personal fees from Kyowa Kirin, Chugai Pharmaceutical, and CMIC, all outside of the submitted work. Isamu Okamoto has received grants from AstraZeneca, Chugai Pharmaceutical, MSD, Daiichi Sankyo, Bristol-Myers Squibb, Boehringer Ingelheim, AbbVie, Amgen, Taiho Pharmaceutical, GSK, Parexel, EPS, PPD, and Syneos and personal fees from AstraZeneca, Chugai Pharma, Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Nippon Boehringer Ingelheim, Pfizer, Taiho Pharmaceutical, Eli Lilly, Novartis, Takeda Pharmaceutical, Nippon Kayaku, Amgen, Thermo Fisher Scientific, and Daiichi Sankyo, all outside of the submitted work. Toshiaki Takahashi has received grants from the National Cancer Center Research and Development Fund and Japan Agency for Medical Research and Development during the conduct of the study, AstraZeneca, MSD, AnHeart Therapeutics, Janssen Pharmaceutical, and Amgen; consulting fees from Nippon Kayaku; and personal fees from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, MSD, Janssen Pharmaceutical, Pfizer, Taiho Pharmaceutical, Eli Lilly, Amgen, Daiichi Sankyo, and Bristol-Myers Squibb, all outside of the submitted work.

PMID 42636548 · 2026

Community health assessment and monitoring in the pharmacy (CHAMP): Protocol for a randomized stepped-wedge trial of lung cancer screening in community pharmacies.

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jill Kolesar is the founder of Helix Diagnostics and VesiCure Technologies. In addition, she has received funding support to the institution from Eli Lilly and ArtemiLife. Robert Nichols is an independent contractor for Gilead Sciences, Inc. for which he receives honoraria related to advisory board participation. Kalpaj Parekh is on the scientific advisory board for Tract Bio and Therakos.

PMID 42580402 · 2026
01

Current Standard-of-Care Sources

Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.

02

Highest-Priority Research

clinical guideline

[Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua yi xue za zhi · 2026

To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)" through a consensus conference. Compared with the 2025 edition, the 2026 edition incorporates updates and refinements in several as…

PMID 42763208
clinical guideline

[Chinese expert consensus on the clinical application of lung biopsy in interstitial lung disease].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2026

Interstitial lung disease (ILD) comprises a highly heterogeneous group of pulmonary disorders, whose diagnosis often requires the integration of clinical, radiologic, and pathologic evidence. Lung biopsy is a key method for obtaining a histopathologic diagnosis, but unified standards are lacking for determining indications, selecting biopsy techniques, managing patients perioperatively, and integrating pathologic and clinical information. To address these gaps, the Respiratory Physicians Branch of the Chinese Medical Doctor Association and the ILD Group of the Chinese Thoracic Society spearheaded this initiative, collaborating with national experts in respiratory medicine, radiology, patholo…

PMID 42811563
clinical guideline

[Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026

To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)" through a consensus conference. Compared with the 2025 edition, the 2026 edition incorporates updates and refinements in several as…

PMID 42764215
clinical guideline

SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.

Archivos de bronconeumologia · 2026

Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both preoperative and intraoperative mediastinal staging. The recommendations were developed through a structured review of the literature and multidisciplinary expert consensus. This do…

PMID 42276952
clinical guideline

SEPAR-SECT recommendations for perioperative invasive mediastinal staging of non-small cell lung cancer.

Cirugia espanola · 2026

Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both preoperative and intraoperative mediastinal staging. The recommendations were developed through a structured review of the literature and multidisciplinary expert consensus. This do…

PMID 42373333
clinical guideline

ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026

PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains limited. This ESTRO- clinical practice guideline aims to provide expert consensus recommendations for high-dose thoracic reirradiation in NSCLC based on the available literature an…

PMID 42468604
meta analysisn=1569

Effects of enhanced recovery after surgery and prehabilitation interventions on postoperative outcomes after lung resection in patients with lung cancer: a systematic review and meta-analysis.

Frontiers in public health · 2026

INTRODUCTION: Lung resection is the standard curative treatment for resectable lung cancer; however, postoperative pulmonary complications (PPCs) and prolonged hospital length of stay (LOS) remain major barriers to recovery and healthcare efficiency. Enhanced recovery after surgery (ERAS) and prehabilitation are distinct perioperative strategies that differ in their timing, intervention components, and mechanisms of action, but both aim to optimize patients' perioperative condition and improve postoperative recovery. However, their effectiveness compared with conventional perioperative care based solely on randomized controlled trials (RCTs) has not been comprehensively synthesized. OBJECTIV…

PMID 42898494
meta analysisn=4875

Machine Learning, Radiomics, and Clinical Models Predicting Checkpoint Inhibitor Pneumonitis in Lung Cancer: A Systematic Review and Meta-analysis.

Journal of visualized experiments : JoVE · 2026

Checkpoint inhibitor pneumonitis (CIP) is a potentially fatal immune-related adverse event of immune checkpoint inhibitor (ICI) therapy in lung cancer, and many machine-learning (ML), computed tomography (CT) radiomics, deep-learning, and clinical models have been proposed to predict it. This systematic review searched PubMed, Embase, Web of Science, CINAHL, and SinoMed, supplemented by citation searching and other sources, with independent dual-reviewer screening throughout and a reproducible PubMed verification search updated to August 16, 2026. Twelve peer-reviewed lung-cancer CIP-occurrence models (4,875 patients, 1,057 events) formed the main analysis; validation C-statistics were poole…

PMID 42872743
clinical guideline

Guideline for the Comprehensive Perioperative Management of Older Patients With Lung Cancer (2025).

Journal of evidence-based medicine · 2026

With the accelerating population aging, the number of older adult patients with lung cancer continues to increase. These patients often present with multiple chronic diseases and geriatric syndromes, resulting in more complex perioperative management and significantly increased surgical risks. This guideline was developed and reported on the basis of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system and the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. Focusing on 28 key clinical issues commonly encountered among older adults with lung cancer, such as frailty, malnutrition, and falls, a total of 55 recommendations were formulated.…

PMID 42576681
clinical guideline

The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.

The Annals of thoracic surgery · 2026

BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing literature on this topic. A modified Delphi method, with boundaries and thresholds determined a priori, was used until 75% agreement on the statements was reached. RESULTS: The panel ide…

PMID 42320552
clinical guideline

[Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026

To promote the standardization of clinical diagnosis and treatment of lung cancer in China and to apply the latest evidence-based medical evidence to clinical practice, since 2018, the Department of Respiratory and Critical Care Medicine of Shanghai Chest Hospital has taken the lead, in collaboration with more than 50 lung cancer treatment institutions and over 100 experts nationwide, to jointly draft the clinical practice guidelines for lung cancer, with annual updates. The newly added recommendations are primarily based on indications approved by the National Medical Products Administration of China. To enhance the practicality of the guideline, particular emphasis has been placed on adopt…

PMID 42927946
clinical guideline

ACR Appropriateness Criteria® Indolent Lung Cancer.

Journal of the American College of Radiology : JACR · 2026

Persistent or slow-growing subsolid nodules and atypical lung cysts often represent indolent forms of lung cancer. These nodules require careful assessment by a multidisciplinary tumor board to determine risk, natural history, treatment options, and patient preferences. When the preferred management is imaging surveillance rather than active intervention, the main objective is to detect significant changes that could alter patient management. The choice of imaging modality should be based on its accuracy and whether the findings will influence the decision to pursue treatment. If the team determines that treatment is necessary, a diagnostic imaging workup and a biopsy are typically indicated…

PMID 42573542
03

Latest Research — Last 24 Months

04

Treatment Options Studied in the PubMed Collection

These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.

preliminary evidence

surgery

77 linked PMIDs32132 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, quality of life, mortality, recurrence, adverse events, response rate
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; early-stage lung cancer; early-stage; metastatic; EGFR; non-small cell lung cancer; small cell lung cancer; advanced; first-line; EGFR; ALK; KRAS G12C; MET; non-small cell lung cancer; small cell lung cancer; metastatic
Mechanism
Intraoperative strategies, including individualised PEEP titration and erector spinae plane blocks, offer safer alternatives to traditional methods The tumors, lungs, and peritumoral muscle tissues of tumor-bearing mice were surgically removed and incubated with a probe targeting epidermal growth factor receptor (EGFR) for 20 min, and then imaged by a closed-field near-infrared two-zone (NIR-II) fluorescence imaging system
PMID 36480027PMID 36538106PMID 41331231PMID 36627538PMID 37129681PMID 42878898PMID 37540406PMID 42959248
limited evidence

Antineoplastic Agents

60 linked PMIDs43012 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, adverse events, objective response rate, response rate, mortality, progression-free survival, quality of life
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; EGFR; metastatic; non-small cell lung cancer; small cell lung cancer; EGFR; advanced
Mechanism
Besides the C2 also inhibits Topoisomerase II activity in a dose-dependent manner as envisaged by the kDNA decatenation assay Here, we investigate the possibility of a dual-metal targeting strategy using deferasirox (Def), a clinically approved iron chelator, and its titanium(IV) complex, Ti(Def)₂, to disrupt Cu and Fe homeostasis through intracellular transmetalation
PMID 39162830PMID 42398138PMID 41566873PMID 42161101PMID 42635425PMID 42019416PMID 42520532PMID 37058176
moderate-confidence evidence

Biomarkers, Tumor

57 linked PMIDs6016 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, mortality, progression-free survival, recurrence, adverse events, response rate
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; metastatic; localized; EGFR; advanced
Mechanism
Mechanistically, this editing event, mediated by ADAR2, potentially inhibits VPS41 expression by strengthening miR‑3170 binding This study aimed to identify distinct molecular subtypes and establish a robust prognostic signature for LUAD, while exploring potential therapeutic targets associated with cisplatin resistance
PMID 38485857PMID 42596913PMID 41714836PMID 41810845PMID 37847361PMID 42531972PMID 42766897PMID 42716332
preliminary evidence

Immune Checkpoint Inhibitors

41 linked PMIDs120386 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, adverse events, overall survival, response rate, mortality, progression-free survival, pneumonitis, quality of life
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; metastatic; non-small cell lung cancer; small cell lung cancer; PD-L1
Mechanism
Immune checkpoint inhibitors (ICIs) targeting PD-1 frequently cause severe cardiotoxicity, yet the mechanisms involving tumor-host crosstalk remain poorly defined Targeting ferroptosis or its upstream regulators presents a promising cardioprotective strategy for patients receiving cancer immunotherapy
PMID 38372773PMID 42909010PMID 41634558PMID 42520532PMID 38499799PMID 42949492PMID 38507020PMID 39369455
limited evidence

MicroRNAs

37 linked PMIDs78 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, mortality, overall survival
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; metastatic
Mechanism
By systematically integrating mechanistic and regulatory evidence, this review provides a framework for understanding miRNA dysregulation in IPF and LC, with direct implications for biomarker validation and therapeutic targeting Immune checkpoint inhibitors (ICIs) targeting PD-1 frequently cause severe cardiotoxicity, yet the mechanisms involving tumor-host crosstalk remain poorly defined
PMID 42586526PMID 38485857PMID 42938362PMID 36867268PMID 42949492PMID 42958458PMID 39585455PMID 39390216
limited evidence

ErbB Receptors

28 linked PMIDs16909 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, adverse events, quality of life, progression-free survival
Populations represented
EGFR; non-small cell lung cancer; small cell lung cancer; EGFR; non-small cell lung cancer; small cell lung cancer; advanced; EGFR; non-small cell lung cancer; small cell lung cancer; locally advanced; advanced; metastatic; first-line
Mechanism
Pharmacogenomic analysis identified ZLN005, a peroxisome proliferator‑activated receptor γ coactivator‑1α agonist, as a candidate metabolic modulator that synergized with osimertinib to reduce persister cell viability Mechanistically, ZLN005 enhanced mitochondrial oxidative metabolism and reactive oxygen species accumulation, leading to caspase‑3 activation and gasdermin E‑associated pyroptotic cell death
PMID 42757482PMID 42702441PMID 42833150PMID 42858020PMID 42420595PMID 38470555PMID 36044117PMID 37707774
preliminary evidence

radiotherapy

27 linked PMIDs15269 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, reported clinical outcomes, progression-free survival, quality of life, adverse events, local control, objective response rate, response rate
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; PD-L1; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; metastatic; first-line; second-line; PD-L1
Mechanism
Nur77 and Ku80 extranuclear co-localization in the 10E-treated A549 cells suggested that 10E-modulated Nur77 nuclear exportation inhibits DNA damage repair pathways and increases IR-triggered apoptosis The combination of 10E and IR significantly inhibits tumor growth in a tumor xenograft model
PMID 42613912PMID 37043012PMID 42893060PMID 42315464PMID 42251228PMID 38584217PMID 42251230PMID 42413815
limited evidence

Protein Kinase Inhibitors

23 linked PMIDs621 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, adverse events
Populations represented
EGFR; non-small cell lung cancer; small cell lung cancer; EGFR; general population; non-small cell lung cancer; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; MET; non-small cell lung cancer; small cell lung cancer; EGFR; MET
Mechanism
Pharmacogenomic analysis identified ZLN005, a peroxisome proliferator‑activated receptor γ coactivator‑1α agonist, as a candidate metabolic modulator that synergized with osimertinib to reduce persister cell viability Mechanistically, ZLN005 enhanced mitochondrial oxidative metabolism and reactive oxygen species accumulation, leading to caspase‑3 activation and gasdermin E‑associated pyroptotic cell death
PMID 42757482PMID 42833150PMID 42420595PMID 38470555PMID 42341853PMID 38969770PMID 35780205PMID 41459935
preliminary evidence

EGFR protein, human

19 linked PMIDs16601 reported cumulative sample signal
Research status
mostly supportive
Outcomes represented
reported clinical outcomes, adverse events, overall survival, progression-free survival
Populations represented
EGFR; non-small cell lung cancer; small cell lung cancer; EGFR; non-small cell lung cancer; small cell lung cancer; advanced; EGFR
Mechanism
Pharmacogenomic analysis identified ZLN005, a peroxisome proliferator‑activated receptor γ coactivator‑1α agonist, as a candidate metabolic modulator that synergized with osimertinib to reduce persister cell viability Mechanistically, ZLN005 enhanced mitochondrial oxidative metabolism and reactive oxygen species accumulation, leading to caspase‑3 activation and gasdermin E‑associated pyroptotic cell death
PMID 42757482PMID 42702441PMID 42833150PMID 42858020PMID 42420595PMID 38470555PMID 37707774PMID 42341853
limited evidence

Proto-Oncogene Proteins c-akt

16 linked PMIDs— reported cumulative sample signal
Research status
harm signal
Outcomes represented
reported clinical outcomes, overall survival
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; PD-L1; metastatic
Mechanism
Mechanistically, we observed that ECT2 knockdown could inhibit the AKT/mTOR pathway and activate apoptosis, while ECT2 overexpression induced the opposite effect However, its precise mechanism of action remains unclear
PMID 36867268PMID 36695419PMID 36790693PMID 42825378PMID 37479901PMID 38726826PMID 36040682PMID 36056253
preliminary evidence

B7-H1 Antigen

15 linked PMIDs7161 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival, objective response rate, response rate, adverse events
Populations represented
non-small cell lung cancer; small cell lung cancer; PD-L1; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; treatment-naive; PD-L1
Mechanism
Immune checkpoint blockade targeting the PD-1/PD-L1 axis has improved the treatment of non-small cell lung cancer (NSCLC), yet its therapeutic efficacy remains limited by insufficient antitumor immune activation Herein, we developed a biomimetic manganese-amplified STING nanoagonist to potentiate PD-L1 blockade immunotherapy
PMID 42462537PMID 42566931PMID 36795259PMID 38597996PMID 37555904PMID 42958183PMID 42955441PMID 42912151
limited evidence

Cisplatin

14 linked PMIDs356 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival, objective response rate, response rate, adverse events, quality of life
Populations represented
general population; non-small cell lung cancer; small cell lung cancer; small cell lung cancer; advanced; metastatic; treatment-naive; small cell lung cancer; PD-L1; advanced; metastatic; first-line
Mechanism
This study aimed to identify distinct molecular subtypes and establish a robust prognostic signature for LUAD, while exploring potential therapeutic targets associated with cisplatin resistance Cisplatin resistance remains a primary challenge in the clinical management of non-small-cell lung cancer (NSCLC), yet the regulatory targets underlying this resistance remain largely unknown
PMID 42958320PMID 42958928PMID 42680101PMID 37833562PMID 39500874PMID 39042337PMID 36056253PMID 41858068
preliminary evidence

osimertinib

13 linked PMIDs16683 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, adverse events, overall survival, progression-free survival
Populations represented
EGFR; non-small cell lung cancer; small cell lung cancer; EGFR; non-small cell lung cancer; small cell lung cancer; first-line; EGFR; non-small cell lung cancer; small cell lung cancer; locally advanced; advanced; metastatic; first-line; non-small cell lung cancer; small cell lung cancer; EGFR; MET
Mechanism
Pharmacogenomic analysis identified ZLN005, a peroxisome proliferator‑activated receptor γ coactivator‑1α agonist, as a candidate metabolic modulator that synergized with osimertinib to reduce persister cell viability Mechanistically, ZLN005 enhanced mitochondrial oxidative metabolism and reactive oxygen species accumulation, leading to caspase‑3 activation and gasdermin E‑associated pyroptotic cell death
PMID 42757482PMID 42964983PMID 42698678PMID 42648586PMID 38824269PMID 38300281PMID 40481213PMID 41723914
preliminary evidence

CD274 protein, human

11 linked PMIDs7161 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival, objective response rate, response rate, adverse events
Populations represented
PD-L1; non-small cell lung cancer; small cell lung cancer; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; treatment-naive; PD-L1
Mechanism
METHODS: We obtained the active components and specific targets of semen coicis in the treatment of NSCLC from various databases, namely TCMSP, GeneCard, and OMIM Its primary targets include PIK3R1, PIK3CD, PIK3CA, AKT2, and mTOR
PMID 42958183PMID 42955441PMID 42912151PMID 38554191PMID 42566931PMID 38597996PMID 42843316PMID 33142852
limited evidence

Phosphatidylinositol 3-Kinases

11 linked PMIDs— reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes
Populations represented
general population; non-small cell lung cancer; small cell lung cancer
Mechanism
Nrf2/HO-1, PI3K/Akt, NF-κB, STAT3, MAPKs, TLR4, and NLRP3 are important targets in the pulmonary therapeutic effects of BIA on different lung disease models However, its precise mechanism of action remains unclear
PMID 37725153PMID 36867268PMID 36695419PMID 36790693PMID 37479901PMID 38726826PMID 36040682PMID 41858068
preliminary evidence

Programmed Cell Death 1 Receptor

10 linked PMIDs3969 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, disease-free survival, overall survival, objective response rate, response rate, adverse events, progression-free survival
Populations represented
general population; PD-L1; non-small cell lung cancer; small cell lung cancer; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; first-line; second-line; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; PD-L1; non-small cell lung cancer; small cell lung cancer
Mechanism
Immune checkpoint inhibitors (ICIs) targeting PD-1 frequently cause severe cardiotoxicity, yet the mechanisms involving tumor-host crosstalk remain poorly defined Targeting ferroptosis or its upstream regulators presents a promising cardioprotective strategy for patients receiving cancer immunotherapy
PMID 42909010PMID 42949492PMID 36577929PMID 41787604PMID 38554191PMID 39542906PMID 42838248PMID 42331381
preliminary evidence

Antibodies, Monoclonal, Humanized

10 linked PMIDs607 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, objective response rate, response rate, adverse events, reported clinical outcomes
Populations represented
non-small cell lung cancer; small cell lung cancer; advanced; metastatic; PD-L1; advanced; metastatic; treatment-naive; non-small cell lung cancer; small cell lung cancer; advanced; first-line; treatment-naive; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; non-small cell lung cancer; small cell lung cancer; stage II; non-small cell lung cancer; small cell lung cancer; advanced; PD-L1
Mechanism
Additionally, while prior studies documented that IgG Ab responses to TAA can identify targets of a coordinated T and B cell response and evidence of immune surveillance, this study found that high autoantibody responses, while not statistically significant, trended toward a worse outcome (p = 0.06) Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma
PMID 42127535PMID 41871716PMID 42216493PMID 41949826PMID 42003237PMID 42126144PMID 41732954PMID 42485106
preliminary evidence

pembrolizumab

10 linked PMIDs142 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, progression-free survival, objective response rate, response rate, adverse events, overall survival
Populations represented
non-small cell lung cancer; small cell lung cancer; metastatic; PD-L1; metastatic; advanced; metastatic; treatment-naive; non-small cell lung cancer; small cell lung cancer; metastatic; non-small cell lung cancer; small cell lung cancer; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; first-line
Mechanism
The ICI mechanism of action involves the blockade of regulatory cell surface molecules using antibodies against the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) (ipilimumab, tremelimumab); the programmed death receptor-1 (PD-1; nivolumab, pembrolizumab); or the PD ligand-1 (PD-L1; atezolizumab, durvalumab) Antibodies targeted against immune checkpoint inhibitors such as anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-CTLA-4 antibodies (e.g., Ipilimumab), and experimental drugs targeting LAG-3 and TIM-3, aim to block these interactions and unleash the immune system's ability to recognise and destroy cancer cells
PMID 42967173PMID 37801207PMID 38869298PMID 38158454PMID 41871716PMID 41949826PMID 42126144PMID 41732954
05

Conflicting Research

higher-confidence evidence

surgery · multiple reported outcomes

60 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
null: 11unknown: 46benefit: 1harm: 2
PMID 36348163PMID 42171981PMID 37256368PMID 42928436PMID 39141212PMID 41369813PMID 41794665PMID 42922101PMID 41851742PMID 41800747
higher-confidence evidence

Biomarkers, Tumor · multiple reported outcomes

41 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
null: 1unknown: 36harm: 2mixed: 2
PMID 39141212PMID 38485857PMID 36939982PMID 41320620PMID 42958123PMID 42596913PMID 41714836PMID 41810845PMID 42706728PMID 42149699
higher-confidence evidence

radiotherapy · multiple reported outcomes

29 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 23null: 2benefit: 3harm: 1
PMID 42613912PMID 42171981PMID 37043012PMID 37256368PMID 41921748PMID 41850745PMID 42935767PMID 38536558PMID 42893060PMID 42315464
higher-confidence evidence

surgery · multiple reported outcomes

20 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 17benefit: 1harm: 1null: 1
PMID 42276952PMID 42373333PMID 39734193PMID 37566187PMID 35000034PMID 38836904PMID 35066744PMID 42587156PMID 36064979PMID 42010447
limited evidence

Immune Checkpoint Inhibitors · multiple reported outcomes

17 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 14benefit: 2harm: 1
PMID 42872743PMID 42702183PMID 42613912PMID 42805242PMID 42930170PMID 38372773PMID 42909010PMID 38366007PMID 41634558PMID 42520532
limited evidence

ErbB Receptors · multiple reported outcomes

15 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer; EGFR. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 13harm: 1benefit: 1
PMID 38824269PMID 38300281PMID 27738317PMID 40481213PMID 42697283PMID 42965610PMID 42363408PMID 36790603PMID 42501451PMID 42742903
limited evidence

EGFR protein, human · multiple reported outcomes

11 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer; EGFR. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 9harm: 1benefit: 1
PMID 38824269PMID 38300281PMID 27738317PMID 40481213PMID 42697283PMID 42965610PMID 42363408PMID 42501451PMID 42742903PMID 42360721
higher-confidence evidence

Biomarkers, Tumor · multiple reported outcomes

10 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 8benefit: 1null: 1
PMID 31083179PMID 41049426PMID 39041844PMID 38837024PMID 42587156PMID 42802302PMID 42722534PMID 42679737PMID 39808355PMID 42947476
limited evidence

B7-H1 Antigen · multiple reported outcomes

9 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer; PD-L1. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 7benefit: 1mixed: 1
PMID 39542906PMID 42891757PMID 42462537PMID 42566931PMID 38421562PMID 36795259PMID 38597996PMID 37555904PMID 36759371
limited evidence

osimertinib · multiple reported outcomes

8 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer; EGFR. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 6harm: 1benefit: 1
PMID 38824269PMID 38300281PMID 40481213PMID 36790603PMID 42612716PMID 42742903PMID 37831111PMID 35449204
limited evidence

ErbB Receptors · multiple reported outcomes

6 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer; advanced; EGFR. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
harm: 1null: 1unknown: 4
PMID 42887461PMID 37610516PMID 42464567PMID 38916849PMID 38864966PMID 38941043
limited evidence

CD274 protein, human · multiple reported outcomes

5 studies

Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer; PD-L1. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 3benefit: 1mixed: 1
PMID 39542906PMID 42891757PMID 42566931PMID 38421562PMID 38597996
06

Failed or Negative Trials

07

Emerging and Experimental Research

08

Evidence Gaps

Detailed risk-of-bias assessment remains limited

PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.

R

Complete Ranked PubMed Index

The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.

Current Standard Of Care73 records
Rank112.0
Clinical guideline or consensus statement

[Chinese expert consensus on the clinical application of lung biopsy in interstitial lung disease].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2026 · PMID 42811563

Interstitial lung disease (ILD) comprises a highly heterogeneous group of pulmonary disorders, whose diagnosis often requires the integration of clinical, radiologic, and pathologic evidence. Lung biopsy is a key method for obtaining a histopathologic diagnosis, but unified standards are lacking for determining indications, selecting biopsy techniques, managing patients perioperatively, and integrating pathologic and clinical information. To address these gaps, the Respiratory Physicians Branch of the Chinese Medic…

Rank112.0
Clinical guideline or consensus statement

[Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 42764215

To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagno…

Rank112.0
Clinical guideline or consensus statement

SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.

Archivos de bronconeumologia · 2026 · PMID 42276952

Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…

Rank112.0
Clinical guideline or consensus statement

[Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua yi xue za zhi · 2026 · PMID 42763208

To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagno…

Rank112.0
Clinical guideline or consensus statement

SEPAR-SECT recommendations for perioperative invasive mediastinal staging of non-small cell lung cancer.

Cirugia espanola · 2026 · PMID 42373333

Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…

Rank112.0
Clinical guideline or consensus statement

ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42468604

PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains …

Rank110.4
Systematic review or meta-analysis

Machine Learning, Radiomics, and Clinical Models Predicting Checkpoint Inhibitor Pneumonitis in Lung Cancer: A Systematic Review and Meta-analysis.

Journal of visualized experiments : JoVE · 2026 · PMID 42872743

Checkpoint inhibitor pneumonitis (CIP) is a potentially fatal immune-related adverse event of immune checkpoint inhibitor (ICI) therapy in lung cancer, and many machine-learning (ML), computed tomography (CT) radiomics, deep-learning, and clinical models have been proposed to predict it. This systematic review searched PubMed, Embase, Web of Science, CINAHL, and SinoMed, supplemented by citation searching and other sources, with independent dual-reviewer screening throughout and a reproducible PubMed verification s…

Rank110.0
Clinical guideline or consensus statement

ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.

The European respiratory journal · 2026 · PMID 42167778

BACKGROUND: In lung cancer, adequate treatment selection relies on accurate diagnosis and staging. Tissue sampling is generally indicated. This guideline explores the role of endosonography via the major airways (endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)) and oesophagus (endoscopic transoesophageal ultrasound-guided fine-needle aspiration (EUS-FNA)). EUS-FNA can also be performed using an EBUS scope (EUS-B-FNA). METHODS: Task force members were selected from the European Respirato…

Rank110.0
Clinical guideline or consensus statement

Guideline for the Comprehensive Perioperative Management of Older Patients With Lung Cancer (2025).

Journal of evidence-based medicine · 2026 · PMID 42576681

With the accelerating population aging, the number of older adult patients with lung cancer continues to increase. These patients often present with multiple chronic diseases and geriatric syndromes, resulting in more complex perioperative management and significantly increased surgical risks. This guideline was developed and reported on the basis of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system and the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. F…

Rank110.0
Clinical guideline or consensus statement

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42372216

[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates a…

Rank110.0
Clinical guideline or consensus statement

[Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 42927946

To promote the standardization of clinical diagnosis and treatment of lung cancer in China and to apply the latest evidence-based medical evidence to clinical practice, since 2018, the Department of Respiratory and Critical Care Medicine of Shanghai Chest Hospital has taken the lead, in collaboration with more than 50 lung cancer treatment institutions and over 100 experts nationwide, to jointly draft the clinical practice guidelines for lung cancer, with annual updates. The newly added recommendations are primaril…

Rank110.0
Clinical guideline or consensus statement

The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.

The Annals of thoracic surgery · 2026 · PMID 42320552

BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…

Rank110.0
Clinical guideline or consensus statement

ACR Appropriateness Criteria® Indolent Lung Cancer.

Journal of the American College of Radiology : JACR · 2026 · PMID 42573542

Persistent or slow-growing subsolid nodules and atypical lung cysts often represent indolent forms of lung cancer. These nodules require careful assessment by a multidisciplinary tumor board to determine risk, natural history, treatment options, and patient preferences. When the preferred management is imaging surveillance rather than active intervention, the main objective is to detect significant changes that could alter patient management. The choice of imaging modality should be based on its accuracy and whethe…

Rank105.4
Systematic review or meta-analysis

Complete Resection of Simultaneous Hepatic and Pulmonary Metastases from Colorectal Cancer in the Era of Modern Systemic and Surgical Therapies: A Systematic Review and Meta-Analysis.

Annals of surgical oncology · 2026 · PMID 42632879

BACKGROUND: Data suggest promising outcomes with resection of simultaneous hepato-pulmonary metastases (HPM) from metastatic colorectal cancer (mCRC). However, there is no consensus regarding the effectiveness of this approach. Therefore, we aimed to evaluate the feasibility and clinical benefit of metastasectomy of simultaneous HPM from mCRC. METHODS: A systematic review and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, inclu…

Rank102.9
Systematic review or meta-analysis

The effect of mind-body exercise in lung cancer patients: a meta-analysis of RCTs.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 37870600

PURPOSE: This study aimed to evaluate the impact of mind-body exercise (yoga, tai chi, qigong, etc.) on lung cancer. METHODS: We performed a literature search of the electronic databases PubMed, Web of Science, Cochrane Library, Embase, CNKI, CBM, WanFang Data, and VIP from their inception to 16 May 2023. The primary outcome was the 6-min walk test (6MWT), while the secondary outcomes were anxiety levels and quality of life (QoL). Two independent reviewers performed the data extraction using a predefined protocol a…

Rank102.6
Systematic review or meta-analysis

Quality in Central Pathology Assessment in Pulmonary Carcinoid and Large Cell Neuroendocrine Carcinoma: A Systematic Review.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026 · PMID 42556470

Accurate pathology classification of lung neuroendocrine neoplasms can be challenging, particularly in small biopsies, resulting in substantial interobserver variability. To overcome this issue, central pathology review is frequently used in clinical and translational studies to improve diagnostic accuracy, but its methodology and impact remain poorly characterized. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and pros…

Rank100.0
Systematic review or meta-analysis

Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.

Cancer nursing · 2026 · PMID 39888667

BACKGROUND: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness. OBJECTIVE: To examine the effectiveness of patient…

Rank96.0
Systematic review or meta-analysis

Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol.

BMJ open · 2026 · PMID 42642084

INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with substantial variations in incidence, stage at diagnosis and outcomes across regions. High-quality, standardised diagnosis and treatment are essential to improving survival and quality of life. Multidisciplinary care (MDC) is a cornerstone of cancer care; however, its implementation faces barriers such as limited resources, uneven policy support and inequitable access to specialised care, particularly in low- and middle-income cou…

Rank96.0
Systematic review or meta-analysis

Nanotechnology-Enabled Immunotherapy for Colorectal Cancer: Overcoming the "Cold" Tumor Microenvironment in Microsatellite-Stable Disease.

International journal of nanomedicine · 2026 · PMID 42928874

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), yet the ~95% of patients with mismatch repair-proficient/microsatellite-stable (pMMR/MSS) disease derive little benefit owing to an immunologically "cold" tumor microenvironment (TME), poor T-cell infiltration, myeloid dominance, TGF-β-enriched stroma, and the systemically immunosuppressive milieu imposed by hepatic metastases. Clinically …

Rank81.8
Multicenter clinical study

PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study.

European journal of nuclear medicine and molecular imaging · 2024 · PMID 37725128

PURPOSE: No consensus on a grading system for invasive lung adenocarcinoma had been built over a long period of time. Until October 2020, a novel grading system was proposed to quantify the whole landscape of histologic subtypes and proportions of pulmonary adenocarcinomas. This study aims to develop a deep learning grading signature (DLGS) based on positron emission tomography/computed tomography (PET/CT) to personalize surgical treatments for clinical stage I invasive lung adenocarcinoma and explore the biologic …

Rank79.3
Multicenter clinical study

Artificial Intelligence-Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer: An International Multicenter Cohort Study.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42715648

BACKGROUND: Pathologic response (PR), expressed as the percentage of residual viable tumor (%RVT), has emerged as a surrogate endpoint after neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC). However, PR assessment remains subject to interobserver variability and is insufficiently standardized across institutions and clinical trials. We hypothesized that artificial intelligence (AI)-based %RVT scoring would be concordant with expert manual assessment and consistent across real-world, multi-scanne…

Rank53.0
Other PubMed-indexed publication

Salivary Glycoprofiling via a Machine Learning-Augmented Lectin Microarray for Noninvasive Risk Stratification of Lung Cancer.

Journal of proteome research · 2026 · PMID 42918128

Although aberrant glycosylation is closely associated with lung cancer (LC), salivary glycopatterns and their discriminatory value across healthy individuals, benign pulmonary disease, and LC remain insufficiently characterized. We profiled saliva from 307 participants using a lectin microarray, comprising a development cohort of 227 participants and an independent test cohort of 80 participants. Five task-specific LASSO-logistic regression models were constructed to distinguish pulmonary disease, LC, and LC subtyp…

Rank49.4
Other PubMed-indexed publication

Optimal timing of two-stage pulmonary metastasectomy for synchronous bilateral colorectal pulmonary metastases: A time-dependent survival analysis.

Surgical oncology · 2026 · PMID 42561871

BACKGROUND: Synchronous bilateral colorectal pulmonary metastases (CPM) present a surgically complex scenario in which two-stage video-assisted thoracoscopic surgery (VATS) is increasingly practised. The optimal inter-VATS interval remains undefined, and conventional analyses of this question are vulnerable to both selection bias and immortal time bias. We aimed to characterize the continuous, non-linear relationship between the inter-VATS interval and overall survival (OS) using three complementary bias-corrected …

Rank48.5
Other PubMed-indexed publication

Deep learning reconstruction for chest MRI: image quality and diagnostic agreement with CT.

European journal of radiology · 2026 · PMID 42314619

PURPOSE: To evaluate whether deep learning reconstruction (DLR) improves chest magnetic resonance imaging (MRI) image quality and to assess the agreement between DLR MRI and computed tomography (CT) for characterization of known pulmonary lesions. METHODS: This prospective study included 54 patients with CT-visible pulmonary lesions who underwent 3.0-T chest MRI between September 2022 and September 2024. T2-weighted imaging with fat suppression and unenhanced/enhanced three-dimensional liver acquisition with volume…

Diagnosis And Screening305 records
Rank109.9
Systematic review or meta-analysis

Accuracy of the COMPASS-CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis.

Journal of thrombosis and thrombolysis · 2024 · PMID 38981978

OBJECTIVE: This systematic review aims to assess the accuracy of the COMPASS-CAT tool in predicting venous thromboembolism (VTE) among cancer patients. METHODS: Relevant studies were searched in PubMed, Web of Science, The Cochrane Library, Embase, CINAHL, OVID, CBM, CNKI, WanFang Data, and VIP database from their inception up to April 19, 2023. The quality of studies was appraised using the diagnostic test accuracy study bias assessment tool (QUADAS-2). Quantitative analysis was performed using Stata MP 17.0. RESU…

Rank107.1
Systematic review or meta-analysis

Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38869739

OBJECTIVE: This study aims to assess the diagnostic utility of circulating tumor cells (CTCs) in conjunction with low-dose computed tomography (LDCT) for differentiating between benign and malignant pulmonary nodules and to substantiate the foundation for their integration into clinical practice. METHODS: A systematic literature review was performed independently by two researchers utilizing databases including PubMed, Web of Science, The Cochrane Library, Embase, and Medline, to collate studies up to September 15,…

Rank106.4
Systematic review or meta-analysis

Adulthood interstitial lung disease due to variants in surfactant related genes: A systematic review.

Pulmonology · 2026 · PMID 42784242

Background: Surfactant-related gene (SRG) variants are an emerging cause of interstitial lung disease/pulmonary fibrosis (ILD/PF). Accurate recognition of these disorders is relevant for diagnosis, genetic counselling, and clinical management.Reaserch question: How do SRG-associated ILD/PF present in adults, and what clinical, radiological, and histopathological features characterize their phenotype?Study design and methods: We performed a systematic review (PROSPERO CRD42024517610) to describe the clinical feature…

Rank100.0
Systematic review or meta-analysis

The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38485857

BACKGROUND: Studies have shown that many exosomal microRNAs (miRNAs) can be used as non-invasive biomarkers of lung cancer, but their diagnostic and prognostic values need to be further clarified. METHODS: We conducted a systematic literature search in Web of Science, PubMed, and ScienceDirect databases, obtained relevant articles and extracted data, and used statistical methods and statistical software to comprehensively evaluate the diagnostic and prognostic value of exosomal miRNAs in lung cancer. REGISTRATION N…

Rank100.0
Systematic review or meta-analysis

Diagnostic Accuracy of Exosomal Long Noncoding RNAs in Diagnosis of NSCLC: A Meta-Analysis.

Molecular diagnosis & therapy · 2024 · PMID 38837024

PURPOSE: Globally, non-small cell lung cancer (NSCLC) is the primary cause of cancer-related mortality, both early and accurate diagnosis are essential for effective treatment and improved patient outcomes. Exosomal noncoding RNAs (ncRNAs) have emerged as promising biomarkers for NSCLC diagnosis. This meta-analysis aims to assess the diagnostic accuracy of exosomal long noncoding RNAs (lncRNAs) for diagnosing NSCLC. METHODS: A comprehensive literature search was conducted to identify relevant studies that assessed …

Rank100.0
Systematic review or meta-analysis

Primary Intrahepatic Mesothelioma: Case Series and Systematic Review of Literature.

Journal of gastrointestinal cancer · 2024 · PMID 39141212

BACKGROUND: Primary intrahepatic mesothelioma (PIHMM) has been rarely reported. Its typical clinical presentation, radiological features and pathology have not been defined. Here, we aimed to summarize its diagnosis and treatment. METHODS: We conducted a retrospective analysis of three cases of PIHMM in the First Affiliated Hospital of Zhejiang University School of Medicine and reviewed the current literature to investigate the clinical and pathological characteristics and prognosis of PIHMM. RESULTS: Based on our …

Rank100.0
Systematic review or meta-analysis

Efficacy and safety of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis.

Frontiers in oncology · 2026 · PMID 42952490

BACKGROUND: Antibody-drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) resistance. We evaluated their efficacy and safety in this setting. METHODS: PubMed, Embase,and the Cochrane Library were searched for prospective clinical studies. Overlapping reports were assessed before endpoint-specific synthesis. Comparable proportional outcomes from non-randomized studies were pooled using random-effects models, …

Rank100.0
Systematic review or meta-analysisResult signal: benefit

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.

Clinical & experimental metastasis · 2024 · PMID 39739072

Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-b…

Rank98.9
Systematic review or meta-analysis

Cancer Screening Behaviors among People with HIV in the United States and the Role of Multi-Level Social and Economic Factors: A Systematic Review.

Current epidemiology reports · 2026 · PMID 42694953

PURPOSE OF REVIEW: In the US, people with HIV (PWH) are more likely to be diagnosed with cancer at advanced stages, contributing to higher cancer-specific mortality rates. As such, the leading cause of non-AIDS death among PWH is cancer, including cancers with guideline recommended screening as a part of preventative care. Nonmedical drivers of health contribute to poor access to timely cancer screening among PWH. Thus, the purpose of this systematic review is to summarize the available evidence on the relationship…

Rank96.0
Systematic review or meta-analysis

[Lung cancer screening: new frontiers].

Radiologie (Heidelberg, Germany) · 2024 · PMID 38772915

CLINICAL/METHODICAL ISSUE: Lung cancer is the leading cause of cancer-related deaths worldwide. In early, asymptomatic stages, curative treatment is possible, but the disease is often diagnosed too late. STANDARD RADIOLOGICAL METHODS: Lung cancer screening (LCS) using low-dose computed tomography (LDCT) helps to detect potentially malignant lesions in early stages and to reduce lung cancer mortality. METHODOLOGICAL INNOVATIONS: The application of artificial intelligence (AI) algorithms enables a more precise analys…

Rank96.0
Systematic review or meta-analysis

Current status of various types of ICG contrast imaging in pediatric thoracic surgery.

Surgery today · 2026 · PMID 42455159

Indocyanine green (ICG) fluorescence imaging is an emerging intraoperative navigation tool. However, its application in pediatric thoracic surgery remains to be elucidated. This review evaluates the current status and clinical utility of ICG-based imaging techniques in the field. A narrative review of studies published between January 2015 and February 2026 was conducted using PubMed, Web of Science, and Cochrane Library. Relevant original articles, reviews, and case reports were included. Data were analyzed by foc…

Rank88.4
Randomized clinical studyResult signal: null

A deep learning model for translating CT to ventilation imaging: analysis of accuracy and impact on functional avoidance radiotherapy planning.

Japanese journal of radiology · 2024 · PMID 38536558

PURPOSE: Radiotherapy planning incorporating functional lung images has the potential to reduce pulmonary toxicity. Free-breathing 4DCT-derived ventilation image (CTVI) may help quantify lung function. This study introduces a novel deep-learning model directly translating planning CT images into CTVI. We investigated the accuracy of generated images and the impact on functional avoidance planning. MATERIALS AND METHODS: Paired planning CT and 4DCT scans from 48 patients with NSCLC were randomized to training (n = 4…

Rank85.0
Randomized clinical study

Screening for liver fibrosis: lessons from colorectal and lung cancer screening.

Nature reviews. Gastroenterology & hepatology · 2024 · PMID 38480849

Many countries have incorporated population screening programmes for cancer, such as colorectal and lung cancer, into their health-care systems. Cirrhosis is more prevalent than colorectal cancer and has a comparable age-standardized mortality rate to lung cancer. Despite this fact, there are no screening programmes in place for early detection of liver fibrosis, the precursor of cirrhosis. In this Perspective, we use insights from colorectal and lung cancer screening to explore the benefits, challenges, implementa…

Rank85.0
Randomized clinical study

Effect of Risedronate on Rib Cortical Thickness After Stereotactic Body Radiotherapy to Peripheral Lung Tumors: Results of a Randomized Phase 2 Trial.

JTO clinical and research reports · 2026 · PMID 42964859

INTRODUCTION: Stereotactic body radiotherapy (SBRT) to peripheral lung tumors is associated with radiation-induced bone effects that may predispose patients to chest wall pain and radiation-induced rib fractures. These effects may be inhibited by bisphosphonates. We aimed to determine the impact of risedronate on the radiologic biomarker of rib cortical thickness (CTh) in patients with peripheral lung tumors treated with SBRT. METHODS: This randomized, double-blind, placebo-controlled phase 2 clinical trial enrolle…

Rank85.0
Randomized clinical study

Characterizing the accuracy of robotic bronchoscopy in localization & targeting of small pulmonary lesions.

International journal of computer assisted radiology and surgery · 2024 · PMID 38890223

PURPOSE: Considering the recent implementation of lung cancer screening guidelines, it is crucial that small pulmonary nodules are accurately diagnosed. There is a significant need for quick, precise, and minimally invasive biopsy methods, especially for patients with small lung lesions in the outer periphery. Robotic bronchoscopy (RB) has recently emerged as a novel solution. The purpose of this study was to evaluate the accuracy of RB compared to the existing standard, electromagnetic navigational bronchoscopy (E…

Rank85.0
Randomized clinical study

Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis.

Naunyn-Schmiedeberg's archives of pharmacology · 2025 · PMID 39073415

In the course of clinical treatment for anti-tumor, the combination of traditional Chinese medicine (TCM) and other treatment schemes can reduce toxicity and increase efficiency. The purpose of this paper is to find out the key TCM and effective components for the treatment of non-small cell lung cancer (NSCLC) and analyze its therapeutic mechanism by analyzing the prescription of TCM combined with chemotherapy for NSCLC. Firstly, the prescriptions of TCM in the randomized controlled trials combined with chemothera…

Rank85.0
Randomized clinical study

PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026.

Journal of hematology & oncology · 2026 · PMID 42966842

PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall survival benefit with ivonescimab plus chemotherapy over tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer (NSCLC), extending survival evidence to an active PD-1-based fir…

Rank85.0
Randomized clinical study

Treatment of lung neuroendocrine tumors with 177Lu-DOTATATE: Experience from a Tertiary Oncology Center.

Revista espanola de medicina nuclear e imagen molecular · 2026 · PMID 41720218

PURPOSE: Evidence from randomized control trials supporting peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu DOTATATE in patients with lung neuroendocrine tumors (NETs) is limited. Real world data is needed. METHODS: We conducted a retrospective cohort study of patients with metastatic or unresectable lung carcinoid tumors treated with [177Lu]Lu-DOTATATE at a single Tertiary Oncology Center. Radiographic response (objective response rate - ORR; disease control rate - DCR), progression-free survival (PFS)…

Rank80.3
Multicenter clinical studyResult signal: mixed

Examined lymph node count as an independent predictive biomarker for adjuvant systemic therapy efficacy in stage IB lung adenocarcinoma.

BMC cancer · 2026 · PMID 42958123

BACKGROUND: Adjuvant systemic therapy (AST) utility for stage IB lung adenocarcinoma (LUAD) remains controversial due to the lack of objective metrics for staging adequacy. We aimed to establish an evidence-based threshold for "unknown nodal status" (Nx) and evaluate examined lymph node (ELN) count as a predictive biomarker for AST benefit. METHODS: Data from a multicenter cohort (N = 443) and SEER database (N = 4,636) were analyzed. Adjuvant systemic therapy (AST) in this study specifically referred to traditional…

Rank78.9
Multicenter clinical study

A decade of Non-Small Cell Lung Cancer management: threats and opportunities in resource-limited setting.

La Tunisie medicale · 2025 · PMID 41879698

INTRODUCTION: Non-small cell lung cancer (NSCLC) poses significant public health challenges in Tunisia.This study analyzes patient characteristics, management, and outcomes to identify improvement areas. METHODS: This retrospective multicenter study included 924 patients diagnosed with NSCLC between 2013 and 2022. The study reviewed clinical data, pathology reports, surgical records, radiation therapy summaries, and imaging findings. The study also examined trends in management features by dividing the study period…

Rank77.3
Multicenter clinical study

MRI-based intratumoral and peritumoral heterogeneity for predicting intracranial progression in EGFR-mutant lung adenocarcinoma patients with treatment-naive brain metastases receiving first-line third-generation EGFR-TKIs.

Journal of translational medicine · 2026 · PMID 42958288

PURPOSE: To develop and externally test a multiparametric MRI habitat-based framework integrating intratumoral heterogeneity (ITH), peritumoral heterogeneity (PTH), and clinical characteristics for predicting intracranial progression in patients with EGFR-mutant lung adenocarcinoma and de novo brain metastases receiving first-line third-generation (3rd-gen) EGFR-TKI monotherapy. MATERIALS AND METHODS: This retrospective multicenter study included patients with EGFR-mutant lung adenocarcinoma and de novo brain metas…

Rank77.2
Multicenter clinical study

Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer.

Medical oncology (Northwood, London, England) · 2026 · PMID 42932091

The aim of this study was to clarify the association between programmed death-ligand 1 (PD-L1) expression and the treatment efficacy of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs), particularly alectinib, in patients with advanced or recurrent ALK-positive non-small cell lung cancer (NSCLC). This multicenter retrospective cohort study involved 129 patients with advanced or recurrent ALK-positive NSCLC treated between July 2014 and December 2022 at 13 Japanese institutions. All patients had av…

Rank77.0
Phase II clinical trial

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

Oncoimmunology · 2026 · PMID 42126144

Retrospective characterization of cell‒cell relationships in the tumor microenvironment provides significantly better predictive power than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles. In this small study assessing the safety and possible efficacy of gemcitabine and pembrolizumab in immunotherapy-naïve patients with NSCLC who have received prior treatment, we investigated both standard and novel immune parameters in 16 enrolled patients (NCT03083808). The combination of gemcitabine …

Rank77.0
Multicenter clinical study

Prognostication of lung adenocarcinomas using CT-based deep learning of morphological and histopathological features: a retrospective dual-institutional study.

European radiology · 2024 · PMID 37861801

OBJECTIVES: To develop and validate CT-based deep learning (DL) models that learn morphological and histopathological features for lung adenocarcinoma prognostication, and to compare them with a previously developed DL discrete-time survival model. METHODS: DL models were trained to simultaneously predict five morphological and histopathological features using preoperative chest CT scans from patients with resected lung adenocarcinomas. The DL score was validated in temporal and external test sets, with freedom fro…

Rank77.0
Phase II clinical trial

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.

Oncoimmunology · 2026 · PMID 41732954

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treate…

Evidence Syntheses135 records
Rank112.0
Clinical guideline or consensus statement

[Chinese expert consensus on the clinical application of lung biopsy in interstitial lung disease].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2026 · PMID 42811563

Interstitial lung disease (ILD) comprises a highly heterogeneous group of pulmonary disorders, whose diagnosis often requires the integration of clinical, radiologic, and pathologic evidence. Lung biopsy is a key method for obtaining a histopathologic diagnosis, but unified standards are lacking for determining indications, selecting biopsy techniques, managing patients perioperatively, and integrating pathologic and clinical information. To address these gaps, the Respiratory Physicians Branch of the Chinese Medic…

Rank111.4
Systematic review or meta-analysis

Effects of enhanced recovery after surgery and prehabilitation interventions on postoperative outcomes after lung resection in patients with lung cancer: a systematic review and meta-analysis.

Frontiers in public health · 2026 · PMID 42898494

INTRODUCTION: Lung resection is the standard curative treatment for resectable lung cancer; however, postoperative pulmonary complications (PPCs) and prolonged hospital length of stay (LOS) remain major barriers to recovery and healthcare efficiency. Enhanced recovery after surgery (ERAS) and prehabilitation are distinct perioperative strategies that differ in their timing, intervention components, and mechanisms of action, but both aim to optimize patients' perioperative condition and improve postoperative recover…

Rank110.4
Systematic review or meta-analysis

Machine Learning, Radiomics, and Clinical Models Predicting Checkpoint Inhibitor Pneumonitis in Lung Cancer: A Systematic Review and Meta-analysis.

Journal of visualized experiments : JoVE · 2026 · PMID 42872743

Checkpoint inhibitor pneumonitis (CIP) is a potentially fatal immune-related adverse event of immune checkpoint inhibitor (ICI) therapy in lung cancer, and many machine-learning (ML), computed tomography (CT) radiomics, deep-learning, and clinical models have been proposed to predict it. This systematic review searched PubMed, Embase, Web of Science, CINAHL, and SinoMed, supplemented by citation searching and other sources, with independent dual-reviewer screening throughout and a reproducible PubMed verification s…

Rank110.0
Clinical guideline or consensus statement

[Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 42927946

To promote the standardization of clinical diagnosis and treatment of lung cancer in China and to apply the latest evidence-based medical evidence to clinical practice, since 2018, the Department of Respiratory and Critical Care Medicine of Shanghai Chest Hospital has taken the lead, in collaboration with more than 50 lung cancer treatment institutions and over 100 experts nationwide, to jointly draft the clinical practice guidelines for lung cancer, with annual updates. The newly added recommendations are primaril…

Rank110.0
Clinical guideline or consensus statement

ACR Appropriateness Criteria® Indolent Lung Cancer.

Journal of the American College of Radiology : JACR · 2026 · PMID 42573542

Persistent or slow-growing subsolid nodules and atypical lung cysts often represent indolent forms of lung cancer. These nodules require careful assessment by a multidisciplinary tumor board to determine risk, natural history, treatment options, and patient preferences. When the preferred management is imaging surveillance rather than active intervention, the main objective is to detect significant changes that could alter patient management. The choice of imaging modality should be based on its accuracy and whethe…

Rank110.0
Systematic review or meta-analysisResult signal: harm

The association between sleep quantity, insomnia and lung cancer risk - A systematic review and meta-analysis.

Sleep & breathing = Schlaf & Atmung · 2024 · PMID 39145902

PURPOSE: The effect of various sleep traits on the risk of lung cancer differs among pre-existing studies. This study aims to systematically review and synthesise the association between sleep duration and insomnia with the incidence of lung cancer. METHODS: PubMed, Embase and The Cochrane Library were searched from inception to 23 April 2023 for observational studies examining the effect of sleep quantity or insomnia on lung cancer incidence. We pooled maximally-adjusted hazard ratios and odds ratios separately us…

Rank109.9
Systematic review or meta-analysis

Accuracy of the COMPASS-CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis.

Journal of thrombosis and thrombolysis · 2024 · PMID 38981978

OBJECTIVE: This systematic review aims to assess the accuracy of the COMPASS-CAT tool in predicting venous thromboembolism (VTE) among cancer patients. METHODS: Relevant studies were searched in PubMed, Web of Science, The Cochrane Library, Embase, CINAHL, OVID, CBM, CNKI, WanFang Data, and VIP database from their inception up to April 19, 2023. The quality of studies was appraised using the diagnostic test accuracy study bias assessment tool (QUADAS-2). Quantitative analysis was performed using Stata MP 17.0. RESU…

Rank109.6
Systematic review or meta-analysis

Cine Magnetic Resonance Imaging for Assessing Chest Wall Invasion in Lung Cancer: A Systematic Review and Meta-Analysis.

Journal of thoracic imaging · 2026 · PMID 42543806

PURPOSE: To conduct a meta-analysis assessing the effectiveness of cine MRI in evaluating tumor invasion of the chest wall, using surgical and histopathologic analysis as the reference standard. MATERIALS AND METHODS: This systematic review and meta-analysis was conducted following the recommendations of the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy and Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy (PRISMA-DTA) guidelines. The study protoc…

Rank108.8
Systematic review or meta-analysis

Effectiveness of psychosocial interventions addressing informal caregivers' mental health: an umbrella systematic review with 26,481 participants.

Clinical psychology review · 2026 · PMID 42863359

AIM: We aimed to provide a comprehensive overview of the effectiveness of psychosocial interventions on informal caregivers' mental health, organized by the clinical condition(s) of the care recipient. METHODS: We conducted an umbrella systematic review and random-effects meta-analyses to pool the results of the included studies for each combination of clinical condition, intervention type, comparison and outcome. RESULTS: We included 19 systematic reviews and 50 meta-analyses, with 26,481 participants. Several int…

Rank108.6
Systematic review or meta-analysisResult signal: harm

Incidence and risk factors for malignancy in patients with incidental solitary pulmonary nodules: a systematic review and meta-analysis.

Annals of medicine · 2026 · PMID 41641734

BACKGROUND: The increasing use of chest imaging has led to a higher detection rate of incidental solitary pulmonary nodules (SPNs), often causing patient anxiety. Determining the malignancy rate and associated risk factors is crucial for developing appropriate follow-up strategies to prevent overdiagnosis, overtreatment, or missed diagnoses. This meta-analysis aims to investigate the malignancy rate and risk factors in patients with incidental SPNs. METHODS: A systematic search of PubMed, Embase, Web of Science, an…

Rank108.4
Systematic review or meta-analysisResult signal: harm

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Targeted oncology · 2024 · PMID 38824269

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer. An updated toxicity profile of EGFR-TKIs proves valuable in guiding clinical decision making. OBJECTIVE: This study comprehensively assessed the risk of EGFR-TKI-related adverse events (AEs) involving different systems/organs. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane library for phase III randomiz…

Rank108.4
Systematic review or meta-analysisResult signal: null

Comparative outcomes of video-assisted thoracic surgery versus open thoracic surgery in pediatric pulmonary metastasectomy: a systematic review and meta-analysis.

Pediatric surgery international · 2024 · PMID 39699640

This meta-analysis aimed to compare the outcomes of video-assisted thoracic surgery (VATS) and open thoracotomy in pediatric patients undergoing pulmonary metastasectomy for various malignancies. We systematically searched PubMed, Embase, and Cochrane Library databases for studies comparing VATS and open thoracotomy in pediatric patients. The treatment effects for continuous outcomes were compared using mean differences (MDs), and binary endpoints were evaluated using odds ratios (ORs), with 95% confidence interval…

Rank108.3
Systematic review or meta-analysis

Effects of preoperative needle biopsy for lung cancer on survival and recurrence: a systematic review and meta-analysis.

Surgery today · 2024 · PMID 36348163

Needle biopsy (NB) is used for the diagnosis of lung cancer, but there is still controversy about its effect on the prognosis after surgery. We conducted this meta-analysis to compare the prognosis of lung cancer patients who underwent preoperative NB with that of those who did not. We systematically searched seven databases and Google Scholar for eligible studies. Recurrence-free survival (RFS) and overall survival (OS) were analyzed as primary outcome measures. Nine articles with a collective total of 13,541 pati…

Rank108.3
Systematic review or meta-analysis

Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis.

International journal of obesity (2005) · 2025 · PMID 39363034

BACKGROUND: The impact of weight loss on survival outcomes remains challenging in patients with lung cancer. The objective of this systematic review with meta-analysis was to assess the association of weight loss with survival outcomes in these patients. METHODS: Two authors conducted a comprehensive literature search of PubMed, Web of Science, and Embase databases up to January 15, 2024. Observational studies that assessed the weight loss as a prognostic factor of overall survival and progression-free survival in …

Rank108.2
Systematic review or meta-analysis

Prognostic value of CT-defined ground-glass opacity in early-stage lung adenocarcinomas: a single-center study and meta-analysis.

European radiology · 2024 · PMID 37650971

OBJECTIVES: The prognostic value of ground-glass opacity at preoperative chest CT scans in early-stage lung adenocarcinomas is a matter of debate. We aimed to clarify the existing evidence through a single-center, retrospective cohort study and to quantitatively summarize the body of literature by conducting a meta-analysis. METHODS: In a retrospective cohort study, patients with clinical stage I lung adenocarcinoma were identified, and the prognostic value of ground-glass opacity was analyzed using multivariable C…

Rank108.1
Systematic review or meta-analysis

Efficacy and safety of curative-intent intensity modulated radiotherapy (IMRT) for inoperable, locally-advanced non-small cell lung cancer: A systematic review.

Journal of cancer research and therapeutics · 2026 · PMID 42955956

Intensity-modulated radiotherapy (IMRT), including volumetric modulated arc therapy (VMAT) is widely used for the treatment of non-small cell lung cancer (NSCLC) despite the lack of prospective, randomized evidence over three-dimensional conformal radiotherapy (3D-CRT). IMRT has been shown to reduce doses to normal tissue and organs at risk (OAR) in planning and retrospective studies. The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD4202123…

Rank108.1
Systematic review or meta-analysisResult signal: benefit

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.

European journal of clinical pharmacology · 2024 · PMID 38300281

BACKGROUND: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small sample sizes and different methods of statistical analysis, which may lead to a lack of valid metrics to assess t…

Rank107.9
Systematic review or meta-analysis

Profiling immune check point inhibitors - Induced arthritis: A systematic review and pooled analyses of cohort studies.

Journal of autoimmunity · 2026 · PMID 42702183

BACKGROUND: The growing use of immune checkpoint inhibitors (ICIs) in the oncology field along with the potential development of the so-called immune-related adverse events (irAEs) has introduced new diagnostic and therapeutic challenges for rheumatologists. Rheumatic irAEs (Rh-irAEs), particularly those involving the musculoskeletal system, are relatively common and sometimes underdiagnosed, with an estimated prevalence of up to 7% of ICIs treated patients. In this context, we conducted a systematic review and poo…

Rank107.8
Systematic review or meta-analysisResult signal: benefit

The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.

Annals of medicine · 2026 · PMID 42613912

BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…

Rank107.7
Systematic review or meta-analysis

A Meta-Analysis-Based Risk Score for Predicting Radiation Pneumonitis After Thoracic Radiation Therapy for Lung Cancer.

International journal of radiation oncology, biology, physics · 2026 · PMID 42140502

PURPOSE: To develop and validate a risk score for predicting radiation pneumonitis (RP) in lung cancer patients following thoracic radiation therapy. METHODS AND MATERIALS: The linear predictor was first derived from a meta-analysis. Risk factors with consistent definitions and statistical significance were identified, and their pooled odds ratios were converted to β-coefficients and then linearly transformed to construct the initial scoring items. An independent Asian calibration cohort (cohort 1, n = 218) was use…

Rank107.7
Systematic review or meta-analysis

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38294563

BACKGROUND: This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. METHODS: We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) …

Rank107.3
Systematic review or meta-analysis

Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42251230

BACKGROUND: Atrial fibrillation (AF) may represent an important component of cardiac toxicity after thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). However, the available evidence remains limited and heterogeneous. METHODS: We conducted a systematic review and meta-analysis of observational studies evaluating AF after thoracic radiotherapy in NSCLC. PubMed, Scopus, Web of Science, Embase, and Cochrane Central were searched from inception to March 2026. The primary outcome was pooled new-o…

Rank107.3
Systematic review or meta-analysis

Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42843316

INTRODUCTION: Postoperative PD-1/PD-L1 blockade after complete resection of non-small-cell lung cancer (NSCLC) is mainly reported using relative disease-free survival (DFS) effects. We estimated absolute effects for distinct completed trial policies. METHODS: We systematically reviewed randomized phase III trials of postoperative single-agent PD-1/PD-L1 blockade. Published Kaplan-Meier curves were reconstructed to estimate trial-specific 36-month restricted mean DFS time (RMST) and DFS probability differences. Prim…

Rank107.3
Systematic review or meta-analysisResult signal: harm

The prognostic value of physical functioning on survival in patients with nonsmall cell lung cancer: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society · 2026 · PMID 42906942

BACKGROUND: Physical functioning has emerged as a potentially valuable prognostic indicator in patients with nonsmall cell lung cancer (NSCLC). This systematic review and meta-analysis aimed to evaluate the prognostic value of objectively measured components of physical functioning on survival outcomes across treatment modalities. METHODS: Medline, Web of Science and Scopus were searched up to May 2025. Eligible studies included adult patients with NSCLC and assessed at least one objectively measured physical funct…

Rank107.2
Systematic review or meta-analysis

Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38030870

OBJECTIVES: The purpose of this meta-analysis was to investigate the relationship between serum carcinoembryonic antigen (CEA) expression and epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC). METHODS: Databases such as PubMed, Cochrane, EMBASE and Google Scholar were systematically searched to identify studies assessing the association of serum CEA expression with EGFR mutations. Across 19 studies, 4168 patients were included between CEA expression and EGFR mutations odd…

Landmark Evidence135 records
Rank110.0
Clinical guideline or consensus statement

Management of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline.

Chest · 2025 · PMID 40562304

BACKGROUND: Lung cancer remains the number 1 cause of cancer death in men and women in the United States and much of the world. This CHEST organization guideline examines the literature on primary treatment of patients with stage I and II non-small cell lung cancer (NSCLC) to provide evidence-based recommendations. STUDY DESIGN AND METHODS: An expert panel conducted a systematic review addressing the treatment options for patients with stage I/II NSCLC and applied the Grading of Recommendations, Assessment, Develop…

Rank110.0
Systematic review or meta-analysisResult signal: harm

The association between sleep quantity, insomnia and lung cancer risk - A systematic review and meta-analysis.

Sleep & breathing = Schlaf & Atmung · 2024 · PMID 39145902

PURPOSE: The effect of various sleep traits on the risk of lung cancer differs among pre-existing studies. This study aims to systematically review and synthesise the association between sleep duration and insomnia with the incidence of lung cancer. METHODS: PubMed, Embase and The Cochrane Library were searched from inception to 23 April 2023 for observational studies examining the effect of sleep quantity or insomnia on lung cancer incidence. We pooled maximally-adjusted hazard ratios and odds ratios separately us…

Rank109.9
Systematic review or meta-analysis

Accuracy of the COMPASS-CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis.

Journal of thrombosis and thrombolysis · 2024 · PMID 38981978

OBJECTIVE: This systematic review aims to assess the accuracy of the COMPASS-CAT tool in predicting venous thromboembolism (VTE) among cancer patients. METHODS: Relevant studies were searched in PubMed, Web of Science, The Cochrane Library, Embase, CINAHL, OVID, CBM, CNKI, WanFang Data, and VIP database from their inception up to April 19, 2023. The quality of studies was appraised using the diagnostic test accuracy study bias assessment tool (QUADAS-2). Quantitative analysis was performed using Stata MP 17.0. RESU…

Rank109.6
Systematic review or meta-analysis

Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis.

Chest · 2024 · PMID 38065405

BACKGROUND: Standard treatment for early-stage or locoregionally advanced non-small cell lung cancer (NSCLC) includes surgical resection. Recurrence after surgery is commonly reported, but a summary estimate for postsurgical recurrence-free survival (RFS) in patients with NSCLC is lacking. RESEARCH QUESTION: What is the RFS after surgery in patients with stage I-III NSCLC at different time points, and what factors are associated with RFS? STUDY DESIGN AND METHODS: A systematic search was performed in MEDLINE, EMBAS…

Rank108.4
Systematic review or meta-analysisResult signal: null

Comparative outcomes of video-assisted thoracic surgery versus open thoracic surgery in pediatric pulmonary metastasectomy: a systematic review and meta-analysis.

Pediatric surgery international · 2024 · PMID 39699640

This meta-analysis aimed to compare the outcomes of video-assisted thoracic surgery (VATS) and open thoracotomy in pediatric patients undergoing pulmonary metastasectomy for various malignancies. We systematically searched PubMed, Embase, and Cochrane Library databases for studies comparing VATS and open thoracotomy in pediatric patients. The treatment effects for continuous outcomes were compared using mean differences (MDs), and binary endpoints were evaluated using odds ratios (ORs), with 95% confidence interval…

Rank108.4
Systematic review or meta-analysisResult signal: harm

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Targeted oncology · 2024 · PMID 38824269

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer. An updated toxicity profile of EGFR-TKIs proves valuable in guiding clinical decision making. OBJECTIVE: This study comprehensively assessed the risk of EGFR-TKI-related adverse events (AEs) involving different systems/organs. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane library for phase III randomiz…

Rank108.3
Systematic review or meta-analysis

Effects of preoperative needle biopsy for lung cancer on survival and recurrence: a systematic review and meta-analysis.

Surgery today · 2024 · PMID 36348163

Needle biopsy (NB) is used for the diagnosis of lung cancer, but there is still controversy about its effect on the prognosis after surgery. We conducted this meta-analysis to compare the prognosis of lung cancer patients who underwent preoperative NB with that of those who did not. We systematically searched seven databases and Google Scholar for eligible studies. Recurrence-free survival (RFS) and overall survival (OS) were analyzed as primary outcome measures. Nine articles with a collective total of 13,541 pati…

Rank108.3
Systematic review or meta-analysis

Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis.

International journal of obesity (2005) · 2025 · PMID 39363034

BACKGROUND: The impact of weight loss on survival outcomes remains challenging in patients with lung cancer. The objective of this systematic review with meta-analysis was to assess the association of weight loss with survival outcomes in these patients. METHODS: Two authors conducted a comprehensive literature search of PubMed, Web of Science, and Embase databases up to January 15, 2024. Observational studies that assessed the weight loss as a prognostic factor of overall survival and progression-free survival in …

Rank108.2
Systematic review or meta-analysis

Sarcopenia and survival in surgically treated non-small cell lung cancer: A systematic review and meta-analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025 · PMID 41138294

OBJECTIVES: Lung cancer is the leading cause of cancer-related death. Early-stage non-small cell lung cancer (NSCLC) patients can be eligible for surgical resection. Sarcopenia has emerged as a negative prognostic factor for overall survival across various cancer types. The aim of this systematic review and meta-analysis was to systematically evaluate the association between CT-derived sarcopenia and overall survival in NSCLC patients undergoing surgical treatment. METHODS: A comprehensive systematic literature sea…

Rank108.2
Systematic review or meta-analysis

Prognostic value of CT-defined ground-glass opacity in early-stage lung adenocarcinomas: a single-center study and meta-analysis.

European radiology · 2024 · PMID 37650971

OBJECTIVES: The prognostic value of ground-glass opacity at preoperative chest CT scans in early-stage lung adenocarcinomas is a matter of debate. We aimed to clarify the existing evidence through a single-center, retrospective cohort study and to quantitatively summarize the body of literature by conducting a meta-analysis. METHODS: In a retrospective cohort study, patients with clinical stage I lung adenocarcinoma were identified, and the prognostic value of ground-glass opacity was analyzed using multivariable C…

Rank108.1
Systematic review or meta-analysisResult signal: benefit

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.

European journal of clinical pharmacology · 2024 · PMID 38300281

BACKGROUND: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small sample sizes and different methods of statistical analysis, which may lead to a lack of valid metrics to assess t…

Rank108.1
Systematic review or meta-analysis

Efficacy and safety of curative-intent intensity modulated radiotherapy (IMRT) for inoperable, locally-advanced non-small cell lung cancer: A systematic review.

Journal of cancer research and therapeutics · 2026 · PMID 42955956

Intensity-modulated radiotherapy (IMRT), including volumetric modulated arc therapy (VMAT) is widely used for the treatment of non-small cell lung cancer (NSCLC) despite the lack of prospective, randomized evidence over three-dimensional conformal radiotherapy (3D-CRT). IMRT has been shown to reduce doses to normal tissue and organs at risk (OAR) in planning and retrospective studies. The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD4202123…

Rank107.7
Systematic review or meta-analysis

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38294563

BACKGROUND: This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. METHODS: We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) …

Rank107.2
Systematic review or meta-analysis

Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38030870

OBJECTIVES: The purpose of this meta-analysis was to investigate the relationship between serum carcinoembryonic antigen (CEA) expression and epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC). METHODS: Databases such as PubMed, Cochrane, EMBASE and Google Scholar were systematically searched to identify studies assessing the association of serum CEA expression with EGFR mutations. Across 19 studies, 4168 patients were included between CEA expression and EGFR mutations odd…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2025 · PMID 39542906

BACKGROUND: The optimal treatment for resectable Non-Small Cell Lung Cancer (NSCLC) remains under investigation, particularly about its effectiveness across different ethnicities. This meta-analysis aims to investigate the potential benefits of adding PD1/PD-L1 inhibitors for treatment, stratified by ethnicity. METHODS: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) that investigated the use of PD1/PD-L1 inhibitors to treat patients with resectable NSCLC. The outcomes eva…

Rank107.1
Systematic review or meta-analysis

Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis.

Cancer treatment reviews · 2024 · PMID 39369455

Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC). However, its impact on surgery has not been fully elucidated. We performed a systematic review and meta-analysis to compare surgical outcomes between neoadjuvant chemoimmunotherapy and chemotherapy alone in resectable NSCLC. PubMed and Embase were searched to select randomized controlled trials (RCTs) evaluating neoadjuvant ICB therapy for resectable NSCLC. T…

Rank107.1
Systematic review or meta-analysis

Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38869739

OBJECTIVE: This study aims to assess the diagnostic utility of circulating tumor cells (CTCs) in conjunction with low-dose computed tomography (LDCT) for differentiating between benign and malignant pulmonary nodules and to substantiate the foundation for their integration into clinical practice. METHODS: A systematic literature review was performed independently by two researchers utilizing databases including PubMed, Web of Science, The Cochrane Library, Embase, and Medline, to collate studies up to September 15,…

Rank106.7
Systematic review or meta-analysisResult signal: mixed

Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.

European journal of clinical pharmacology · 2025 · PMID 39680077

BACKGROUND: Nivolumab and ipilimumab combination immunotherapy has become a standard treatment option for certain cancers. However, the benefits of combination therapy compared to nivolumab monotherapy in lung cancer patients are not entirely clear. We aimed to evaluate whether nivolumab plus ipilimumab improves clinical outcomes in lung cancer patients compared to nivolumab monotherapy. METHODS: A literature search was performed on PubMed, Web of Science, and Scopus from inception until November 2024 to identify r…

Rank106.6
Systematic review or meta-analysisResult signal: harm

Prognostic value of albumin-bilirubin grade in lung cancer: a meta-analysis.

Journal of cardiothoracic surgery · 2024 · PMID 39734193

PURPOSE: To clarify the prognostic role of pretreatment albumin-bilirubin (ALBI) grade in lung cancer patients. METHODS: The PubMed, EMBASE, Web of Science and CNKI databases were searched up to April 20, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis based on the type of lung cancer [non-small cell lung cancer (NSCLC) vs. small cell lung cancer …

Rank106.2
Systematic review or meta-analysis

Risk factors for cancer-related cognitive impairment among individuals with lung cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39287692

OBJECTIVES: Cancer-related cognitive impairment (CRCI) exerts a negative impact on the quality of life in lung cancer survivors. Risk factors for CRCI in lung cancer patients remain unclear.This study aimed to identify risk factors for CRCI in lung cancer patients. METHODS: A comprehensive literature search was conducted across PubMed, CINAHL, Web of Science, Wanfang, VIP Database, Embase, and China National Knowledge Infrastructure (CNKI) from their inception until March 10, 2024. Studies were screened, data extra…

Rank105.6
Systematic review or meta-analysis

Diagnostic potential of [18F]FDG PET/MRI in non-small cell lung cancer lymph node metastasis: a meta-analysis.

Japanese journal of radiology · 2024 · PMID 37566187

PURPOSE: This meta-analysis evaluated the diagnostic accuracy and diagnostic value of [18F]FDG PET/MRI for mediastinal lymph node staging of NSCLC. METHODS: Relevant articles in PubMed, Embase, Web of Science, and the Cochrane Library were searched until January 2023. Research evaluating [18F]FDG PET/MRI for mediastinal lymph node staging of NSCLC was included. Pooled estimates of sensitivity, specificity, PLR, and NLR were calculated by the "Stata" software. RESULTS: Nine researches were included, containing 618 p…

Rank105.2
Systematic review or meta-analysisResult signal: null

Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.

European journal of pediatrics · 2024 · PMID 38019286

This paper aims to explore the epidemiology, clinical characteristics, and prognosis of extracranial malignant rhabdoid tumors (eMRTs) in children. A systematic review and meta-analysis of studies published in PUBMED, MEDLINE, Web of Science, Embase, Cochrane, and China National Knowledge Infrastructure (CNKI) was conducted. The search was limited to studies published between Jan 1, 1990 to Dec 31, 2022, with the last search done on Jan 31, 2023. We identified 496 papers through the literature search, and 12 retros…

Rank105.2
Systematic review or meta-analysis

Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

International journal of clinical pharmacy · 2022 · PMID 35951217

BACKGROUND: Multitargeted tyrosine kinase inhibitors (TKIs) are used to treat advanced non-small cell lung cancer (NSCLC). Their efficacy and safety have been studied in randomized controlled trials. AIM: This meta-analysis aimed to summarize the most up-to-date evidence regarding the efficacy and adverse events of TKIs in NSCLC treatment. METHOD: Randomized controlled trials were searched from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The intervention arm was the TKI-containing group,…

Rank105.0
Systematic review or meta-analysisResult signal: harm

Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis.

World journal of surgical oncology · 2023 · PMID 37349739

BACKGROUND: Although several studies have confirmed the prognostic value of the consolidation to tumor ratio (CTR) in non-small cell lung cancer (NSCLC), there still remains controversial about it. METHODS: We systematically searched the PubMed, Embase, and Web of Science databases from inception to April, 2022 for eligible studies that reported the correlation between CTR and prognosis in NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were extracted and pooled to assess the overall effects. Het…

Rank104.8
Systematic review or meta-analysis

Evaluating eight smoking metrics for modelling survival in non-small cell lung cancer.

Cancer epidemiology · 2026 · PMID 41861692

INTRODUCTION: Smoking is a strong modifiable prognostic factor for lung cancer survival. We compared eight smoking metrics to determine which metric best models the relationship between smoking exposure with overall survival (OS) and lung cancer-specific survival (LCSS). These metrics included cigarettes-per-day, smoking duration, pack-years, square-root pack-years, logcig-years, the comprehensive smoking index, age-of-initiation, and years-since-quit. MATERIALS/METHODS: This retrospective, pooled analysis included…

Most Effective Evidence Supported Treatments139 records
Rank111.4
Systematic review or meta-analysis

Effects of enhanced recovery after surgery and prehabilitation interventions on postoperative outcomes after lung resection in patients with lung cancer: a systematic review and meta-analysis.

Frontiers in public health · 2026 · PMID 42898494

INTRODUCTION: Lung resection is the standard curative treatment for resectable lung cancer; however, postoperative pulmonary complications (PPCs) and prolonged hospital length of stay (LOS) remain major barriers to recovery and healthcare efficiency. Enhanced recovery after surgery (ERAS) and prehabilitation are distinct perioperative strategies that differ in their timing, intervention components, and mechanisms of action, but both aim to optimize patients' perioperative condition and improve postoperative recover…

Rank110.4
Systematic review or meta-analysis

Machine Learning, Radiomics, and Clinical Models Predicting Checkpoint Inhibitor Pneumonitis in Lung Cancer: A Systematic Review and Meta-analysis.

Journal of visualized experiments : JoVE · 2026 · PMID 42872743

Checkpoint inhibitor pneumonitis (CIP) is a potentially fatal immune-related adverse event of immune checkpoint inhibitor (ICI) therapy in lung cancer, and many machine-learning (ML), computed tomography (CT) radiomics, deep-learning, and clinical models have been proposed to predict it. This systematic review searched PubMed, Embase, Web of Science, CINAHL, and SinoMed, supplemented by citation searching and other sources, with independent dual-reviewer screening throughout and a reproducible PubMed verification s…

Rank110.0
Clinical guideline or consensus statement

[Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 42927946

To promote the standardization of clinical diagnosis and treatment of lung cancer in China and to apply the latest evidence-based medical evidence to clinical practice, since 2018, the Department of Respiratory and Critical Care Medicine of Shanghai Chest Hospital has taken the lead, in collaboration with more than 50 lung cancer treatment institutions and over 100 experts nationwide, to jointly draft the clinical practice guidelines for lung cancer, with annual updates. The newly added recommendations are primaril…

Rank108.8
Systematic review or meta-analysis

Effectiveness of psychosocial interventions addressing informal caregivers' mental health: an umbrella systematic review with 26,481 participants.

Clinical psychology review · 2026 · PMID 42863359

AIM: We aimed to provide a comprehensive overview of the effectiveness of psychosocial interventions on informal caregivers' mental health, organized by the clinical condition(s) of the care recipient. METHODS: We conducted an umbrella systematic review and random-effects meta-analyses to pool the results of the included studies for each combination of clinical condition, intervention type, comparison and outcome. RESULTS: We included 19 systematic reviews and 50 meta-analyses, with 26,481 participants. Several int…

Rank108.4
Systematic review or meta-analysisResult signal: null

Comparative outcomes of video-assisted thoracic surgery versus open thoracic surgery in pediatric pulmonary metastasectomy: a systematic review and meta-analysis.

Pediatric surgery international · 2024 · PMID 39699640

This meta-analysis aimed to compare the outcomes of video-assisted thoracic surgery (VATS) and open thoracotomy in pediatric patients undergoing pulmonary metastasectomy for various malignancies. We systematically searched PubMed, Embase, and Cochrane Library databases for studies comparing VATS and open thoracotomy in pediatric patients. The treatment effects for continuous outcomes were compared using mean differences (MDs), and binary endpoints were evaluated using odds ratios (ORs), with 95% confidence interval…

Rank108.4
Systematic review or meta-analysisResult signal: harm

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Targeted oncology · 2024 · PMID 38824269

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer. An updated toxicity profile of EGFR-TKIs proves valuable in guiding clinical decision making. OBJECTIVE: This study comprehensively assessed the risk of EGFR-TKI-related adverse events (AEs) involving different systems/organs. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane library for phase III randomiz…

Rank108.3
Systematic review or meta-analysis

Effects of preoperative needle biopsy for lung cancer on survival and recurrence: a systematic review and meta-analysis.

Surgery today · 2024 · PMID 36348163

Needle biopsy (NB) is used for the diagnosis of lung cancer, but there is still controversy about its effect on the prognosis after surgery. We conducted this meta-analysis to compare the prognosis of lung cancer patients who underwent preoperative NB with that of those who did not. We systematically searched seven databases and Google Scholar for eligible studies. Recurrence-free survival (RFS) and overall survival (OS) were analyzed as primary outcome measures. Nine articles with a collective total of 13,541 pati…

Rank108.1
Systematic review or meta-analysisResult signal: benefit

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.

European journal of clinical pharmacology · 2024 · PMID 38300281

BACKGROUND: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small sample sizes and different methods of statistical analysis, which may lead to a lack of valid metrics to assess t…

Rank108.1
Systematic review or meta-analysis

Efficacy and safety of curative-intent intensity modulated radiotherapy (IMRT) for inoperable, locally-advanced non-small cell lung cancer: A systematic review.

Journal of cancer research and therapeutics · 2026 · PMID 42955956

Intensity-modulated radiotherapy (IMRT), including volumetric modulated arc therapy (VMAT) is widely used for the treatment of non-small cell lung cancer (NSCLC) despite the lack of prospective, randomized evidence over three-dimensional conformal radiotherapy (3D-CRT). IMRT has been shown to reduce doses to normal tissue and organs at risk (OAR) in planning and retrospective studies. The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD4202123…

Rank107.9
Systematic review or meta-analysis

Profiling immune check point inhibitors - Induced arthritis: A systematic review and pooled analyses of cohort studies.

Journal of autoimmunity · 2026 · PMID 42702183

BACKGROUND: The growing use of immune checkpoint inhibitors (ICIs) in the oncology field along with the potential development of the so-called immune-related adverse events (irAEs) has introduced new diagnostic and therapeutic challenges for rheumatologists. Rheumatic irAEs (Rh-irAEs), particularly those involving the musculoskeletal system, are relatively common and sometimes underdiagnosed, with an estimated prevalence of up to 7% of ICIs treated patients. In this context, we conducted a systematic review and poo…

Rank107.8
Systematic review or meta-analysisResult signal: benefit

The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.

Annals of medicine · 2026 · PMID 42613912

BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…

Rank107.7
Systematic review or meta-analysis

A Meta-Analysis-Based Risk Score for Predicting Radiation Pneumonitis After Thoracic Radiation Therapy for Lung Cancer.

International journal of radiation oncology, biology, physics · 2026 · PMID 42140502

PURPOSE: To develop and validate a risk score for predicting radiation pneumonitis (RP) in lung cancer patients following thoracic radiation therapy. METHODS AND MATERIALS: The linear predictor was first derived from a meta-analysis. Risk factors with consistent definitions and statistical significance were identified, and their pooled odds ratios were converted to β-coefficients and then linearly transformed to construct the initial scoring items. An independent Asian calibration cohort (cohort 1, n = 218) was use…

Rank107.7
Systematic review or meta-analysis

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38294563

BACKGROUND: This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. METHODS: We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) …

Rank107.3
Systematic review or meta-analysis

Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42843316

INTRODUCTION: Postoperative PD-1/PD-L1 blockade after complete resection of non-small-cell lung cancer (NSCLC) is mainly reported using relative disease-free survival (DFS) effects. We estimated absolute effects for distinct completed trial policies. METHODS: We systematically reviewed randomized phase III trials of postoperative single-agent PD-1/PD-L1 blockade. Published Kaplan-Meier curves were reconstructed to estimate trial-specific 36-month restricted mean DFS time (RMST) and DFS probability differences. Prim…

Rank107.3
Systematic review or meta-analysis

Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42251230

BACKGROUND: Atrial fibrillation (AF) may represent an important component of cardiac toxicity after thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). However, the available evidence remains limited and heterogeneous. METHODS: We conducted a systematic review and meta-analysis of observational studies evaluating AF after thoracic radiotherapy in NSCLC. PubMed, Scopus, Web of Science, Embase, and Cochrane Central were searched from inception to March 2026. The primary outcome was pooled new-o…

Rank107.3
Systematic review or meta-analysisResult signal: harm

The prognostic value of physical functioning on survival in patients with nonsmall cell lung cancer: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society · 2026 · PMID 42906942

BACKGROUND: Physical functioning has emerged as a potentially valuable prognostic indicator in patients with nonsmall cell lung cancer (NSCLC). This systematic review and meta-analysis aimed to evaluate the prognostic value of objectively measured components of physical functioning on survival outcomes across treatment modalities. METHODS: Medline, Web of Science and Scopus were searched up to May 2025. Eligible studies included adult patients with NSCLC and assessed at least one objectively measured physical funct…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2025 · PMID 39542906

BACKGROUND: The optimal treatment for resectable Non-Small Cell Lung Cancer (NSCLC) remains under investigation, particularly about its effectiveness across different ethnicities. This meta-analysis aims to investigate the potential benefits of adding PD1/PD-L1 inhibitors for treatment, stratified by ethnicity. METHODS: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) that investigated the use of PD1/PD-L1 inhibitors to treat patients with resectable NSCLC. The outcomes eva…

Rank107.2
Systematic review or meta-analysis

Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38030870

OBJECTIVES: The purpose of this meta-analysis was to investigate the relationship between serum carcinoembryonic antigen (CEA) expression and epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC). METHODS: Databases such as PubMed, Cochrane, EMBASE and Google Scholar were systematically searched to identify studies assessing the association of serum CEA expression with EGFR mutations. Across 19 studies, 4168 patients were included between CEA expression and EGFR mutations odd…

Rank107.0
Systematic review or meta-analysisResult signal: null

Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42815252

INTRODUCTION: Brain metastases (BM) remain a major clinical challenge in patients with non-small cell lung cancer (NSCLC). Although antibody-drug conjugates (ADCs) have emerged as important treatment options for advanced NSCLC, their efficacy in patients with BM remains uncertain because of concerns regarding blood-brain barrier penetration and the underrepresentation of patients with BM in clinical trials. METHODS: A systematic literature search was conducted to identify studies evaluating ADCs in patients with NS…

Rank106.8
Systematic review or meta-analysis

PD-1/ PD-l1 Inhibitors and Stereotactic Radiosurgery for Brain Metastases: a systematic review and meta-analysis.

Clinical & experimental metastasis · 2026 · PMID 42891757

PURPOSE: Stereotactic radiosurgery (SRS) is the treatment of choice for limited brain metastases (BM), and its combination with PD-1/PD-L1 inhibitors is hypothesized to offer synergistic therapeutic benefits. However, there are concerns regarding augmented risk of radiation-induced brain necrosis (RIBN). This systematic review and meta-analysis evaluate the efficacy and toxicity profile of PD-1/PD-L1 inhibitors combined with SRS or fractionated stereotactic radiotherapy (FSRT). METHODS: Four databases were screened…

Rank106.7
Systematic review or meta-analysisResult signal: mixed

Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.

European journal of clinical pharmacology · 2025 · PMID 39680077

BACKGROUND: Nivolumab and ipilimumab combination immunotherapy has become a standard treatment option for certain cancers. However, the benefits of combination therapy compared to nivolumab monotherapy in lung cancer patients are not entirely clear. We aimed to evaluate whether nivolumab plus ipilimumab improves clinical outcomes in lung cancer patients compared to nivolumab monotherapy. METHODS: A literature search was performed on PubMed, Web of Science, and Scopus from inception until November 2024 to identify r…

Rank106.6
Systematic review or meta-analysisResult signal: benefit

Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42171981

PURPOSE: Whole-brain radiotherapy (WBRT) remains the standard treatment for patients with multiple brain metastases (BM), who are not candidates for focal radiotherapy or surgery. A novel approach, WBRT with simultaneous integrated boost (WBRT-SIB), has shown promising results in improving intracranial control and survival compared with WBRT alone. However, no meta-analysis has comprehensively compared those strategies. METHODS/PATIENTS: A systematic review and meta-analysis was performed in accordance with the PRI…

Rank106.4
Systematic review or meta-analysis

Adulthood interstitial lung disease due to variants in surfactant related genes: A systematic review.

Pulmonology · 2026 · PMID 42784242

Background: Surfactant-related gene (SRG) variants are an emerging cause of interstitial lung disease/pulmonary fibrosis (ILD/PF). Accurate recognition of these disorders is relevant for diagnosis, genetic counselling, and clinical management.Reaserch question: How do SRG-associated ILD/PF present in adults, and what clinical, radiological, and histopathological features characterize their phenotype?Study design and methods: We performed a systematic review (PROSPERO CRD42024517610) to describe the clinical feature…

Rank106.2
Systematic review or meta-analysis

Risk factors for cancer-related cognitive impairment among individuals with lung cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39287692

OBJECTIVES: Cancer-related cognitive impairment (CRCI) exerts a negative impact on the quality of life in lung cancer survivors. Risk factors for CRCI in lung cancer patients remain unclear.This study aimed to identify risk factors for CRCI in lung cancer patients. METHODS: A comprehensive literature search was conducted across PubMed, CINAHL, Web of Science, Wanfang, VIP Database, Embase, and China National Knowledge Infrastructure (CNKI) from their inception until March 10, 2024. Studies were screened, data extra…

Rank106.1
Systematic review or meta-analysis

Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.

Clinical & experimental metastasis · 2026 · PMID 42891869

Epidermal Growth Factor Receptor (EGFR) mutations are a significant driver of NSCLC. Although EGFR-Tyrosine Kinase Inhibitors (TKIs) improve outcomes, the development of resistance limits the survival advantages. Local Ablative Therapy (LAT), particularly radiotherapy, may further enhance outcomes in oligometastatic NSCLC, but its benefit remains uncertain. This meta-analysis evaluates the efficacy of LAT with TKI vs. TKI alone. We systematically searched PubMed, Embase, Web of Science, and Cochrane from inception …

New Research Last 24 Months309 records
Rank102.0
Systematic review or meta-analysis

Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy.

Frontiers in immunology · 2026 · PMID 42908912

OBJECTIVE: Antibody-drug conjugates (ADCs) are being investigated in advanced small-cell lung cancer (SCLC), but the evidence is dominated by early-phase studies conducted in non-exchangeable treatment settings. We evaluated the activity and toxicity of ADCs while separating later-line monotherapy from frontline combination therapy, later-line combination therapy, and post-induction maintenance. METHODS: PubMed, Embase, the Cochrane Library, and Web of Science Core Collection were searched from inception and in 28 …

Rank100.0
Systematic review or meta-analysis

Efficacy and safety of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis.

Frontiers in oncology · 2026 · PMID 42952490

BACKGROUND: Antibody-drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) resistance. We evaluated their efficacy and safety in this setting. METHODS: PubMed, Embase,and the Cochrane Library were searched for prospective clinical studies. Overlapping reports were assessed before endpoint-specific synthesis. Comparable proportional outcomes from non-randomized studies were pooled using random-effects models, …

Rank100.0
Systematic review or meta-analysisResult signal: benefit

Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis.

Oncoimmunology · 2026 · PMID 42965526

Some patients with metastatic non-small-cell lung cancer (NSCLC) receiving anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) progress at a few sites while disease elsewhere stays controlled, a pattern consistent with focal, oligo-acquired immune escape rather than systemic treatment failure. Ablating the escaping focus may eliminate the resistant clone and preserve an otherwise effective immunotherapy line. We performed a PRISMA 2020-compliant, PROSPERO-registered systematic review and meta-analysis of lo…

Rank100.0
Systematic review or meta-analysis

Stage II Non-Small Cell Lung Cancer: Upfront Surgery or Neoadjuvant Chemoimmunotherapy.

The Annals of thoracic surgery · 2026 · PMID 42264017

BACKGROUND: Neoadjuvant chemoimmunotherapy adoption in stage II non-small cell lung cancer is shrouded by lack of clear survival advantages and stratification across randomized clinical trials. METHODS: An individual patient data (IPD) meta-analysis was conducted comparing overall survival of stage II patients (according to the American Joint Committee on Cancer TNM staging, eighth edition) receiving neoadjuvant chemoimmunotherapy in phase 3 randomized controlled trials with overall survival of patients undergoing …

Rank98.7
Randomized controlled trial

Thalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial.

Frontiers in immunology · 2026 · PMID 42964306

BACKGROUND: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a characteristic cutaneous adverse event associated with immune checkpoint inhibitors. This study compared two prophylactic thalidomide doses to identify the more promising dose for further evaluation. METHODS: In this multicenter, randomized clinical trial, patients with advanced esophageal squamous cell carcinoma or non-small cell lung cancer (NSCLC) were randomly assigned to receive thalidomide 50 mg/day (Group A) or 100 mg/day (Group …

Rank98.0
Systematic review or meta-analysisCorrection flagged

Inconsistent definitions of local control for stereotactic body radiation therapy for early-stage lung cancer - A systematic review.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42431270

INTRODUCTION: Assessments of local control (LC) following stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) play a crucial role in evaluating treatment efficacy. However, there is significant variability in how LC is defined and assessed across studies, making it challenging to compare outcomes and establish standardized benchmarks. This heterogeneity impacts clinical decision-making, prognostic assessments, and interpretations of lung SBRT efficacy in both research and c…

Rank96.0
Systematic review or meta-analysis

Current status of various types of ICG contrast imaging in pediatric thoracic surgery.

Surgery today · 2026 · PMID 42455159

Indocyanine green (ICG) fluorescence imaging is an emerging intraoperative navigation tool. However, its application in pediatric thoracic surgery remains to be elucidated. This review evaluates the current status and clinical utility of ICG-based imaging techniques in the field. A narrative review of studies published between January 2015 and February 2026 was conducted using PubMed, Web of Science, and Cochrane Library. Relevant original articles, reviews, and case reports were included. Data were analyzed by foc…

Rank96.0
Systematic review or meta-analysis

Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).

Clinical and translational radiation oncology · 2027 · PMID 42898625

Single-fraction stereotactic body radiotherapy (SF-SBRT) represents one of the most advanced frontiers in modern radiation oncology. While ultra-hypofractionation has entered everyday clinical practice in different fields of the oncological care, curative treatments in one session are increasingly attractive for the potential favorable combination of logistic advantages with safety and clinical outcomes. This collaborative systematic review promoted by the ESTRO SBRT Focus Group in participation with members of dif…

Rank96.0
Systematic review or meta-analysis

Cost-Effectiveness Analysis of the 5 First-Line Treatment Regimens for Anaplastic-Lymphoma-Kinase-Positive Non-Small Cell Lung Cancer in China: An Economic Evaluation Based on Network Meta-Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026 · PMID 42767340

OBJECTIVES: With multiple first-line treatment options now available for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, clinicians and patients face significant challenges in selecting the optimal therapeutic strategy. This study aims to evaluate the cost-effectiveness of 5 tyrosine kinase inhibitors (TKIs) as first-line therapies from the perspective of the Chinese healthcare system. METHODS: Using crizotinib as a common comparator, we performed indirect comparisons across 5 ALK-TKI…

Rank95.2
Randomized controlled trial

Early functional deterioration during first-line ICI-based therapy in advanced NSCLC: implications for supportive care.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42965695

PURPOSE: To compare objective functional measures for identifying early functional deterioration during first-line ICI-based therapy in advanced NSCLC and explore their relevance for supportive-care monitoring. METHODS: This secondary exploratory analysis used prospectively collected data from a randomized trial of pulmonary rehabilitation. Forty-two participants with baseline and 8-week assessments were evaluated using quadriceps force, SPPB, and 6MWD. Early deterioration was defined as decline in at least one dom…

Rank93.6
Randomized clinical study

Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.

Clinical and translational radiation oncology · 2027 · PMID 42935767

PURPOSE: The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects. METHODS: Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at …

Rank93.5
Randomized clinical studyResult signal: benefit

Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.

JAMA oncology · 2026 · PMID 42955021

IMPORTANCE: Consolidation immunotherapy improves outcomes after chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Disease progression remains common, and more effective consolidation strategies are needed. OBJECTIVE: To evaluate the efficacy and safety of benmelstobart with or without anlotinib as consolidation therapy after chemoradiotherapy for unresectable stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter double-blind phase 3 randomized clinical trial took place …

Rank92.0
Randomized controlled trial

Implementation fidelity of the blended optimal physical recovery after hospitalization (OPRAH) intervention for patients after oncological surgery.

Journal of cancer survivorship : research and practice · 2026 · PMID 41331231

PURPOSE: To evaluate the implementation fidelity of a blended intervention aimed at optimizing physical recovery following gastrointestinal or lung cancer surgery, involving patients, dietitians, and physiotherapist. METHODS: Implementation fidelity was evaluated alongside a Randomized Controlled Trial (RCT) investigating the effect of the Optimal Physical Recovery After Hospitalization (OPRAH) intervention. For three months post-discharge, dietitians and physiotherapists remotely coached patients using data on phy…

Rank90.7
Randomized clinical study

Metastasis Extraction From Non-Small Cell Lung Cancer Clinical Notes Using Large Language Model-Based Classification: Retrospective Comparative Study.

JMIR cancer · 2026 · PMID 42886999

BACKGROUND: Identification of metastasis status in non-small cell lung cancer (NSCLC) is a critical part of understanding disease prognosis, treatment courses, trial eligibility, and population-level cancer surveillance. However, metastasis status is inconsistently recorded in structured cancer registry fields, since manual abstraction of clinical notes is often an error-prone process. This challenge highlights an opportunity for leveraging large language models (LLMs) to conduct high-scale metastasis extraction fr…

Rank90.4
Randomized clinical studyResult signal: benefit

Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42933639

BACKGROUND: Interim analysis of the Neotorch study demonstrated significant benefit in event-free survival (EFS) and major pathological response (MPR) rate for perioperative toripalimab plus chemotherapy in patients with resectable stage Ⅲ non-small-cell lung cancer (NSCLC). In this article, we report the overall final analysis results of the stage Ⅱ and Ⅲ patients in this study. PATIENTS AND METHODS: Eligible patients with treatment-naïve resectable stage II or stage IIIA, IIIB (N2) NSCLC were randomly assigned to…

Rank89.6
Randomized clinical study

Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416).

Clinical lung cancer · 2026 · PMID 42966192

PURPOSE: Older and vulnerable patients with metastatic non-small-cell lung cancer (NSCLC) are underrepresented in clinical trials, and evidence guiding treatment intensity remains limited. We investigated whether a modified Cancer and Aging Research Group (mCARG) score could prospectively guide chemotherapy intensity according to estimated toxicity risk. METHODS: In this randomized, open-label phase II study, 201 patients with metastatic NSCLC aged ≥ 70 years and/or Charlson Comorbidity Index (CCI) > 1 and/or ECOG …

Rank89.4
Randomized clinical study

Study protocol for the TROG 21.08 VITaL trial: a randomized controlled trial investigating ventilation imaging to improve the quality of life for patients with lung cancer treated with radiation therapy.

Clinical and translational radiation oncology · 2027 · PMID 42910049

BACKGROUND: Radiation therapy (RT) is indicated for 77% of patients with lung cancer. Over 20% of patients are affected by radiation-induced lung injury. Computed tomography ventilation imaging (CTVI) estimates high and low functioning lung regions. During RT planning, CTVI can guide preferential avoidance of higher ventilated regions by redirecting dose to less well ventilated regions, sparing healthy lung tissue. The double-masked randomized Trans-Tasman Radiation Oncology Group (TROG) 21.08 VITaL trial will inve…

Rank88.9
Randomized clinical study

Protocol of a randomized trial of "pathways," a hope intervention for people undergoing treatment for advanced lung cancer.

Contemporary clinical trials · 2026 · PMID 42648399

OBJECTIVE: Advanced cancer and its treatment can disrupt personal goal pursuits and attainment, which can imperil patient quality of life and increase risk for depression. Hope interventions foster the goal-pursuit skills exemplified by high-hope individuals and, based on a pilot trial, are a promising approach to support these patients. The current Phase II trial (NCT06047301) aims to determine the efficacy of a brief, hope intervention, "Pathways," in improving depression symptoms for people undergoing treatment …

Rank85.0
Randomized clinical study

Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung Cancer in China.

Expert review of pharmacoeconomics & outcomes research · 2026 · PMID 42958810

BACKGROUND: There is a scarcity of pharmacoeconomic information in China regarding utilising sintilimab as the second-line therapy for squamous non-small cell lung cancer (NSCLC). This study aimed to estimate the cost-effectiveness of sintilimab compared with docetaxel for treating squamous NSCLC in China. METHODS: A partitioned survival model was developed using data from the phase III ORIENT-3 trial (NCT03150875), which randomised patients 1:1 to receive sintilimab (200 mg every 3 weeks) or docetaxel (75 mg/m2 ev…

Rank85.0
Randomized clinical study

PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026.

Journal of hematology & oncology · 2026 · PMID 42966842

PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall survival benefit with ivonescimab plus chemotherapy over tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer (NSCLC), extending survival evidence to an active PD-1-based fir…

Rank85.0
Randomized clinical study

Effect of Risedronate on Rib Cortical Thickness After Stereotactic Body Radiotherapy to Peripheral Lung Tumors: Results of a Randomized Phase 2 Trial.

JTO clinical and research reports · 2026 · PMID 42964859

INTRODUCTION: Stereotactic body radiotherapy (SBRT) to peripheral lung tumors is associated with radiation-induced bone effects that may predispose patients to chest wall pain and radiation-induced rib fractures. These effects may be inhibited by bisphosphonates. We aimed to determine the impact of risedronate on the radiologic biomarker of rib cortical thickness (CTh) in patients with peripheral lung tumors treated with SBRT. METHODS: This randomized, double-blind, placebo-controlled phase 2 clinical trial enrolle…

Rank85.0
Randomized clinical studyResult signal: benefit

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42933636

BACKGROUND: In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS; P < 0.001), progression-free survival (PFS; P = 0.002), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended follow-up in patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: In this phase III, open-label trial, patients with SCLC whose disease had progressed on or after…

Rank85.0
Randomized clinical study

Treatment of lung neuroendocrine tumors with 177Lu-DOTATATE: Experience from a Tertiary Oncology Center.

Revista espanola de medicina nuclear e imagen molecular · 2026 · PMID 41720218

PURPOSE: Evidence from randomized control trials supporting peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu DOTATATE in patients with lung neuroendocrine tumors (NETs) is limited. Real world data is needed. METHODS: We conducted a retrospective cohort study of patients with metastatic or unresectable lung carcinoid tumors treated with [177Lu]Lu-DOTATATE at a single Tertiary Oncology Center. Radiographic response (objective response rate - ORR; disease control rate - DCR), progression-free survival (PFS)…

Rank83.9
Phase II clinical trialResult signal: harm

Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42887461

BACKGROUND: Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether continuing EGFR inhibition with lazertinib combined with platinum-pemetrexed chemotherapy could extend clinical benefit after progression on prior lazertinib. METHODS: In the multicenter, single-arm, phase II LUCAS study (NCT05786430), patients with advanced EGFR-mutant NSCLC who had progressed on lazertinib …

Preclinical Research279 records
Rank88.0
Randomized clinical study

Global Landscape of Clinical Studies Open to Enrollment in Carbon Ion Radiotherapy: A PTCOG Review.

International journal of particle therapy · 2026 · PMID 42893060

BACKGROUND: Radiotherapy with high linear energy transfer (LET) has shown promise for improving cancer outcomes. Carbon ion radiotherapy (CIRT) combines charged-particle dose conformality with enhanced biological effectiveness. However, clinical development remains constrained by limited center availability, modest trial accrual, and few randomized studies. We reviewed the global landscape of CIRT studies open to enrollment to identify current priorities and gaps. METHODS: This Particle Therapy Cooperative Group (P…

Rank85.0
Randomized clinical study

Characterizing the accuracy of robotic bronchoscopy in localization & targeting of small pulmonary lesions.

International journal of computer assisted radiology and surgery · 2024 · PMID 38890223

PURPOSE: Considering the recent implementation of lung cancer screening guidelines, it is crucial that small pulmonary nodules are accurately diagnosed. There is a significant need for quick, precise, and minimally invasive biopsy methods, especially for patients with small lung lesions in the outer periphery. Robotic bronchoscopy (RB) has recently emerged as a novel solution. The purpose of this study was to evaluate the accuracy of RB compared to the existing standard, electromagnetic navigational bronchoscopy (E…

Rank82.0
Randomized clinical study

Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.

Current treatment options in oncology · 2022 · PMID 36394791

KRASp.G12C mutation occurs in 12% of newly diagnosed advanced NSCLC and has recently emerged as a positive predictive biomarker for the selection of advanced NSCLC patients who may respond to novel KRASp.G12C inhibitors. The recent discovery of a new binding pocket under the effector region of KRAS G12C oncoprotein has made direct pharmacological inhibition of the KRASp.G12 mutation possible, leading to the clinical development of a new series of direct selective inhibitors, with a potential major impact on patient…

Rank74.0
Phase II clinical trial

A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG).

Medical oncology (Northwood, London, England) · 2023 · PMID 37261532

Immune checkpoint inhibitors (ICIs) ± chemotherapy is the standard treatment for driver mutation-negative non-small cell lung cancer (NSCLC). However, accessibility to ICIs in LMICs is limited due to high cost, and platinum-based chemotherapy remains the mainstay of treatment. Metformin has anticancer properties, and studies suggest synergism between metformin and pemetrexed. Based on preclinical evidence, this combination may be more beneficial for STK11-mutated NSCLC, a subgroup, inherently resistant to ICIs. In …

Rank73.0
Multicenter clinical study

The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.

Cancer letters · 2026 · PMID 42800661

Aggressive progression of small-cell lung cancer (SCLC) is orchestrated by a dynamic tumor microenvironment (TME). However, profiling this ecosystem remains a major constraint. The critical role of CD31+ aneuploid circulating tumor endothelial cells expressing vimentin (i.e. Vim + CTECs amid Endo-MT process) in promoting SCLC metastasis was systematically investigated in this study. Large cohorts of 142 treatment-naïve SCLC patients were prospectively enrolled in the current multicenter study. Patients were subject…

Rank48.0
Other PubMed-indexed publication

Structure-grouped QSAR validation reveals modest ranking performance for ToxRefDB-recorded lung neoplastic findings.

Ecotoxicology and environmental safety · 2026 · PMID 42858595

Organ-specific quantitative structure-activity relationship (QSAR) modeling is constrained by sparse, heterogeneous animal pathology data. We evaluated molecular structure and bioactivity data from the Toxicity Forecaster (ToxCast) program for a database-derived lung neoplastic pathology endpoint using a dataset of 560 standardized parent representations (53 positive and 507 database-supported otherwise-negative) in 328 structure-validation groups. Of 2189 contributing studies, 95.7% used oral administration and 1.…

Rank46.6
Other PubMed-indexed publication

Maximum resistance pressure at the time of lung tissue rupture after porcine lung transection using automatic linear staplers with different reinforcement methods.

Surgery today · 2024 · PMID 38691222

PURPOSES: Polyglycolic acid (PGA) sheets, fibrin glue, and staple line reinforcement are frequently used to prevent air leakage during lung resection. However, the optimal staple-line reinforcement method remains unclear. METHODS: Cranial lung lobes of pigs were used to evaluate different staple line reinforcement methods (n = 6). Ventilator-assisted manometry was used to measure the maximum resistance pressure at the time of rupture of the lung tissue after stapling. RESULTS: The mean maximum resistance pressures …

Rank45.0
Other PubMed-indexed publication

A method for predicting drugs that can boost the efficacy of immune checkpoint blockade.

Nature immunology · 2024 · PMID 38499799

Combination therapy is a promising therapeutic strategy to enhance the efficacy of immune checkpoint blockade (ICB); however, predicting drugs for effective combination is challenging. Here we developed a general data-driven method called CM-Drug for screening compounds that can boost ICB treatment efficacy based on core and minor gene sets identified between responsive and nonresponsive samples in ICB therapy. The CM-Drug method was validated using melanoma and lung cancer mouse models, with combined therapeutic e…

Rank45.0
Other PubMed-indexed publication

Vaccine-based therapeutic interventions in lung cancer management: A recent perspective.

Medical oncology (Northwood, London, England) · 2024 · PMID 39316239

The incidence of lung cancer continues to grow globally, contributing to an ever-increasing load on healthcare systems. Emerging evidence has indicated lowered efficacy of conventional treatment strategies, such as chemotherapy, surgical interventions and radiotherapy, prompting the need for exploring alternative interventions. A growing focus on immunotherapy and the development of personalized medicine has paved the way for vaccine-based delivery in lung cancer. With various prominent targets such as CD8+T cells …

Rank45.0
Other PubMed-indexed publication

CD73 targeted combination therapy reverses PD-1 inhibitor resistance in CD73-high PD-L1-negative NSCLC: Evidence from pleural effusion organoids.

Global medical genetics · 2026 · PMID 42927277

OBJECTIVES: Patients with PD-L1-negative non-small cell lung cancer (NSCLC) often exhibit inherent PD-1 inhibitor resistance, leading to poor monotherapy efficacy and unfavorable clinical outcomes. Notably, no effective stratification biomarkers are currently available to overcome this resistance. Thus, this study aimed to reverse PD-1 inhibitor resistance in PD-L1-negative NSCLC by identifying novel predictive biomarkers and developing effective targeted immunotherapeutic regimens. METHODS: Pleural effusion-derive…

Rank45.0
Other PubMed-indexed publication

Biophysical insights into interaction mechanism of cediranib with human serum albumin: In-vitro and in-silico perspectives.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2027 · PMID 42570632

Cediranib (CB), a tyrosine kinase inhibitor, exhibits encouraging anticancer activity against breast, prostate, glioblastoma, and non-small cell lung cancer cells. This study used multi-spectral and computational analyses to elucidate the binding mechanism of CB to human serum albumin (HSA). The HSA fluorescence was substantially quenched upon CB binding and a static quenching mode was detected. An intermediate binding affinity was observed to govern the CB-HSA complex formation, while H-bonds, van der Waals, and h…

Rank45.0
Other PubMed-indexed publication

Vacuum-assisted laser ablation induces pulmonary cavity formation: insights from a rabbit model.

Journal of cardiothoracic surgery · 2026 · PMID 42958398

BACKGROUND: Pulmonary nodules are common findings in low‑dose CT screening, and thermal ablation is a minimally invasive treatment option. However, incomplete ablation and tissue fragment dispersion remain challenges. METHODS: In this rabbit model study, laser ablation and microwave ablation were performed at three energy settings (600 J, 1,200 J, and 1,800 J) under CT guidance. An innovative three‑way vacuum adapter was integrated with the puncture needle to apply negative pressure suction during ablation. Gross p…

Rank45.0
Other PubMed-indexed publication

Ultrasound Molecular Imaging and Visualization of Immune Biomarkers: A New Paradigm for Tumor Immunotherapy Response Assessment.

Ultrasound in medicine & biology · 2026 · PMID 42722534

Cancer immunotherapy has revolutionized the treatment landscape, yet its clinical efficacy is limited by modest objective response rates and the emergence of atypical response patterns such as pseudoprogression and hyperprogression. Conventional RECIST criteria relying on anatomical size changes and invasive tissue biopsies suffer from prominent sampling bias and cannot dynamically reflect the heterogeneous tumor immune microenvironment (TIME), creating an urgent demand for non-invasive, real-time functional imagin…

Rank45.0
Other PubMed-indexed publication

Scorpiones, Scolopendra and Gekko Inhibit Lung Cancer Growth and Metastasis by Ameliorating Hypoxic Tumor Microenvironment via PI3K/AKT/mTOR/HIF-1α Signaling Pathway.

Chinese journal of integrative medicine · 2024 · PMID 38850481

OBJECTIVE: To investigate whether Buthus martensii karsch (Scorpiones), Scolopendra subspinipes mutilans L. Koch (Scolopendra) and Gekko gecko Linnaeus (Gekko) could ameliorate the hypoxic tumor microenvironment and inhibit lung cancer growth and metastasis by regulating phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin/hypoxia-inducible factor-1α (PI3K/AKT/mTOR/HIF-1α) signaling pathway. METHODS: Male C57BL/6J mice were inoculated with luciferase labeled LL/2-luc-M38 cell suspension to devel…

Rank45.0
Other PubMed-indexed publication

Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer.

Current treatment options in oncology · 2024 · PMID 39392556

Lung cancer is expected to contribute to about 0.234 million new cases and about 0.125 million mortalities in the United States in the year 2024. Small cell lung cancer (SCLC), a neuroendocrine carcinoma, has lesser prevalence but is more aggressive at an extensive stage where the tumor is not only confined to hemithorax, mediastinum, and supraclavicular region but spread beyond the supraclavicular region. The prognosis of SCLC, irrespective of the limited or extensive stage, is very poor. Only a 5-10% overall surv…

Rank45.0
Other PubMed-indexed publication

Baicalin and lung diseases.

Naunyn-Schmiedeberg's archives of pharmacology · 2024 · PMID 37725153

Studies focusing on natural products have been conducted worldwide, and the results suggest that their natural ingredients effectively treat a wide range of illnesses. Baicalin (BIA) is a glycoside derived from the flavonoid baicalein present in Scutellaria baicalensis of the Lamiaceae family. Interestingly, BIA has been shown to protect the lungs in several animal models used in numerous studies. Therefore, we fully analyzed the data of the studies that focused on BIA's lung protective function against various inj…

Rank45.0
Other PubMed-indexed publication

A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.

Cancer gene therapy · 2024 · PMID 38177307

KRAS mutations occur commonly in the lung and can lead to the development of non-small cell lung cancer (NSCLC). While the mutated KRAS protein is a neoantigen, it usually does not generate an effective anti-tumor immune response on mucosal/epithelial surfaces. Despite this, mutated KRAS remains a potential target for immunotherapy since immune targeting of this protein in animal models has been effective at eliminating tumor cells. We attempted to develop a KRAS vaccine using mutated and wild-type KRAS peptides in…

Rank45.0
Other PubMed-indexed publication

Dual-glycolipid engineered vaccine platform empowers delivery route customization to intercept tumor lung metastasis.

Journal of controlled release : official journal of the Controlled Release Society · 2026 · PMID 42826903

Pulmonary metastasis remains a lethal challenge, necessitating potent mRNA vaccines to establish proactive immune surveillance. Although lipid nanoparticles (LNPs) are the gold standard for delivery mRNA, the "PEG dilemma"-comprising immunogenicity and poor cellular engagement-critically limits their efficacy. Here, we developed a biocompatibility, PEG-free mRNA platform (SG-LNP) co-modified with sialic acid-dimyristoyl-glycerol (SA-DMG) and monosialotetrahexosylganglioside (GM1), enabling a customizable tissue-tar…

Rank45.0
Other PubMed-indexed publication

Systemic inflammation enhances metastatic growth in a syngeneic neuroblastoma mouse model.

Pediatric surgery international · 2024 · PMID 39017743

BACKGROUND: We previously showed that total tumor resection enhances metastatic growth in a syngeneic metastatic mouse model of neuroblastoma. In this study, we further investigated which surgical factors contributed most to metastatic growth. METHODS: Tumor cells derived from MYCN transgenic mice were subcutaneously injected into wild-type mice. Mice were randomly assigned to receive partial resection (PR group), subcutaneous implantation of a sponge (Sp group), or observation (Obs group). The lymph node metastasi…

Rank45.0
Other PubMed-indexed publication

Single-cell RNA sequencing analysis of bone cancer pain model induced by Lewis lung cancer cells in male mice.

Annals of medicine · 2026 · PMID 41758238

BACKGROUND: Bone cancer pain (BCP) is one of the most severe complications faced by cancer patients, with complex physiological and pathological mechanisms and unclear molecular characteristics. METHODS: The BCP model was established by inoculating Lewis lung cancer cells into the femur to induce hyperalgesia and spontaneous pain. Single-cell RNA sequencing technology was used to characterize the cell composition and molecular features of the L2-L4 spinal cord after BCP modelling. RESULTS: Our research results iden…

Rank43.0
Other PubMed-indexed publicationCorrection flagged

An engineered influenza virus to deliver antigens for lung cancer vaccination.

Nature biotechnology · 2024 · PMID 37231262

The development of cancer neoantigen vaccines that prime the anti-tumor immune responses has been hindered in part by challenges in delivery of neoantigens to the tumor. Here, using the model antigen ovalbumin (OVA) in a melanoma model, we demonstrate a chimeric antigenic peptide influenza virus (CAP-Flu) system for delivery of antigenic peptides bound to influenza A virus (IAV) to the lung. We conjugated attenuated IAVs with the innate immunostimulatory agent CpG and, after intranasal administration to the mouse l…

Rank42.0
Other PubMed-indexed publication

Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylation.

In vitro cellular & developmental biology. Animal · 2023 · PMID 37002491

Palmitoylation is a post-translational modification occurring on cysteine residues, which process is catalyzed by a family of zinc finger Asp-His-His-Cys (DHHC) domain-containing (ZDHHC) protein acyltransferases. As a family member, ZDHHC9 plays a crucial role in varied malignancies by regulating protein stability via protein substrate palmitoylation. Based on the bioinformatic analysis of GEO gene microarray GSE75037 (|log2 fold change|> 1, P < 0.05), ZDHHC9 was defined as a significantly upregulated gene in lung …

Rank42.0
Other PubMed-indexed publication

Ginsenoside Rg3 enhances the radiosensitivity of lung cancer A549 and H1299 cells via the PI3K/AKT signaling pathway.

In vitro cellular & developmental biology. Animal · 2023 · PMID 36790693

Lung cancer is one of the most common cancers and the leading cause of cancer-related deaths in the world. Radiation is widely used for the treatment of lung cancer. However, radioresistance and toxicity limit its effectiveness. Ginsenoside Rg3 (Rg3) is a positive monomer extracted from ginseng and has been shown to the anti-cancer ability on many tumors. The aim of the present study was to ascertain whether Rg3 is able to enhance the radiosensitivity of lung cancer cells and investigate the underlying mechanisms. …

Rank42.0
Other PubMed-indexed publication

The effect of Moringa oleifera leaf extracts against urethane-induced lung cancer in rat model.

Environmental science and pollution research international · 2023 · PMID 36567388

Lung cancer is one of the most common malignancies in the world, and chemotherapy can have unfavorable side effects. The aim of the present study is to evaluate the therapeutic anticancer role of Moringa oleifera leaf extracts (MLE) in urethane-induced lung cancer in adult male albino rats as compared to standard chemotherapy. Rats were categorized into four groups (10 rats/group), including negative control rats, urethane lung cancer model rats, MLE-treated lung cancer rats, and cisplatin-treated rats. Estimation …

Rank42.0
Other PubMed-indexed publication

New and effective EGFR-targeted fluorescence imaging technology for intraoperative rapid determination of lung cancer in freshly isolated tissue.

European journal of nuclear medicine and molecular imaging · 2023 · PMID 36207638

PURPOSE: During lung cancer surgery, it is very important to define tumor boundaries and determine the surgical margin distance. In previous research, systemically application of fluorescent probes can help medical professionals determine the boundaries of tumors and find small tumors and metastases, thereby improving the accuracy of surgical resection. However, there are very few safe and effective probes that can be applied to clinical trials up to now, which limits the clinical application of fluorescence imagin…

Promising Experimental Therapies111 records
Rank107.7
Systematic review or meta-analysis

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38294563

BACKGROUND: This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. METHODS: We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) …

Rank103.6
Systematic review or meta-analysis

Efficacy of Aidi injection combined with chemotherapy, radiotherapy or chemoradiotherapy for unresectable esophageal cancer treatment: A meta-analysis and systematic review of 29 randomized controlled trials based on Asian populations (China).

European journal of clinical pharmacology · 2023 · PMID 37043012

OBJECTIVES: This study aimed to assess the efficacy of Aidi combined with standard treatment, including radiotherapy (R), chemotherapy (C), or chemoradiotherapy (CR), for unresectable esophageal cancer (EC). METHODS: Eight online databases were queried to collect randomized controlled trials (RCTs) published from database construction to August 2022. Patients in the control group underwent standard treatment with R, C, or CR, whereas those in the experimental group underwent Aidi combined with standard treatment. R…

Rank100.0
Systematic review or meta-analysisResult signal: harm

Risk of cancer incidence and mortality in patients with chronic pain: A systematic review and meta-analysis.

Cancer metastasis reviews · 2026 · PMID 42115445

Evidence from experimental studies suggests that pain may influence cancer development. We conducted a systematic review (registration osf.io/ms437) of the epidemiological studies assessing whether chronic pain, with minimal or non-inflammatory features, increases the risk of cancer incidence or mortality. The search used Scopus and Web of Science up to 11/03/2025. Quality assessment used the Newcastle-Ottawa Scale. Study characteristics and outcomes were analysed using narrative synthesis, with random-effects meta…

Rank98.7
Randomized controlled trial

Thalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial.

Frontiers in immunology · 2026 · PMID 42964306

BACKGROUND: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a characteristic cutaneous adverse event associated with immune checkpoint inhibitors. This study compared two prophylactic thalidomide doses to identify the more promising dose for further evaluation. METHODS: In this multicenter, randomized clinical trial, patients with advanced esophageal squamous cell carcinoma or non-small cell lung cancer (NSCLC) were randomly assigned to receive thalidomide 50 mg/day (Group A) or 100 mg/day (Group …

Rank97.9
Randomized controlled trialResult signal: null

Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial.

Annals of surgical oncology · 2026 · PMID 41369813

BACKGROUND: Hepatectomy for isolated colorectal liver metastases is associated with 5 year overall survival (OS) of 58% and is accepted as standard of care. However, the role of liver resection with unresectable low-volume lung metastases is unknown. LUNA was a phase II randomized trial designed to study the survival benefit of hepatectomy with unresectable lung metastases. METHODS: After stratification by KRAS status and primary tumor in the colon versus rectum, patients were randomized 1:1 to hepatectomy plus che…

Rank95.2
Randomized controlled trialResult signal: benefit

Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial.

Signal transduction and targeted therapy · 2026 · PMID 42869886

Definitive chemoradiotherapy followed by immunotherapy consolidation is the current standard of care for limited-stage small cell lung cancer (LS-SCLC). We conducted a randomized phase II trial (ChiCTR2000032275) to evaluate a camrelizumab-based induction-consolidation strategy in previously untreated patients with LS-SCLC. Patients were randomly assigned (1:1) to receive induction camrelizumab plus etoposide-platinum followed by concurrent chemoradiotherapy (CRT) and camrelizumab consolidation (camrelizumab group)…

Rank89.0
Randomized controlled trial

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Nature medicine · 2023 · PMID 37429923

Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively randomized phase 2 study investigating first-line pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily), anti-CTLA-4 quavonlimab (25 mg every 6 weeks) or anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks) in advanced NSCLC. Patients were categorized by T-cell-inflam…

Rank85.0
Randomized clinical study

Effects of Temporal Information Structure on Causal Explanations Generated by Large Language Models: Experimental Study Using Lung Cancer Incidence Data.

Journal of medical Internet research · 2026 · PMID 42932869

BACKGROUND: Large language models (LLMs) are increasingly applied to causal explanation in public health and epidemiology. However, recent studies suggest that LLMs exhibit instability in processing temporal information, which raises concerns about their suitability for generating coherent causal explanations. Despite this, little is known about how distinct components of temporal information influence LLM-generated causal explanations in epidemiological contexts. OBJECTIVE: This study aimed to examine how event or…

Rank85.0
Randomized clinical study

Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis.

Naunyn-Schmiedeberg's archives of pharmacology · 2025 · PMID 39073415

In the course of clinical treatment for anti-tumor, the combination of traditional Chinese medicine (TCM) and other treatment schemes can reduce toxicity and increase efficiency. The purpose of this paper is to find out the key TCM and effective components for the treatment of non-small cell lung cancer (NSCLC) and analyze its therapeutic mechanism by analyzing the prescription of TCM combined with chemotherapy for NSCLC. Firstly, the prescriptions of TCM in the randomized controlled trials combined with chemothera…

Rank83.9
Phase II clinical trial

Phase II Multicenter Clinical Trial of Intraoperative Molecular Imaging with Abenacianine During Lung Cancer Surgery.

Annals of surgical oncology · 2026 · PMID 42502096

BACKGROUND: Surgery is the cornerstone for locally contained lung cancer; however, intraoperative challenges include accurate lesion localization and assessment of surgical margins. Intraoperative molecular imaging (IMI) using near-infrared fluorescence-guided surgery is a real-time tumor-targeted optical imaging technique. A multicenter phase II clinical trial evaluated abenacianine (VGT-309), a cathepsin-targeted near-infrared (NIR) IMI agent for visualization of pulmonary nodules and margins during surgery. The …

Rank83.9
Phase II clinical trialResult signal: harm

Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42887461

BACKGROUND: Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether continuing EGFR inhibition with lazertinib combined with platinum-pemetrexed chemotherapy could extend clinical benefit after progression on prior lazertinib. METHODS: In the multicenter, single-arm, phase II LUCAS study (NCT05786430), patients with advanced EGFR-mutant NSCLC who had progressed on lazertinib …

Rank83.4
Phase II clinical trial

Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42574065

PURPOSE: Rilvegostomig, an anti-PD-1/T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domain bispecific antibody, was evaluated in this first-in-human, multicenter, phase I/II, open-label study (NCT04995523) in checkpoint inhibitor (CPI)-experienced patients with programmed cell death ligand-1 (PD-L1)-positive advanced or metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: In part A, patients (n = 51) received intravenous rilvegostomig at escalating doses of 70, 210,…

Rank83.4
Phase II clinical trial

Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42507540

PURPOSE: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1) expression. PATIENTS AND METHODS: This nonrandomized, multicenter, open-label, single-arm phase II trial included patients with previously untreated advanced NSCLC who had a PD-L1 tumor proportion score of ≥50%. Patients received pembrolizumab and necitumumab every 3 weeks for up to 35 cycles. The …

Rank80.8
Phase II clinical trialResult signal: null

Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).

Investigational new drugs · 2023 · PMID 36355317

The survival benefit of icotinib (an oral epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in patients with advanced lung cancer has been confirmed in several studies. This study (ICAPE) evaluated the efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma. Patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma were enrolled in the multicenter, open-label, single-arm, phase II study. Eligible patients received or…

Rank80.2
Phase II clinical trial

First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42767923

BACKGROUND: Immune-antiangiogenic combinations have shown promising signals of activity in ES-SCLC, but the optimal timing of anti-angiogenic therapy and biomarkers associated with benefit remain undefined. This study evaluated the efficacy and safety of combining apatinib with camrelizumab during maintenance and explored immune-molecular biomarkers of benefit. METHODS: In this single-arm phase II trial, apatinib plus camrelizumab as maintenance therapy following induction therapy with camrelizumab plus platinum-et…

Rank79.9
Phase II clinical trial

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology · 2026 · PMID 42426863

BACKGROUND: Resistance to anti-PD-1/PD-L1 therapy is a major unmet need. Growth Differentiation Factor 15 (GDF-15) has been identified as a key resistance factor for anti-PD-1/PD-L1 immunotherapy. Visugromab, a neutralizing anti-GDF-15 antibody, plus the anti-PD-1 antibody nivolumab (V+N) was evaluated in the first-in-human phase 1/2a GDFATHER-01 trial in heavily pretreated participants with locally advanced/metastatic non-squamous non-small-cell lung cancer (nsq NSCLC), urothelial carcinoma (UC), or hepatocellular…

Rank79.9
Phase II clinical trial

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.

International journal of clinical oncology · 2024 · PMID 38758397

BACKGROUND: MET exon 14 skipping mutations occur in 3-4% and MET high amplifications occur in < 1% of patients with non-small-cell lung cancer (NSCLC). Crizotinib, a selective ATP-competitive small-molecule inhibitor of c-Met, ALK, and ROS1 tyrosine kinases, has shown activity in cancer models with various types of MET activation. METHODS: The Co-MET study is a single-arm phase 2 trial to assess the safety and efficacy of crizotinib in MET inhibitor-naïve patients with advanced NSCLC harboring MET exon 14 skipping …

Rank79.7
Phase II clinical trial

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42385125

PURPOSE: Presently, to our knowledge, there are no approved targeted therapies for neuregulin 1 gene fusion-positive (NRG1+) cholangiocarcinoma. Zenocutuzumab, a HER2 × HER3 bispecific antibody, is approved for previously treated, advanced/metastatic NRG1+ non-small cell lung cancer and pancreatic adenocarcinoma. Here, we report results for 22 patients with NRG1+ cholangiocarcinoma in the eNRGy trial. METHODS: eNRGy is a single-arm, phase II study of zenocutuzumab in advanced NRG1+ solid tumors. Patients were age 1…

Rank79.2
Phase II clinical trial

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Oncoimmunology · 2026 · PMID 42684015

Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) therapy, but only 25% of patients have durable responses. TG4010, a mucin 1 (MUC1) vaccine, has demonstrated activity in NSCLC. We conducted a multi-institutional study to determine the safety and activity of nivolumab plus TG4010 in ICI naïve NSCLC patients (NCT02823990). The target accrual was 29 evaluable patients. The primary endpoint was the response rate requiring at least 10/29 responders. The study was terminated early d…

Rank77.0
Phase II clinical trial

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.

Oncoimmunology · 2026 · PMID 41732954

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treate…

Rank77.0
Phase II clinical trialResult signal: null

Adjuvant Chemotherapy for Resected Stage-IA Lung Adenocarcinoma With Micropapillary Histologic Pattern.

Interdisciplinary cardiovascular and thoracic surgery · 2026 · PMID 42266006

OBJECTIVES: The micropapillary pattern (MP) is a high-risk factor for postoperative recurrence in lung adenocarcinoma (LUAD), but the role of adjuvant chemotherapy (ACT) in stage IA LUAD with MP (LUADmp) after resection remains unclear. METHODS: From September 2017 to August 2020, in the phase II trial, resected stage IA LUADmp patients received ACT (pemetrexed and carboplatin), forming the ACT-group. Patients who met the trial criteria but declining ACT during the same period were designated as the standard of car…

Rank77.0
Phase II clinical trial

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

Oncoimmunology · 2026 · PMID 42126144

Retrospective characterization of cell‒cell relationships in the tumor microenvironment provides significantly better predictive power than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles. In this small study assessing the safety and possible efficacy of gemcitabine and pembrolizumab in immunotherapy-naïve patients with NSCLC who have received prior treatment, we investigated both standard and novel immune parameters in 16 enrolled patients (NCT03083808). The combination of gemcitabine …

Rank76.8
Phase II clinical trial

Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.

International journal of clinical oncology · 2022 · PMID 36241930

BACKGROUND: Nedaplatin and nab-paclitaxel are each efficacious in the treatment of squamous cell lung cancer. PATIENTS AND METHODS: Eligibility criteria were: no prior chemotherapy, advanced squamous cell lung cancer; performance status 0-1, age > 20 years but < 75 years, and adequate hematologic, hepatic and renal function. Patients received escalating doses of nab-paclitaxel under a fixed dose of nedaplatin (100 mg/m2, day 1) every 3 weeks in phase I. The initial nab-paclitaxel dose was 100 mg/m2 on days 1 and 8 …

Rank75.4
Multicenter clinical study

Radiomics under 2D regions, 3D regions, and peritumoral regions reveal tumor heterogeneity in non-small cell lung cancer: a multicenter study.

La Radiologia medica · 2023 · PMID 37486526

PURPOSE: Lung cancer has significant genetic and phenotypic heterogeneity, leading to poor prognosis. Radiomic features have emerged as promising predictors of the tumor phenotype. However, the role of underlying information surrounding the cancer remains unclear. MATERIALS AND METHODS: We conducted a retrospective study of 508 patients with NSCLC from three institutions. Radiomics models were built using features from six tumor regions and seven classifiers to predict three prognostically significant tumor phenoty…

Rank74.0
Phase II clinical trial

A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG).

Medical oncology (Northwood, London, England) · 2023 · PMID 37261532

Immune checkpoint inhibitors (ICIs) ± chemotherapy is the standard treatment for driver mutation-negative non-small cell lung cancer (NSCLC). However, accessibility to ICIs in LMICs is limited due to high cost, and platinum-based chemotherapy remains the mainstay of treatment. Metformin has anticancer properties, and studies suggest synergism between metformin and pemetrexed. Based on preclinical evidence, this combination may be more beneficial for STK11-mutated NSCLC, a subgroup, inherently resistant to ICIs. In …

Prospective Cohort Studies99 records
Rank102.8
Systematic review or meta-analysis

Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.

Clinical and experimental medicine · 2023 · PMID 36315311

Circulating tumor DNA (ctDNA) detection holds promise for genetic analyses and quantitative assessment of tumor burden. A systematic review and meta-analysis were conducted to investigate the clinical relevance of ctDNA among patients with localized non-small cell lung cancer (NSCLC). PubMed, EMBASE, and the Cochrane Library were searched for eligible studies published from January 2001 to April 2022. After quality assessments and data extraction, diagnostic accuracy variables and prognostic data were calculated an…

Rank102.5
Systematic review or meta-analysis

Liquid Biopsies for Cancer: A Translational Science Review.

JAMA · 2026 · PMID 42574031

IMPORTANCE: Circulating tumor DNA (ctDNA) evaluation, in which fragments of tumor DNA circulating in a patient's bloodstream are extracted and analyzed, can be used to monitor cancer progression, detect residual cancer after treatment, and identify genetic changes within cancer cells that could affect treatment response. OBSERVATIONS: ctDNA sequencing identifies cancer cell gene variants that inform the selection of molecularly directed therapies in several types of cancer, including non-small cell lung cancer, col…

Rank102.2
Systematic review or meta-analysis

A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients.

Clinical and experimental medicine · 2023 · PMID 37027065

A high level of circulating tumor DNA (ctDNA) has been linked to poor survival in patients with certain solid tumors. In spite of this, it is still unclear whether ctDNA is associated with poor survival in small cell lung cancer (SCLC). To investigate the above association, we conducted a systematic review and meta-analysis. PubMed, Web of Science, Cochrane's Library, and Embase were searched for relevant cohort studies from the inception of the databases to November 28, 2022. Data collection, literature search, an…

Rank102.2
Systematic review or meta-analysis

Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.

Pulmonology · 2026 · PMID 41560513

BACKGROUND: Clinical guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as the initial diagnostic tool for lung cancer staging. However, despite the availability of mediastinal forceps biopsy and cryobiopsy, the optimal diagnostic approaches for other mediastinal conditions remain unclear. METHODS: We searched multiple databases and sources up to February 21, 2025, and employed single-arm, pairwise, and network meta-analytical approaches to comprehensively evaluate EBU…

Rank102.1
Systematic review or meta-analysis

The association between sleep duration and lung cancer: a meta-analysis.

Sleep & breathing = Schlaf & Atmung · 2024 · PMID 37770794

PURPOSE: The link between sleep duration and lung cancer risk has been suggested by some epidemiological studies. This meta-analysis was performed to further understand this relationship. METHODS: MEDLINE and EMBASE entries up to December 2022 were searched for eligible publications. A random effects model was used to calculate pooled relative risks (RRs) with 95% confidence intervals (95% CIs). Publication bias was estimated using Begg's and Egger's regression asymmetry test. RESULTS: The meta-analysis included 11…

Rank97.0
Randomized controlled trial

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Clinical lung cancer · 2026 · PMID 42697029

BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥ 50%; however, up to 30% of patients experience early progression or death, including cases of hyperprogressive disease (HPD). High baseline levels (≥ 30.5%) of circulating CD10- low-density neutrophils (LDNs) have been associated with increased HPD occurrence. Emerging evidence suggests that combining ICI with platinum-based chemotherapy (PCT) may mitigate the r…

Rank97.0
Systematic review or meta-analysisResult signal: null

The impact of previous extrapulmonary malignancies on survival of surgically treated primary lung cancer: a comprehensive systematic review and meta-analysis.

Updates in surgery · 2023 · PMID 36840795

Whether a history of previous extrapulmonary malignancies had an impact on the survival of surgically treated primary lung cancer patients remains unknown. To better answer this question, we, therefore, conducted the first meta-analysis to compare the survival of lung cancer patients after surgical resection with previous extrapulmonary malignancies and those without. We systematically searched PubMed, Embase, and the Cochrane Library to identify relevant studies up to April 1, 2022. Data for analysis were obtained…

Rank96.5
Randomized controlled trial

Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial.

Chinese journal of integrative medicine · 2024 · PMID 39266862

OBJECTIVE: To investigate whether the combination of chemotherapy with staged Chinese herbal medicine (CHM) therapy could enhance health-related quality of life (QoL) in non-small-cell lung cancer (NSCLC) patients and prolong the time before deterioration of lung cancer symptoms, in comparison to chemotherapy alone. METHODS: A prospective, double-blind, randomized, controlled trial was conducted from December 14, 2017 to August 28, 2020. A total of 180 patients with stage I B-IIIA NSCLC from 5 hospitals in Shanghai…

Rank96.4
Randomized controlled trial

Analgesic Efficacy of Different Doses of Esketamine as an Adjuvant to Ropivacaine for Thoracoscopy-Guided Thoracic Paravertebral Block After Thoracoscopic Radical Resection for Lung Cancer: A Prospective Randomized Controlled Trial.

Drug design, development and therapy · 2026 · PMID 42764888

PURPOSE: Thoracoscopy-guided thoracic paravertebral block (TG-TPVB) is a new analgesia technique; however, the duration of a single TG-TPVB is short. Esketamine combined with local anesthetics can prolong the duration of nerve block. This study compared the analgesic efficacy of three doses of esketamine combined with ropivacaine for TG-TPVB in patients undergoing thoracoscopic radical resection for lung cancer. METHODS: 160 patients were randomly allocated into the control, S1, S2, and S3 groups. All patients rece…

Rank95.8
Randomized controlled trialResult signal: null

Closed Versus Open Vent Port Techniques and the Disconnection Technique for Optimizing Lung Collapse With Bronchial Blockers in Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial.

The clinical respiratory journal · 2026 · PMID 42922101

INTRODUCTION: For patients undergoing video-assisted thoracoscopic surgery (VATS) for lung cancer or other pulmonary lesions, effective one-lung ventilation (OLV) is essential to provide surgical exposure. Bronchial blockers (BBs) are increasingly used for OLV, but the optimal management of their vent port to accelerate lung collapse remains unclear. METHODS: In this prospective, randomized, controlled trial, 75 patients were allocated to three groups (n = 25 each): Group 1-BB with vent port closed; Group 2 (contro…

Rank95.2
Randomized controlled trial

Early functional deterioration during first-line ICI-based therapy in advanced NSCLC: implications for supportive care.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42965695

PURPOSE: To compare objective functional measures for identifying early functional deterioration during first-line ICI-based therapy in advanced NSCLC and explore their relevance for supportive-care monitoring. METHODS: This secondary exploratory analysis used prospectively collected data from a randomized trial of pulmonary rehabilitation. Forty-two participants with baseline and 8-week assessments were evaluated using quadriceps force, SPPB, and 6MWD. Early deterioration was defined as decline in at least one dom…

Rank94.0
Randomized controlled trial

Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial.

International journal of radiation oncology, biology, physics · 2026 · PMID 42173326

PURPOSE: To report long-term toxicity and disease outcomes from a randomized trial comparing passive scattering proton therapy (PSPT) and intensity modulated photon radiation therapy (IMRT), both with concurrent chemotherapy, for non-small cell lung cancer. METHODS AND MATERIALS: One hundred forty-nine patients with locally advanced non-small cell lung cancer were randomly assigned to IMRT or PSPT; 147 completed the assigned treatment. Local failure, radiation pneumonitis (RP), major adverse cardiac events (MACEs),…

Rank93.7
Randomized controlled trialResult signal: harm

Factors associated with perceived cognitive impairment in patients with advanced lung cancer: a cross-sectional analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36178636

PURPOSE: Perceived cognitive impairment refers to cognitive dysfunction that particularly involves impairment in working or short-term memory, and inattention. This study aimed to identify factors associated with perceived cognitive impairment in patients with advanced lung cancer. METHODS: This cross-sectional analysis used pooled data from a prospective, ongoing randomized controlled trial examining the effectiveness of exercise in patients with advanced lung cancer (Trial Registration: NCT04119778). Patients dia…

Rank92.4
Randomized clinical study

Efficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled, multicenter phase II trial protocol (BEAM-LUNG).

Frontiers in immunology · 2026 · PMID 42857095

BACKGROUND: The PACIFIC and GEMSTONE-301 trials established consolidation immunotherapy post-chemoradiotherapy for unresectable stage III NSCLC, but 22-30% of patients fail initial chemoradiotherapy, precluding consolidation. PACIFIC-2 and CheckMate 73L failures highlight the need for better integration. Induction chemoimmunotherapy before radiotherapy may improve downstaging and immune activation. This trial evaluates whether induction benmelstobart (PD-L1 inhibitor) plus anlotinib (TKI) and chemotherapy, followed…

Rank92.0
Randomized controlled trial

Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

International journal of radiation oncology, biology, physics · 2026 · PMID 42086125

PURPOSE: We report mature outcomes of patients with limited-stage small cell lung cancer randomly assigned to the 61.2 Gy concomitant boost (CB) thoracic radiation therapy (TRT) arm of Cancer and Leukemia Group B (CALGB) 30610/Radiation Therapy Oncology Group (RTOG) 0538. The CB arm was discontinued after planned interim analysis; however, the study provides the largest prospective data set using 61.2 Gy CB TRT. METHODS AND MATERIALS: Eligible patients had limited-stage small cell lung cancer with regional lymph no…

Rank89.8
Randomized clinical study

One-stage versus two-stage video-assisted thoracic surgery for synchronous bilateral pulmonary nodules: protocol for a prospective, multicentre, randomised controlled clinical trial in China (OTVATS-2).

BMJ open · 2026 · PMID 42810792

INTRODUCTION: With the increasing detection of synchronous bilateral pulmonary nodules in clinical practice, both one-stage and two-stage video-assisted thoracic surgery (VATS) have been widely applied. This study protocol describes the OTVATS-2 trial, which aims to compare perioperative complications and long-term outcomes between these two surgical strategies. METHODS AND ANALYSIS: A prospective, multicentre, randomised controlled clinical trial will be conducted to compare the surgical outcomes of one-stage vers…

Rank89.0
Randomized controlled trial

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Nature medicine · 2023 · PMID 37429923

Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively randomized phase 2 study investigating first-line pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily), anti-CTLA-4 quavonlimab (25 mg every 6 weeks) or anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks) in advanced NSCLC. Patients were categorized by T-cell-inflam…

Rank87.4
Randomized clinical study

Short-term effects of preoperative nutritional intervention in lung surgery for malignant tumors: a single-center prospective study.

General thoracic and cardiovascular surgery · 2024 · PMID 38165558

OBJECTIVES: Preoperative malnutrition is a risk factor for postoperative morbidity and mortality in patients with lung cancer. Assessing the preoperative nutritional status should be considered essential for patients scheduled to undergo lung surgery. This prospective study aimed to investigate whether preoperative nutritional intervention improves the nutritional conditions and short-term postoperative outcomes. METHODS: The primary endpoints included safety, feasibility and short-term therapeutic efficacy of preo…

Rank85.0
Randomized clinical study

Characterizing the accuracy of robotic bronchoscopy in localization & targeting of small pulmonary lesions.

International journal of computer assisted radiology and surgery · 2024 · PMID 38890223

PURPOSE: Considering the recent implementation of lung cancer screening guidelines, it is crucial that small pulmonary nodules are accurately diagnosed. There is a significant need for quick, precise, and minimally invasive biopsy methods, especially for patients with small lung lesions in the outer periphery. Robotic bronchoscopy (RB) has recently emerged as a novel solution. The purpose of this study was to evaluate the accuracy of RB compared to the existing standard, electromagnetic navigational bronchoscopy (E…

Rank83.8
Phase II clinical trial

ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 42336205

INTRODUCTION: The benefit of durvalumab after chemoradiotherapy (CRT) varies widely in unresectable stage III NSCLC. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection may help identify patients at high risk of early treatment failure during and after durvalumab. METHODS: In this prospective multicenter study, patients with unresectable stage III NSCLC received CRT followed by durvalumab. Plasma samples were collected at screening, after CRT, at predefined time points during durvalumab, an…

Rank81.8
Multicenter clinical study

PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study.

European journal of nuclear medicine and molecular imaging · 2024 · PMID 37725128

PURPOSE: No consensus on a grading system for invasive lung adenocarcinoma had been built over a long period of time. Until October 2020, a novel grading system was proposed to quantify the whole landscape of histologic subtypes and proportions of pulmonary adenocarcinomas. This study aims to develop a deep learning grading signature (DLGS) based on positron emission tomography/computed tomography (PET/CT) to personalize surgical treatments for clinical stage I invasive lung adenocarcinoma and explore the biologic …

Rank79.6
Phase II clinical trial

Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.

International journal of cancer · 2026 · PMID 42003237

Immune checkpoint inhibitors have shown promising results in the neoadjuvant treatment of resectable non-small cell lung cancer. This open-label, single-arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in patients with resectable non-squamous non-small cell lung cancer. Patients with previously untreated, pathologically confirmed, non-squamous non-small cell lung cancer in stage II, IIIA, and select IIIB (T3N2 only) were treated with a…

Rank77.9
Multicenter clinical study

Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis.

Genes · 2026 · PMID 42938349

OBJECTIVES: Precision medicine has improved outcomes in advanced lung cancer, but its implementation remains limited. The prospective LANTERN project (NCT05802771) involves comprehensive clinical and multi-omics data collection. Here, we report preliminary genomic findings, focusing on the prognostic impact of gene mutations, pairwise co-mutational patterns, and their stage-specific association with PD-L1 analysis on patients speciments. METHODS: This prospective, multicenter observational study enrolled 271 consec…

Rank77.6
Multicenter clinical study

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42826612

BACKGROUND: Extensive-stage small cell lung cancer (ES-SCLC) has a dismal prognosis as patients progress within months after first-line systemic treatment. Until recently, topotecan was the only approved second-line treatment in Europe. However, due to its limited efficacy, various treatment strategies are being employed. This study aimed to depict the therapeutic landscape of second-line treatment in ES-SCLC and to evaluate survival outcomes in a real-world setting. METHODS: Data from the Austrian LALUCA registry,…

Rank77.5
Multicenter clinical studyResult signal: harm

Risk Factors for Pneumonitis Induced by Combined Radiotherapy and Immunotherapy: A Multicenter Prospective Study.

Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42805242

BACKGROUND: The combination of radiotherapy (RT) and immune checkpoint inhibitors (ICIs) has become an important therapeutic approach for lung cancer. However, pneumonitis remains a major treatment-related toxicity of this therapeutic approach, and the risk factors for pneumonitis associated with combined RT and ICIs under different treatment sequences have not been clearly defined. PATIENTS AND METHODS: Patients with lung cancer who received thoracic RT were prospectively enrolled from 3 centers. Pneumonitis was a…

Quality Of Life115 records
Rank111.4
Systematic review or meta-analysis

Effects of enhanced recovery after surgery and prehabilitation interventions on postoperative outcomes after lung resection in patients with lung cancer: a systematic review and meta-analysis.

Frontiers in public health · 2026 · PMID 42898494

INTRODUCTION: Lung resection is the standard curative treatment for resectable lung cancer; however, postoperative pulmonary complications (PPCs) and prolonged hospital length of stay (LOS) remain major barriers to recovery and healthcare efficiency. Enhanced recovery after surgery (ERAS) and prehabilitation are distinct perioperative strategies that differ in their timing, intervention components, and mechanisms of action, but both aim to optimize patients' perioperative condition and improve postoperative recover…

Rank106.2
Systematic review or meta-analysis

Risk factors for cancer-related cognitive impairment among individuals with lung cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39287692

OBJECTIVES: Cancer-related cognitive impairment (CRCI) exerts a negative impact on the quality of life in lung cancer survivors. Risk factors for CRCI in lung cancer patients remain unclear.This study aimed to identify risk factors for CRCI in lung cancer patients. METHODS: A comprehensive literature search was conducted across PubMed, CINAHL, Web of Science, Wanfang, VIP Database, Embase, and China National Knowledge Infrastructure (CNKI) from their inception until March 10, 2024. Studies were screened, data extra…

Rank103.4
Systematic review or meta-analysis

Effectiveness of healthy lifestyle-based interventions in lung cancer survivors: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36542189

PURPOSE: To assess the effectiveness of healthy lifestyle-based interventions in lung cancer survivors. METHODS: We performed a literature search using PubMed, Web of Science, and Science Direct (last search March 2022). Quality assessment and risk of bias were assessed using the Downs and Black scale and the Cochrane tool. A systematic review and meta-analysis of randomized controlled trials were performed. We included controlled trials testing the effect of healthy lifestyle-based interventions in lung cancer sur…

Rank102.9
Systematic review or meta-analysis

The effect of mind-body exercise in lung cancer patients: a meta-analysis of RCTs.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 37870600

PURPOSE: This study aimed to evaluate the impact of mind-body exercise (yoga, tai chi, qigong, etc.) on lung cancer. METHODS: We performed a literature search of the electronic databases PubMed, Web of Science, Cochrane Library, Embase, CNKI, CBM, WanFang Data, and VIP from their inception to 16 May 2023. The primary outcome was the 6-min walk test (6MWT), while the secondary outcomes were anxiety levels and quality of life (QoL). Two independent reviewers performed the data extraction using a predefined protocol a…

Rank100.0
Systematic review or meta-analysis

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.

International journal of clinical oncology · 2024 · PMID 38353907

BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer. METHODS: We extracted studi…

Rank100.0
Systematic review or meta-analysis

The Prevalence and Factors of Dyspnea Among Advanced Cancer Survivors: A Systematic Review and Meta-analysis.

Cancer nursing · 2026 · PMID 40179263

BACKGROUND: Dyspnea is a significant symptom in advanced cancer patients, yet comprehensive evidence on its prevalence and related factors is lacking. OBJECTIVE: This review aims to summarize the prevalence of dyspnea among advanced cancer survivors and identify associated factors. METHODS: MEDLINE, EMBASE, Cochrane Library, PsycINFO, CINAHL Plus, and Web of Science were searched from inception to May 2024. Observational studies focusing on advanced cancer patients reporting dyspnea were included. Two reviewers per…

Rank99.0
Systematic review or meta-analysis

Is physical activity effective against cancer-related fatigue in lung cancer patients? An umbrella review of systematic reviews and meta-analyses.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 36781549

OBJECTIVES: To discuss the effects of physical activity on cancer-related fatigue (CRF) in lung cancer patients, summarize the types of physical activity in the published reviews, assess the quality of the evidence, and provide suggestions for the clinical selection of exercise intervention. METHODS: PubMed, EMBASE, Web of Science, and the Cochrane Database of Systematic Reviews were searched through 8 November 2021 to identify relevant systematic reviews and meta-analyses. We also performed a manual search of the …

Rank99.0
Randomized controlled trial

A Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutations: JCOG2506 (DECIDE-MET).

Clinical lung cancer · 2026 · PMID 42753422

BACKGROUND: MET exon 14 skipping (METex14) mutations represent a rare subset of non-small cell lung cancer (NSCLC) for which MET tyrosine kinase inhibitors (MET-TKIs) are recommended as first-line therapy. Patients with METex14-mutant NSCLC are often older and frequently exhibit high programmed death-ligand 1 (PD-L1) expression, providing a rationale for considering immune checkpoint inhibitor (ICI)-based therapy. Retrospective studies indicate that ICI-based therapy may offer survival outcomes comparable to, or po…

Rank97.4
Randomized controlled trialResult signal: mixed

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

The Lancet. Oncology · 2026 · PMID 42727592

BACKGROUND: Patient-reported outcome (PRO) symptom monitoring has been shown to improve overall survival. Yet, available evidence largely derives from resource-intensive studies limited to patients with advanced cancer. We aimed to assess the effect of PRO symptom monitoring on overall and progression-free survival in patients with stage I-IV lung cancer in a real-world clinical setting, with follow-up extending to 5 years. METHODS: The SYMPRO-Lung trial was a multicentre, stepped-wedged, cluster-randomised clinica…

Rank96.5
Randomized controlled trial

Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial.

Chinese journal of integrative medicine · 2024 · PMID 39266862

OBJECTIVE: To investigate whether the combination of chemotherapy with staged Chinese herbal medicine (CHM) therapy could enhance health-related quality of life (QoL) in non-small-cell lung cancer (NSCLC) patients and prolong the time before deterioration of lung cancer symptoms, in comparison to chemotherapy alone. METHODS: A prospective, double-blind, randomized, controlled trial was conducted from December 14, 2017 to August 28, 2020. A total of 180 patients with stage I B-IIIA NSCLC from 5 hospitals in Shanghai…

Rank93.7
Randomized controlled trialResult signal: null

Effect of Baduanjin qigong on postoperative pulmonary rehabilitation in patients with non-small cell lung cancer: a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 38158422

PURPOSE: The purpose of this study was to explore the effect of Baduanjin qigong on improving lung function and postoperative quality of life of patients with non-small cell lung cancer (NSCLC) and to find an effective home-based pulmonary rehabilitation method. METHODS: A randomised controlled trial was carried out from July 2019 to October 2021, which included 216 NSCLC postoperative participants from Beijing China-Japan Friendship Hospital and Cancer Hospital of Chinese Academy of Medical Science. Participants w…

Rank93.7
Randomized controlled trialResult signal: harm

Factors associated with perceived cognitive impairment in patients with advanced lung cancer: a cross-sectional analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36178636

PURPOSE: Perceived cognitive impairment refers to cognitive dysfunction that particularly involves impairment in working or short-term memory, and inattention. This study aimed to identify factors associated with perceived cognitive impairment in patients with advanced lung cancer. METHODS: This cross-sectional analysis used pooled data from a prospective, ongoing randomized controlled trial examining the effectiveness of exercise in patients with advanced lung cancer (Trial Registration: NCT04119778). Patients dia…

Rank93.6
Randomized clinical study

Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.

Clinical and translational radiation oncology · 2027 · PMID 42935767

PURPOSE: The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects. METHODS: Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at …

Rank93.2
Randomized clinical study

A randomized phase III study optimizing adjuvant osimertinib for resected EGFR-mutant stage II-III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01).

Japanese journal of clinical oncology · 2026 · PMID 42955056

The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II-III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non…

Rank93.0
Randomized controlled trial

Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023 · PMID 37126140

PURPOSE: The TORG0503 study was undertaken to select a preferred platinum-based third-generation regimen for patients with completely resected non-small cell lung cancer (NSCLC). This study aimed to describe the quality of life (QOL) analysis of that study. METHODS: Patients with completely resected NSCLC were randomized to receive three cycles of docetaxel plus cisplatin (DC) or paclitaxel plus carboplatin (PC) on day 1 every 3 weeks. QOL was assessed at three time points (baseline, after two cycles, and after thr…

Rank91.2
Randomized clinical study

Subgroup variations in benefit from telehealth palliative care for advanced lung cancer.

Journal of the National Cancer Institute · 2026 · PMID 42954305

We examined whether the impact on quality of life (QOL) of early palliative care delivered via video versus in-person visits varied across patients with advanced non-small cell lung cancer (NSCLC). Between 6/2018 and 5/2023, 1250 patients with advanced NSCLC enrolled in a randomized trial comparing early palliative care delivered via video or in-person visits at 22 cancer centers. Using the Functional Assessment of Cancer Therapy-Lung scale, we examined whether the effect of palliative care delivery modality on pat…

Rank90.0
Randomized clinical study

Effects of Immersive Virtual Reality and Relaxation Video on Symptom Severity, Distress, and Quality of Life in Lung Cancer Patients During Initial Chemotherapy Cycles: A Three-Arm Randomised Controlled Trial.

Healthcare (Basel, Switzerland) · 2026 · PMID 42940439

BACKGROUND/OBJECTIVES: To examine the effects of immersive virtual reality (VR) and a theme-matched relaxation video (RV) on symptom severity, distress, and quality of life in lung cancer patients. METHODS: In this open-label, three-arm, parallel-group randomised controlled trial, 315 patients were allocated (1:1:1) to the VR (n = 106), RV (n = 104), or control (CG; n = 105) group. During the first two chemotherapy cycles, the VR and RV groups were assigned two 20 min sessions of immersive nature-themed VR or theme…

Rank89.8
Randomized clinical studyResult signal: null

Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial.

Asia-Pacific journal of oncology nursing · 2026 · PMID 41625083

OBJECTIVE: This study aims to determine the impact of PROM with a personalized follow-up program on the evaluation of quality of life and self-management for patients after lung cancer resection. METHODS: Given a formal power calculation a total of 240 patients with lung cancer. Participants were randomly assigned to either the experimental or the control groups. Patients in the experimental group received a personalized follow-up program of patient-reported outcomes. The control group received only the telephone f…

Rank89.4
Randomized clinical study

Study protocol for the TROG 21.08 VITaL trial: a randomized controlled trial investigating ventilation imaging to improve the quality of life for patients with lung cancer treated with radiation therapy.

Clinical and translational radiation oncology · 2027 · PMID 42910049

BACKGROUND: Radiation therapy (RT) is indicated for 77% of patients with lung cancer. Over 20% of patients are affected by radiation-induced lung injury. Computed tomography ventilation imaging (CTVI) estimates high and low functioning lung regions. During RT planning, CTVI can guide preferential avoidance of higher ventilated regions by redirecting dose to less well ventilated regions, sparing healthy lung tissue. The double-masked randomized Trans-Tasman Radiation Oncology Group (TROG) 21.08 VITaL trial will inve…

Rank89.0
Randomized clinical studyResult signal: benefit

Effectiveness of Pharmaceutical Care in Reducing the Incidence of Immune Checkpoint Inhibitor-related Pneumonitis in Patients with NSCLC: A Randomized Controlled Trial.

Journal of the American Pharmacists Association : JAPhA · 2026 · PMID 42874870

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC), yet immune checkpoint inhibitor-related pneumonitis (CIP) remains a potentially life-threatening adverse event that may be mitigated through structured pharmaceutical care interventions. OBJECTIVE: To assess the effectiveness of pharmacy services in reducing the occurrence of CIP among patients with NSCLC receiving ICIs. METHODS: Patients who underwent immunotherapy at our hospital between Novemb…

Rank88.9
Randomized clinical study

Protocol of a randomized trial of "pathways," a hope intervention for people undergoing treatment for advanced lung cancer.

Contemporary clinical trials · 2026 · PMID 42648399

OBJECTIVE: Advanced cancer and its treatment can disrupt personal goal pursuits and attainment, which can imperil patient quality of life and increase risk for depression. Hope interventions foster the goal-pursuit skills exemplified by high-hope individuals and, based on a pilot trial, are a promising approach to support these patients. The current Phase II trial (NCT06047301) aims to determine the efficacy of a brief, hope intervention, "Pathways," in improving depression symptoms for people undergoing treatment …

Rank88.0
Randomized clinical study

InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.

Frontiers in oncology · 2026 · PMID 42908627

BACKGROUND: The optimal integration of surgery and definitive chemoradiotherapy (CRT) following modern neoadjuvant immunochemotherapy in stage IIB-IIIA/B non-small-cell lung cancer (NSCLC) remains controversial. Although immune checkpoint inhibitors have substantially improved outcomes in both resectable and unresectable disease, prospective randomized data directly comparing surgery and definitive CRT after neoadjuvant immunochemotherapy are lacking. METHODS: InDuRanS is a prospective, multicenter, randomized, ope…

Rank88.0
Randomized clinical studyResult signal: benefit

Implementation of oncological clinical trials in primary health care in Cuba: a program generalization study.

Contemporary clinical trials communications · 2026 · PMID 42890327

BACKGROUND: Primary health care (PHC) offers a strategic opportunity to conduct research with immunotherapeutic products for cancer treatment. OBJECTIVES: To evaluate the implementation of a program for conducting oncological clinical trials in PHC settings. The implementation objectives focused on assessing structure, process, and outcome indicators against predefined standards; the intervention objectives compared process and clinical outcomes (overall survival, quality of life, and patient satisfaction) in PHC s…

Rank87.9
Randomized clinical study

Experience of participating in a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in stage III-N2 non-small cell lung cancer: PIONEER.

BMJ open respiratory research · 2026 · PMID 42933815

INTRODUCTION: Multimodality treatment is recommended for potentially resectable stage III-N2 non-small cell lung cancer. However, no clear evidence states that surgery benefits survival and health-related quality of life (HRQoL). This multicentre (n=10, but 5 actively recruited) study explored experiences of patients, carers and multidisciplinary teams (MDTs) participating in a feasibility trial to inform the design of a phase III randomised trial with HRQoL as a primary outcome. METHODS: Patient participants were …

Rank87.8
Randomized clinical study

Effects of qigong exercise on physical fitness and patient-reported health outcomes in lung cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38214783

PURPOSE: The aim of this study was to investigate the effects of a three-month Guolin Qigong (GQ) intervention on physical fitness and patient-reported health outcomes among patients with lung cancer. METHODS: This pilot study was a non-randomized controlled trial. Eligible participants who were over 18 years of age and diagnosed with stage I-IV lung cancer were enrolled in the study and received either the GQ intervention or usual care (UC). Participants in the GQ group performed GQ at least twice a week (one hour…

Randomized Controlled Trials113 records
Rank111.4
Systematic review or meta-analysis

Effects of enhanced recovery after surgery and prehabilitation interventions on postoperative outcomes after lung resection in patients with lung cancer: a systematic review and meta-analysis.

Frontiers in public health · 2026 · PMID 42898494

INTRODUCTION: Lung resection is the standard curative treatment for resectable lung cancer; however, postoperative pulmonary complications (PPCs) and prolonged hospital length of stay (LOS) remain major barriers to recovery and healthcare efficiency. Enhanced recovery after surgery (ERAS) and prehabilitation are distinct perioperative strategies that differ in their timing, intervention components, and mechanisms of action, but both aim to optimize patients' perioperative condition and improve postoperative recover…

Rank108.4
Systematic review or meta-analysisResult signal: harm

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Targeted oncology · 2024 · PMID 38824269

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer. An updated toxicity profile of EGFR-TKIs proves valuable in guiding clinical decision making. OBJECTIVE: This study comprehensively assessed the risk of EGFR-TKI-related adverse events (AEs) involving different systems/organs. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane library for phase III randomiz…

Rank108.1
Systematic review or meta-analysisResult signal: benefit

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.

European journal of clinical pharmacology · 2024 · PMID 38300281

BACKGROUND: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small sample sizes and different methods of statistical analysis, which may lead to a lack of valid metrics to assess t…

Rank108.1
Systematic review or meta-analysis

Efficacy and safety of curative-intent intensity modulated radiotherapy (IMRT) for inoperable, locally-advanced non-small cell lung cancer: A systematic review.

Journal of cancer research and therapeutics · 2026 · PMID 42955956

Intensity-modulated radiotherapy (IMRT), including volumetric modulated arc therapy (VMAT) is widely used for the treatment of non-small cell lung cancer (NSCLC) despite the lack of prospective, randomized evidence over three-dimensional conformal radiotherapy (3D-CRT). IMRT has been shown to reduce doses to normal tissue and organs at risk (OAR) in planning and retrospective studies. The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD4202123…

Rank107.8
Systematic review or meta-analysisResult signal: benefit

The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.

Annals of medicine · 2026 · PMID 42613912

BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…

Rank107.7
Systematic review or meta-analysis

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38294563

BACKGROUND: This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. METHODS: We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) …

Rank107.3
Systematic review or meta-analysis

Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42843316

INTRODUCTION: Postoperative PD-1/PD-L1 blockade after complete resection of non-small-cell lung cancer (NSCLC) is mainly reported using relative disease-free survival (DFS) effects. We estimated absolute effects for distinct completed trial policies. METHODS: We systematically reviewed randomized phase III trials of postoperative single-agent PD-1/PD-L1 blockade. Published Kaplan-Meier curves were reconstructed to estimate trial-specific 36-month restricted mean DFS time (RMST) and DFS probability differences. Prim…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2025 · PMID 39542906

BACKGROUND: The optimal treatment for resectable Non-Small Cell Lung Cancer (NSCLC) remains under investigation, particularly about its effectiveness across different ethnicities. This meta-analysis aims to investigate the potential benefits of adding PD1/PD-L1 inhibitors for treatment, stratified by ethnicity. METHODS: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) that investigated the use of PD1/PD-L1 inhibitors to treat patients with resectable NSCLC. The outcomes eva…

Rank106.7
Systematic review or meta-analysisResult signal: mixed

Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.

European journal of clinical pharmacology · 2025 · PMID 39680077

BACKGROUND: Nivolumab and ipilimumab combination immunotherapy has become a standard treatment option for certain cancers. However, the benefits of combination therapy compared to nivolumab monotherapy in lung cancer patients are not entirely clear. We aimed to evaluate whether nivolumab plus ipilimumab improves clinical outcomes in lung cancer patients compared to nivolumab monotherapy. METHODS: A literature search was performed on PubMed, Web of Science, and Scopus from inception until November 2024 to identify r…

Rank106.1
Systematic review or meta-analysisResult signal: null

Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis.

Thoracic cancer · 2026 · PMID 42876373

Trilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor administered before chemotherapy, reduces chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), but its efficacy across solid tumors remains unclear. This meta-analysis evaluated the efficacy and safety of trilaciclib in solid tumor patients receiving chemotherapy. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to January 21, 2026. Randomized controlled trials (RCTs) an…

Rank105.2
Systematic review or meta-analysis

Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

International journal of clinical pharmacy · 2022 · PMID 35951217

BACKGROUND: Multitargeted tyrosine kinase inhibitors (TKIs) are used to treat advanced non-small cell lung cancer (NSCLC). Their efficacy and safety have been studied in randomized controlled trials. AIM: This meta-analysis aimed to summarize the most up-to-date evidence regarding the efficacy and adverse events of TKIs in NSCLC treatment. METHOD: Randomized controlled trials were searched from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The intervention arm was the TKI-containing group,…

Rank103.8
Systematic review or meta-analysisResult signal: null

Sublobar resection versus lobectomy for stage IA non-small-cell lung cancer ≤ 2 cm: a systematic review and patient-level meta-analysis.

Updates in surgery · 2023 · PMID 37563486

Despite lobectomy being the standard of care for early-stage non-small-cell lung cancer (NSCLC), sublobar resection (segmentectomy or wedge resection) has recently been suggested to achieve similar outcomes. An electronic literature search was conducted to retrieve randomized controlled trials (RCTs) or propensity score-matched studies (PSMs) comparing lobectomy to sublobar resection in stage IA NSCLC ≤ 2 cm in size, with provision of Kaplan-Meier curves for overall survival (OS) and disease-free survival (DFS). A …

Rank103.6
Systematic review or meta-analysis

Efficacy of Aidi injection combined with chemotherapy, radiotherapy or chemoradiotherapy for unresectable esophageal cancer treatment: A meta-analysis and systematic review of 29 randomized controlled trials based on Asian populations (China).

European journal of clinical pharmacology · 2023 · PMID 37043012

OBJECTIVES: This study aimed to assess the efficacy of Aidi combined with standard treatment, including radiotherapy (R), chemotherapy (C), or chemoradiotherapy (CR), for unresectable esophageal cancer (EC). METHODS: Eight online databases were queried to collect randomized controlled trials (RCTs) published from database construction to August 2022. Patients in the control group underwent standard treatment with R, C, or CR, whereas those in the experimental group underwent Aidi combined with standard treatment. R…

Rank103.4
Systematic review or meta-analysis

Effectiveness of healthy lifestyle-based interventions in lung cancer survivors: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36542189

PURPOSE: To assess the effectiveness of healthy lifestyle-based interventions in lung cancer survivors. METHODS: We performed a literature search using PubMed, Web of Science, and Science Direct (last search March 2022). Quality assessment and risk of bias were assessed using the Downs and Black scale and the Cochrane tool. A systematic review and meta-analysis of randomized controlled trials were performed. We included controlled trials testing the effect of healthy lifestyle-based interventions in lung cancer sur…

Rank102.9
Systematic review or meta-analysis

The effect of mind-body exercise in lung cancer patients: a meta-analysis of RCTs.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 37870600

PURPOSE: This study aimed to evaluate the impact of mind-body exercise (yoga, tai chi, qigong, etc.) on lung cancer. METHODS: We performed a literature search of the electronic databases PubMed, Web of Science, Cochrane Library, Embase, CNKI, CBM, WanFang Data, and VIP from their inception to 16 May 2023. The primary outcome was the 6-min walk test (6MWT), while the secondary outcomes were anxiety levels and quality of life (QoL). Two independent reviewers performed the data extraction using a predefined protocol a…

Rank102.0
Systematic review or meta-analysis

Solitary Lung Nodule: CT-Guided Transthoracic Biopsy vs Transbronchial Biopsy With Endobronchial Ultrasound and Flexible Bronchoscope, a Meta-Analysis of Randomized Controlled Trials.

Lung · 2023 · PMID 36695890

BACKGROUND: Transbronchial lung biopsy with radial endobronchial ultrasound (rEBUS-TBB) and Computed tomography (CT) scan-guided transthoracic biopsy (CT-TTB) are commonly used to investigate peripheral lung nodules but high-quality data are still not clear about the diagnostic and safety profile comparison of these two modalities. METHOD: We included all randomized controlled trials (RCT) comparing rEBUS-TBB with a flexible bronchoscope and CT-TTB for solitary lung nodules. Two reviewers extracted data independent…

Rank102.0
Systematic review or meta-analysis

Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy.

Frontiers in immunology · 2026 · PMID 42908912

OBJECTIVE: Antibody-drug conjugates (ADCs) are being investigated in advanced small-cell lung cancer (SCLC), but the evidence is dominated by early-phase studies conducted in non-exchangeable treatment settings. We evaluated the activity and toxicity of ADCs while separating later-line monotherapy from frontline combination therapy, later-line combination therapy, and post-induction maintenance. METHODS: PubMed, Embase, the Cochrane Library, and Web of Science Core Collection were searched from inception and in 28 …

Rank101.4
Systematic review or meta-analysis

A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

PharmacoEconomics · 2023 · PMID 37268866

BACKGROUND: The anaplastic lymphoma kinase (ALK) inhibitor treatment landscape is rapidly evolving, providing patients with ALK-positive (+) non-small cell lung cancer (NSCLC) with multiple therapy options, multiple lines of treatments, and prolonged survival. However, these recent treatment advances have resulted in additional increases in treatment costs. The objective of this article is to review the economic evidence of ALK inhibitors in patients with ALK+ NSCLC. METHODS: The systematic review was conducted in …

Rank101.1
Randomized controlled trial

Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 42119729

INTRODUCTION: Segmentectomy has become a standard treatment for small-sized peripheral NSCLC. However, its advantages compared with lobectomy in NSCLC harboring pathologically invasive features remain unclear. METHODS: We conducted a post hoc supplementary analysis of randomized controlled phase 3 trial JCOG0802/WJOG4607L in patients with clinical stage IA NSCLC (≤2 cm) harboring one or more of the following pathologically invasive features: lymphatic, vascular, or pleural invasion and lymph node metastasis. The pr…

Rank100.7
Randomized controlled trial

Automated Opportunistic Bone Mineral Density Assessment at Low-Dose CT Lung Cancer Screening: Incident Vertebral Fractures and Mortality.

Radiology · 2026 · PMID 42937536

Background Low-dose CT (LDCT) for lung cancer screening enables opportunistic volumetric bone mineral density (vBMD) assessment, but its prognostic value is unclear. Purpose To evaluate fully automated LDCT-derived vBMD for predicting vertebral fractures and its association with mortality in individuals who heavily smoke. Materials and Methods This secondary analysis included 55-74-year-old individuals who heavily smoked (≥30 pack-years) from the CT arm of the National Lung Screening Trial (NLST), a multicenter ran…

Rank100.4
Randomized controlled trial

Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42679738

BACKGROUND: Extensive-stage small cell lung cancer (ES-SCLC) is associated with a high symptom burden and impaired health-related quality of life (HRQoL). This prespecified analysis from the phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) for tarlatamab versus standard-of-care (SoC) chemotherapy following first-line platinum-based therapy. METHODS: DeLLphi-304 is a multicenter, open-label, randomized phase 3 study in adults with ES-SCLC. PROs were assessed using validated instruments, including…

Rank100.3
Randomized controlled trial

Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

The New England journal of medicine · 2026 · PMID 42734213

BACKGROUND: Tambotatug pelitecan (known as Tam-Peli, a new antibody-drug conjugate that targets the immune-checkpoint molecule B7-H3) showed promising clinical efficacy in patients with relapsed extensive-stage small-cell lung cancer in early-phase trials. METHODS: In this phase 3, multicenter, open-label, randomized trial, we assigned eligible patients with small-cell lung cancer that had progressed after first-line platinum-based therapy in a 1:1 ratio to receive tambotatug pelitecan or topotecan. The primary end…

Rank100.0
Systematic review or meta-analysisResult signal: benefit

Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38625495

BACKGROUND: The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC…

Rank100.0
Systematic review or meta-analysisResult signal: null

Interventions to increase participation in lung cancer screening programmes: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society · 2026 · PMID 42906938

INTRODUCTION: We aimed to systematically review and meta-analyse the effectiveness of interventions in increasing informed choice and participation in lung cancer screening based on low-dose computed tomography (LDCT). METHODS: Five electronic databases, Medline (PubMed version), Embase, Cinahl (Ebsco version), Scopus and Cochrane CENTRAL, were searched for randomised controlled trials, nonrandomised controlled trials and before-after studies published from 2000 until 15 March 2023. A random-effects meta-analysis w…

Rank100.0
Systematic review or meta-analysisResult signal: benefit

Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis.

Oncoimmunology · 2026 · PMID 42965526

Some patients with metastatic non-small-cell lung cancer (NSCLC) receiving anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) progress at a few sites while disease elsewhere stays controlled, a pattern consistent with focal, oligo-acquired immune escape rather than systemic treatment failure. Ablating the escaping focus may eliminate the resistant clone and preserve an otherwise effective immunotherapy line. We performed a PRISMA 2020-compliant, PROSPERO-registered systematic review and meta-analysis of lo…

Safety And Adverse Effects309 records
Rank108.4
Systematic review or meta-analysisResult signal: harm

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

Targeted oncology · 2024 · PMID 38824269

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer. An updated toxicity profile of EGFR-TKIs proves valuable in guiding clinical decision making. OBJECTIVE: This study comprehensively assessed the risk of EGFR-TKI-related adverse events (AEs) involving different systems/organs. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane library for phase III randomiz…

Rank108.1
Systematic review or meta-analysis

Efficacy and safety of curative-intent intensity modulated radiotherapy (IMRT) for inoperable, locally-advanced non-small cell lung cancer: A systematic review.

Journal of cancer research and therapeutics · 2026 · PMID 42955956

Intensity-modulated radiotherapy (IMRT), including volumetric modulated arc therapy (VMAT) is widely used for the treatment of non-small cell lung cancer (NSCLC) despite the lack of prospective, randomized evidence over three-dimensional conformal radiotherapy (3D-CRT). IMRT has been shown to reduce doses to normal tissue and organs at risk (OAR) in planning and retrospective studies. The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD4202123…

Rank108.1
Systematic review or meta-analysisResult signal: benefit

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.

European journal of clinical pharmacology · 2024 · PMID 38300281

BACKGROUND: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small sample sizes and different methods of statistical analysis, which may lead to a lack of valid metrics to assess t…

Rank107.8
Systematic review or meta-analysisResult signal: benefit

The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.

Annals of medicine · 2026 · PMID 42613912

BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…

Rank107.7
Systematic review or meta-analysis

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38294563

BACKGROUND: This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. METHODS: We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) …

Rank106.7
Systematic review or meta-analysisResult signal: mixed

Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.

European journal of clinical pharmacology · 2025 · PMID 39680077

BACKGROUND: Nivolumab and ipilimumab combination immunotherapy has become a standard treatment option for certain cancers. However, the benefits of combination therapy compared to nivolumab monotherapy in lung cancer patients are not entirely clear. We aimed to evaluate whether nivolumab plus ipilimumab improves clinical outcomes in lung cancer patients compared to nivolumab monotherapy. METHODS: A literature search was performed on PubMed, Web of Science, and Scopus from inception until November 2024 to identify r…

Rank106.0
Systematic review or meta-analysisResult signal: harm

Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Pulmonology · 2026 · PMID 42339520

BACKGROUND: Although smoking is a well-established risk factor for idiopathic pulmonary fibrosis (IPF) development, its impact on clinical outcomes remains unclear. RESEARCH QUESTION: Is smoking associated with clinical outcomes of IPF? METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted to identify studies reporting associations between smoking status and IPF outcomes, including mortality, acute exacerbation (AE), lung cancer development, and baseline lung function. Summary estim…

Rank104.8
Systematic review or meta-analysis

Evaluating eight smoking metrics for modelling survival in non-small cell lung cancer.

Cancer epidemiology · 2026 · PMID 41861692

INTRODUCTION: Smoking is a strong modifiable prognostic factor for lung cancer survival. We compared eight smoking metrics to determine which metric best models the relationship between smoking exposure with overall survival (OS) and lung cancer-specific survival (LCSS). These metrics included cigarettes-per-day, smoking duration, pack-years, square-root pack-years, logcig-years, the comprehensive smoking index, age-of-initiation, and years-since-quit. MATERIALS/METHODS: This retrospective, pooled analysis included…

Rank103.6
Systematic review or meta-analysis

Efficacy of Aidi injection combined with chemotherapy, radiotherapy or chemoradiotherapy for unresectable esophageal cancer treatment: A meta-analysis and systematic review of 29 randomized controlled trials based on Asian populations (China).

European journal of clinical pharmacology · 2023 · PMID 37043012

OBJECTIVES: This study aimed to assess the efficacy of Aidi combined with standard treatment, including radiotherapy (R), chemotherapy (C), or chemoradiotherapy (CR), for unresectable esophageal cancer (EC). METHODS: Eight online databases were queried to collect randomized controlled trials (RCTs) published from database construction to August 2022. Patients in the control group underwent standard treatment with R, C, or CR, whereas those in the experimental group underwent Aidi combined with standard treatment. R…

Rank102.4
Systematic review or meta-analysis

Endobronchial ultrasound-guided transbronchial needle aspiration in peripheral pulmonary lesions: a systematic review and meta-analysis.

Clinical & experimental metastasis · 2023 · PMID 36401666

The diagnosis of peripheral pulmonary lesions (PPLs) remains a challenge for physicians. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been applied in the diagnosis of PPLs, but its diagnostic rate varies widely. The systematic review and meta-analysis was conducted to figure out the accuracy and safety of EBUS-TBNA in the diagnosis of PPLs. We searched the PubMed and Embase databases for relevant studies published from January 1, 2000 to December 30, 2021 and used PICO (Participa…

Rank102.4
Systematic review or meta-analysis

Efficacy of neoadjuvant stereotactic radiotherapy in brain metastases from solid cancer: a systematic review of literature and meta-analysis.

Neurosurgical review · 2023 · PMID 37256368

Neoadjuvant stereotactic radiotherapy (NaSRT) is a novel strategy for brain metastasis (BM) treatment, promising to achieve good local control, improved survival, and low toxicity. This is a systematic review of available literature and meta-analysis of 8 articles eligible for inclusion after searching MEDLINE via PubMed, Web-of-science, Cochrane Wiley, and Embase databases up to March 2023. A total of 484 patients undergoing NaSRT to treat 507 lesions were included. The median age was 60.9 (IQR 57-63) years, with …

Rank102.2
Systematic review or meta-analysis

Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.

Pulmonology · 2026 · PMID 41560513

BACKGROUND: Clinical guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as the initial diagnostic tool for lung cancer staging. However, despite the availability of mediastinal forceps biopsy and cryobiopsy, the optimal diagnostic approaches for other mediastinal conditions remain unclear. METHODS: We searched multiple databases and sources up to February 21, 2025, and employed single-arm, pairwise, and network meta-analytical approaches to comprehensively evaluate EBU…

Rank102.0
Systematic review or meta-analysis

Solitary Lung Nodule: CT-Guided Transthoracic Biopsy vs Transbronchial Biopsy With Endobronchial Ultrasound and Flexible Bronchoscope, a Meta-Analysis of Randomized Controlled Trials.

Lung · 2023 · PMID 36695890

BACKGROUND: Transbronchial lung biopsy with radial endobronchial ultrasound (rEBUS-TBB) and Computed tomography (CT) scan-guided transthoracic biopsy (CT-TTB) are commonly used to investigate peripheral lung nodules but high-quality data are still not clear about the diagnostic and safety profile comparison of these two modalities. METHOD: We included all randomized controlled trials (RCT) comparing rEBUS-TBB with a flexible bronchoscope and CT-TTB for solitary lung nodules. Two reviewers extracted data independent…

Rank102.0
Systematic review or meta-analysis

Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy.

Frontiers in immunology · 2026 · PMID 42908912

OBJECTIVE: Antibody-drug conjugates (ADCs) are being investigated in advanced small-cell lung cancer (SCLC), but the evidence is dominated by early-phase studies conducted in non-exchangeable treatment settings. We evaluated the activity and toxicity of ADCs while separating later-line monotherapy from frontline combination therapy, later-line combination therapy, and post-induction maintenance. METHODS: PubMed, Embase, the Cochrane Library, and Web of Science Core Collection were searched from inception and in 28 …

Rank101.7
Systematic review or meta-analysis

The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.

Journal of neuro-oncology · 2023 · PMID 37086369

PURPOSE: The phenomenon of radiation therapy (RT) causing regression of targeted lesions as well as lesions outside of the radiation field is known as the abscopal effect and is thought to be mediated by immunologic causes. This phenomena has been described following whole brain radiation (WBRT) and stereotactic radiosurgery (SRS) of brain metastasis (BM) in advanced melanoma and non-small-cell lung cancer (NSCLC). We systematically reviewed the available literature to identify which radiation modality and immunoth…

Rank100.0
Systematic review or meta-analysis

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.

International journal of clinical oncology · 2024 · PMID 38353907

BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer. METHODS: We extracted studi…

Rank100.0
Systematic review or meta-analysis

Efficacy and safety of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis.

Frontiers in oncology · 2026 · PMID 42952490

BACKGROUND: Antibody-drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) resistance. We evaluated their efficacy and safety in this setting. METHODS: PubMed, Embase,and the Cochrane Library were searched for prospective clinical studies. Overlapping reports were assessed before endpoint-specific synthesis. Comparable proportional outcomes from non-randomized studies were pooled using random-effects models, …

Rank100.0
Systematic review or meta-analysis

Stage II Non-Small Cell Lung Cancer: Upfront Surgery or Neoadjuvant Chemoimmunotherapy.

The Annals of thoracic surgery · 2026 · PMID 42264017

BACKGROUND: Neoadjuvant chemoimmunotherapy adoption in stage II non-small cell lung cancer is shrouded by lack of clear survival advantages and stratification across randomized clinical trials. METHODS: An individual patient data (IPD) meta-analysis was conducted comparing overall survival of stage II patients (according to the American Joint Committee on Cancer TNM staging, eighth edition) receiving neoadjuvant chemoimmunotherapy in phase 3 randomized controlled trials with overall survival of patients undergoing …

Rank100.0
Systematic review or meta-analysis

Wood dust exposure and small cell lung cancer: a systematic review and meta-analysis.

Journal of exposure science & environmental epidemiology · 2024 · PMID 37012384

INTRODUCTION: Occupational exposure role on small cell lung cancer (SCLC) onset has been little studied. Wood dust has been recognized as a human carcinogen, and many occupations have high wood-dust exposure. The aim of this study was therefore to perform a systematic review and meta-analysis of the scientific literature to summarize and analyse the risks of wood dust-related occupations on development of SCLC, taking tobacco use into account. METHODS: We conducted a literature search of PubMed, EMBASE, Web of Scie…

Rank100.0
Systematic review or meta-analysisResult signal: benefit

Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38625495

BACKGROUND: The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC…

Rank98.7
Randomized controlled trial

Thalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial.

Frontiers in immunology · 2026 · PMID 42964306

BACKGROUND: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a characteristic cutaneous adverse event associated with immune checkpoint inhibitors. This study compared two prophylactic thalidomide doses to identify the more promising dose for further evaluation. METHODS: In this multicenter, randomized clinical trial, patients with advanced esophageal squamous cell carcinoma or non-small cell lung cancer (NSCLC) were randomly assigned to receive thalidomide 50 mg/day (Group A) or 100 mg/day (Group …

Rank97.0
Systematic review or meta-analysisResult signal: null

Uniportal versus multiportal video-assisted thoracoscopic segmentectomy for non-small cell lung cancer: a systematic review and meta-analysis.

Surgery today · 2023 · PMID 35066744

It remains controversial whether one-port video-assisted thoracoscopic surgery (VATS) or multiportal VATS is better for segmentectomy in patients with early non-small cell lung cancer (NSCLC). We conducted this meta-analysis of eight published studies to compare the clinical effectiveness and safety of the two surgical approaches. The uniportal group had a shorter postoperative hospital stay (mean difference (MD): - 0.40, 95% CI [- 0.71 to - 0.08] days, p = 0.01), lower postoperative pain scores on day 3 (MD: - 0.9…

Rank97.0
Systematic review or meta-analysisResult signal: harm

Occupational exposures in the rubber tire industry and risk of cancer: a systematic review.

International archives of occupational and environmental health · 2023 · PMID 37083761

OBJECTIVE: This study aimed at investigate the association between cancer and the rubber tire industry using indicators used to estimate exposure, such as duration or historical time period of exposure. METHODS: A systematic review using MEDLINE was carried out. The Preferred Reporting Items for Systematic Reviews (PRISMA) statement guided the systematic review. The Risk of Bias in Non-Randomized Studies of Exposures (ROBINS-E) was used to analyze biases in the selected studies. RESULTS: A total of 240 articles wer…

Rank97.0
Systematic review or meta-analysis

Exposure to outdoor particulate matter and risk of respiratory diseases: a systematic review and meta-analysis.

Environmental geochemistry and health · 2023 · PMID 38153542

According to epidemiological studies, particulate matter (PM) is an important air pollutant that poses a significant threat to human health. The relationship between particulate matter and respiratory diseases has been the subject of numerous studies, but these studies have produced inconsistent findings. The purpose of this systematic review was to examine the connection between outdoor particulate matter (PM2.5 and PM10) exposure and respiratory disorders (COPD, lung cancer, LRIs, and COVID-19). For this purpose,…

Rank97.0
Systematic review or meta-analysis

The sound and surprise: overlapping meta-analyses on the topic of safety and efficacy of PD-1 and PD-L1 inhibitors in the treatment of non-small cell lung cancer.

European journal of clinical pharmacology · 2023 · PMID 37796282

PURPOSE: To analyze the characteristics of overlapping meta-analyses based on randomized controlled trials (RCTs) which reported PD-1/PD-L1 inhibitors in non-small cell cancer (NSCLC). METHODS: Meta-analyses were identified from English and Chinese databases until January 1, 2022. Differences in characteristics of overlapping meta-analyses that conducted in China and other countries were compared to assess their publication propensity. The corrected covered area (CCA) and coverage of relevant RCTs were analyzed for…

Treatments That Failed Clinical Trials68 records
Rank99.3
Randomized controlled trial

Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer.

Journal for immunotherapy of cancer · 2026 · PMID 42134900

BACKGROUND: Circadian biology suggests that synchronizing immune checkpoint inhibitor (ICI) dosing with morning peaks in immune activation could improve clinical outcomes, but well-powered studies using appropriate causal inference methodology are sparse. METHODS: We emulated a pragmatic randomized controlled trial of AM versus PM ICI infusions using Veterans Health Administration records from 2010 to 2024. In the emulated trial, stage IV non-small-cell lung cancer patients planned to undergo first-line or second-l…

Rank98.5
Randomized controlled trial

Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.

Drug design, development and therapy · 2026 · PMID 42453934

OBJECTIVE: To evaluate the effects of hydrogen-oxygen inhalation on nodule diameter and peripheral blood inflammatory factors in patients with small pulmonary nodules (SPNs), and to further analyze its efficacy in the smoking subgroup. The primary endpoint was the change in pulmonary nodule diameter before and after intervention; secondary endpoints included alterations in serum IL-6, CRP, peripheral blood neutrophil count, and Mayo malignant transformation risk score. METHODS: A total of 59 patients with SPNs conf…

Rank97.9
Randomized controlled trialResult signal: null

Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.

AJR. American journal of roentgenology · 2026 · PMID 41848489

BACKGROUND. The impact of artificial intelligence (AI) tools for lung nodule evaluation on low-dose CT (LDCT) has been evaluated primarily using experimental retrospective reader designs, outside of clinical practice. OBJECTIVE. The purpose of this study was to compare interpretation times and lung nodule detection rates between real-world interpretations conducted with versus without an AI-based lung nodule evaluation tool for LDCT examinations in asymptomatic individuals. METHODS. This prospective single-center, …

Rank97.5
Randomized controlled trial

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.

The Lancet. Oncology · 2026 · PMID 41825453

BACKGROUND: PD-1 and PD-L1 inhibitors have been shown to synergise with anti-angiogenic agents in non-small-cell lung cancer (NSCLC). We aimed to compare benmelstobart plus anlotinib with pembrolizumab in patients with previously untreated, driver gene-negative, PD-L1-positive, advanced NSCLC. METHODS: The blinded, randomised, controlled, phase 3 CAMPASS trial was conducted in 79 centres across China. Patients aged 18-75 years with stage IIIB-IV squamous or non-squamous NSCLC, no previous systemic treatment for adv…

Rank97.4
Randomized controlled trialResult signal: harm

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Lancet (London, England) · 2026 · PMID 42702214

BACKGROUND: Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). We aimed to test the addition of neoadjuvant, concurrent, and adjuvant atezolizumab with SBRT for early-stage NSCLC. METHODS: In this multicentre, open-label, phase 3, randomised controlled trial, eligible patients from 146 institutions across the USA who had T1-T3N0M0 NSCLC ≤7 cm, and were medically inoperable or declined surgery, and had at least one risk factor …

Rank97.4
Randomized controlled trialResult signal: mixed

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

The Lancet. Oncology · 2026 · PMID 42727592

BACKGROUND: Patient-reported outcome (PRO) symptom monitoring has been shown to improve overall survival. Yet, available evidence largely derives from resource-intensive studies limited to patients with advanced cancer. We aimed to assess the effect of PRO symptom monitoring on overall and progression-free survival in patients with stage I-IV lung cancer in a real-world clinical setting, with follow-up extending to 5 years. METHODS: The SYMPRO-Lung trial was a multicentre, stepped-wedged, cluster-randomised clinica…

Rank97.2
Randomized controlled trialResult signal: null

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42127535

BACKGROUND: The phase III APPLE trial evaluated the efficacy of adding bevacizumab to atezolizumab with carboplatin plus pemetrexed (APP) for individuals with advanced nonsquamous non-small cell lung cancer (NSCLC). We here report the long-term outcomes of this trial with 3.5 years of follow-up. METHODS: Patients with advanced nonsquamous NSCLC were randomized 1:1 to receive APP or APP plus bevacizumab (APPB). Stratification factors were clinical stage, driver oncogenes, and PD-L1 expression. Endpoints included pro…

Rank97.0
Randomized controlled trialResult signal: null

Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.

European journal of nuclear medicine and molecular imaging · 2026 · PMID 41801367

BACKGROUND: The prognostic value of baseline 18F-FDG PET/CT-derived metrics in limited-stage small-cell lung cancer (LS-SCLC) remains uncertain. We evaluated whether baseline PET-derived parameters provide prognostic information beyond tumour volume and clinical factors in patients treated with curative-intent chemoradiotherapy within the phase III CONVERT trial. METHODS: CONVERT was an international, multi-centre randomised controlled trial. This study is a post-hoc analysis of baseline 18F-FDG PET/CT from the mul…

Rank96.8
Randomized controlled trialResult signal: benefit

Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 41921748

INTRODUCTION: In ADRIATIC, consolidation durvalumab significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with limited-stage SCLC without progression after concurrent chemoradiotherapy (cCRT). Exploratory analyses were conducted in prespecified subgroups per protocol-permitted cCRT components, prophylactic cranial irradiation (PCI) receipt, and time from end of cCRT to randomization. METHODS: Prior cCRT comprised cisplatin-etoposide or carboplatin-etoposide with…

Rank96.8
Randomized controlled trialResult signal: null

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41702246

INTRODUCTION: More stage III non-small-cell lung cancer patients experience long-term survival (OS). ESPATUE-trial looked at surgery versus boost-radiochemotherapy following induction chemotherapy, consisting of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 every 21 days, as well as concurrent chemoradiotherapy to 45 Gy given as 1.5 Gy twice daily, concurrent cisplatin 50 mg/m2 on days 2 and 9, and concurrent vinorelbine 20 mg/m2 on days 2 and 9 (Eberhardt et al, J Clin Oncol …

Rank96.7
Randomized controlled trial

Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42425045

INTRODUCTION: We aimed to clarify the prognostic impact of adjuvant chemotherapy intensity in patients with high-grade neuroendocrine carcinoma (HGNEC) of the lung using a post hoc analysis of the phase III JCOG1205/1206 trial comparing irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP). MATERIAL AND METHODS: We included 217 patients (109 and 108 received EP and IP, respectively) with p-stage I-IIIA HGNEC. Prognosis was assessed based on treatment completion (four cycles) and relative dose intensity …

Rank96.7
Randomized controlled trialResult signal: benefit

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.

Nature · 2026 · PMID 42587156

Perioperative nivolumab significantly improved event-free survival (EFS) compared with placebo in patients with resectable non-small cell lung cancer (NSCLC) in the CheckMate 77T study (ClinicalTrials.gov NCT04025879 )1. Here, after randomization, 98 out of 229 patients who received nivolumab and 92 out of 232 patients who received placebo had evaluable biomarkers (41% of randomized patients). Of the 98 patients receiving nivolumab, 83 (85%) had detectable circulating tumour DNA (ctDNA) before initiating neoadjuvan…

Rank96.7
Randomized controlled trialResult signal: null

Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42000139

INTRODUCTION: We aimed to evaluate the long-term follow-up overall survival (OS) of irinotecan plus cisplatin (IP) versus etoposide plus cisplatin (EP) as postoperative adjuvant chemotherapy in patients with pathological Stage I-IIIA high-grade neuroendocrine carcinoma (HGNEC) of the lung. METHODS: The JCOG1205/1206 randomized, open-label, phase III study compared the efficacy of IP and EP as adjuvant chemotherapy. Patients with pathological Stage I-IIIA and completely resected HGNEC of the lung were randomized to …

Rank96.5
Randomized controlled trial

Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42691846

BACKGROUND: Concurrent chemoradiotherapy (CRT) remains the primary treatment for limited stage (LS) small cell lung cancer (SCLC). Although most patients respond, the majority relapse and die from the disease, and treatment-related toxicity is common. Molecular subtyping has been extensively investigated in SCLC, but its clinical relevance remains uncertain, and most studies have focused on systemic treatment of extensive-stage SCLC. We analysed baseline tumor samples from a subset of participants (n = 77) in a ran…

Rank96.2
Randomized controlled trial

Effect of preoperative respiratory prehabilitation on cardiopulmonary function in patients undergoing lung resection for non-small cell lung cancer: a randomized controlled trial.

Journal of cardiothoracic surgery · 2026 · PMID 42010447

BACKGROUND: Preoperative respiratory prehabilitation has attracted increasing attention as a perioperative strategy in thoracic surgery, but evidence regarding its short-term effects on early postoperative functional recovery remains limited. This randomized controlled trial investigated the effect of a 7-day preoperative respiratory prehabilitation program on postoperative pulmonary function, cardiopulmonary exercise capacity, and postoperative complications in patients undergoing curative-intent lung resection fo…

Rank96.2
Randomized controlled trialResult signal: null

Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial.

BMC anesthesiology · 2026 · PMID 41794665

BACKGROUND: Elevated high-sensitivity troponin T levels shortly after noncardiac surgery are closely linked to myocardial injury, a key factor in 30-day postoperative mortality. Intravenous lidocaine, known for its potent anti-inflammatory and membrane-stabilizing properties, has shown cardioprotective potential in other surgical settings, but its efficacy in noncardiac thoracic surgery remains unclear. OBJECTIVES: This study was a double-blind, placebo-controlled randomized trial. Participants were randomly alloca…

Rank96.2
Randomized controlled trial

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42636548

BACKGROUND: Daily low-dose carboplatin with concurrent thoracic radiotherapy is the standard treatment for older patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) in Japan. METHODS: This open-label phase 3 trial was conducted at 38 institutions in Japan. Patients aged ≥ 75 years with LA-NSCLC were randomly assigned (1:1) to receive daily carboplatin (30 mg/m2) or weekly carboplatin (area under the curve, 2 mg·min/mL) plus nab-paclitaxel (30 mg/m2) with thoracic radiotherapy. Durvalum…

Rank96.1
Randomized controlled trial

Dexketoprofen Trometamol Plus Sufentanil for Analgesia After Thoracoscopic Radical Resection of Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.

Drug design, development and therapy · 2026 · PMID 42830882

BACKGROUND: Evidence for adding dexketoprofen trometamol to sufentanil-based patient-controlled intravenous analgesia (PCIA) after thoracoscopic radical resection of lung cancer remains limited. OBJECTIVE: To evaluate 48-hour opioid consumption, pain outcomes, and short-term adverse events with dexketoprofen trometamol plus sufentanil versus sufentanil-based PCIA alone. METHODS: In this randomized, double-blind, placebo-controlled trial, 108 patients scheduled for thoracoscopic radical resection of lung cancer were…

Rank95.9
Randomized controlled trial

Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial.

Cancer medicine · 2026 · PMID 42036773

BACKGROUND: Although physical activity is associated with improved survival in lung cancer, most patients remain inactive. This study examined the impact of an oncologist's recommendation on exercise quantity, sedentary behavior, and quality of life (QoL) in patients with lung cancer. METHODS: In this single-blind, 3-arm randomized controlled trial, patients with lung cancer (stages I-IV) were assigned to: (1) usual care, (2) the oncologist's verbal and written exercise recommendation, or (3) the recommendation plu…

Rank95.8
Randomized controlled trialResult signal: null

Closed Versus Open Vent Port Techniques and the Disconnection Technique for Optimizing Lung Collapse With Bronchial Blockers in Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial.

The clinical respiratory journal · 2026 · PMID 42922101

INTRODUCTION: For patients undergoing video-assisted thoracoscopic surgery (VATS) for lung cancer or other pulmonary lesions, effective one-lung ventilation (OLV) is essential to provide surgical exposure. Bronchial blockers (BBs) are increasingly used for OLV, but the optimal management of their vent port to accelerate lung collapse remains unclear. METHODS: In this prospective, randomized, controlled trial, 75 patients were allocated to three groups (n = 25 each): Group 1-BB with vent port closed; Group 2 (contro…

Rank95.7
Randomized controlled trialCorrection flagged

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology · 2026 · PMID 42398520

BACKGROUND: Baseline exposure to antibiotics and proton pump inhibitors has been associated with reduced efficacy of immune checkpoint inhibitors in patients with advanced tumours, possibly through gut microbiome disruption. Whether this outcome extends to those with earlier-stage disease remains unclear. We aimed to assess the association of baseline antibiotics and proton pump inhibitors with progression-free survival and overall survival in patients with unresectable stage III non-small cell lung cancer (NSCLC).…

Rank95.7
Randomized controlled trial

SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 41950998

INTRODUCTION: Tiragolumab may synergize with other immunotherapies to enhance antitumor immune responses. We report efficacy, safety, and biomarker findings from SKYSCRAPER-02C (NCT04665856), comparing tiragolumab plus atezolizumab plus carboplatin and etoposide (CE; experimental arm) with atezolizumab plus CE (control arm) in patients with untreated extensive-stage SCLC (ES-SCLC) in China. METHODS: Patients were randomized (1:1) to tiragolumab 600 mg or placebo, plus atezolizumab 1200 mg and CE (four cycles), then…

Rank95.6
Randomized controlled trial

Long-Term Effects of High-Intensity Training after Lung Cancer Surgery-A 5-Yr Follow-Up of a Randomized Controlled Trial.

Medicine and science in sports and exercise · 2026 · PMID 41851742

PURPOSE: To evaluate long-term extended effects of 20 wk of high-intensity training (HIT) performed shortly after lung cancer surgery on physical fitness, muscle mass, pulmonary function, quality of life (QoL), and survival. METHODS: All participants in the original HIT-trial were invited 5 yr after surgery. Original measures were repeated by the same technician and equipment. All-cause mortality was registered 5- and 10-yr postsurgery. RESULTS: Of 61 patients who completed the 20-wk intervention, 40 (66%) were ali…

Rank95.6
Randomized controlled trialResult signal: mixed

Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.

BMC cancer · 2026 · PMID 41888696

BACKGROUND: Diffuse Pleural Mesothelioma (DPM) is an aggressive cancer with limited treatment options and a poor prognosis. Maintenance therapy has emerged as a potential strategy to delay disease progression following first-line chemotherapy. This study evaluates the efficacy and safety of gemcitabine maintenance therapy compared to best supportive care (BSC) in patients with unresectable DPM. METHODS: This single-center, randomized, phase II, open-label trial included 64 patients with unresectable DPM who achieve…

Rank95.6
Randomized controlled trialResult signal: null

Clinical Application of Progressive Suspension in Thoracoscopic Right Upper Lobectomy.

ANZ journal of surgery · 2026 · PMID 41800747

OBJECTIVE: To compare the clinical efficacy of the progressive suspension method and conventional thoracoscopic pulmonary resection in right upper lobectomy. METHODS: A prospective cohort study was conducted involving 60 patients admitted to the Department of Thoracic Surgery at Cangzhou Central Hospital from January 2024 to March 2025. Patients were randomly divided into the observation group (n = 30, using the progressive suspension method, including 15 cases of trans-thoracic puncture fixation and 15 cases of in…

i
Research information notice

Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.